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GENERAL INTRODUCTION 
Low molecular weight heterocycles and carbocycles are among the most highly 
valued targets in modern synthetic chemistry for use as biological probes. However, 
many routes to these important classes of molecules require harsh reaction conditions or 
have poor selectivity. Recent research in the Larock group has investigated the 
electrophilic cylization of functionalized alkynes to form various heterocycles and 
carbocycles. Over the last 25 years, the Larock group has also been heavily involved in 
examining palladium-catalyzed transformations. This thesis describes several novel and 
useful methodologies that target important biological scaffolds through the use of 
electrophilic iodine reactions and palladium-catalyzed chemistry. 
Dissertation organization 
This dissertation is divided into five chapters. Each chapter is written in American 
Chemical Society format as required by the Journal of Organic Chemistry and the 
Journal of Combinatorial Chemistry and is composed of an abstract, introduction, results 
and discussion, conclusions, experimental, acknowledgments, and references. 
Chapter 1 describes an efficient, simple method for the synthesis of highly 
substituted isoxazoles. O-Methyl oximes of 2-alkyn-l-ones react in the presence of IC1 to 
afford the corresponding 3,5-disubstituted-4-iodoisoxazoles in good yields. The resulting 
4-iodoisoxazoles undergo various palladium-catalyzed reactions. An efficient synthesis 
of the potent COX-II inhibitor, valdecoxib, using this methodology is reported. Many 
functional groups are tolerated using mild reaction conditions. 
2 
The isoxazole skeleton is an important heteroaromatic pharmacophore, which is 
known to possess a variety of biological activities. A library of highly substituted 
isoxazoles have been prepared in high purities starting from the corresponding 3,5-
disubstituted 4-iodoisoxazoles through various palladium-catalyzed reactions. By using 
this methodology a 51-member library of highly substituted isoxazoles has been 
generated. 
Dehydration/iodination of /V-acyldihydropryazolcs could be a potentially useful way 
to selectively synthesize substituted /V-acyl-1 //-pyrazoles from readily available starting 
materials. A variety of substituted yV-acyl-4-iodopyrazoles have been synthesized in 
good yields by the dehydration/iodination of 1 -acctyl-5-hydroxy-4,5-dihydro-1H-
pyrazoles under mild reaction conditions. 
The electrophilic cyclization of alkynamides has led to the formation of oxazolium 
salts in good yields. The resulting oxazolium salts are extremely stable and efforts 
towards conversion to the corresponding free bases have been met with only limited 
success. 
The fluoren-9-one core is present in a variety of substrates exhibiting interesting 
biological activities and has been recently discovered in natural products. Fluoren-9-ones 
and analogues have been readily synthesized by the palladium-catalyzed reactions of o-
haloarenecarboxaldehydes with o-silylaryl triflates in the presence of CsF. 
Finally, all of the ^ and 13C NMR spectra for the previously unknown starting 
materials and products are compiled in appendices A-E. 
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CHAPTER 1. The Synthesis of Highly Substituted Isoxazoles by Electrophilic 
Cyclization. An Efficient Synthesis of Valdecoxib 
Based on a paper published in the Journal of Organic Chemistry1 
Jesse P. Waldo and Richard C. Larock* 
Department of Chemistry, Iowa State University, Ames, Iowa 50011 
larock@iastate.edu 
Abstract 
.OMe 
Ft1 = H, Me, Ar, n-C6H13, t-Bu, etc. Ft3 = aryl, alkynyl, vinylic, C0 2 R, C 0 2 N H R 
Ft2 = Me, Ar, t-Bu, etc. 
A large number of functionally-substituted 2-alkyn-l-one O-methyl oximes have 
been cyclized under mild reaction conditions in the presence of IC1 to give the 
corresponding 4-iodoisoxazoles in moderate to excellent yields. The resulting 4-
iodoisoxazoles undergo various palladium-catalyzed reactions to yield 3,4,5-
trisubstituted isoxazoles, including valdecoxib. 
Introduction 
The isoxazole skeleton has been the focus of many biological studies in recent years.2 
Our group and others have reported that the electrophilic cyclization of functionally-
substituted acetylenes is a powerful synthetic tool for constructing a diverse assortment 
of ring systems, including benzo[£>]thiophenes,3 isoquinolines and naphthyridines,4 
isocoumarins and a-pyrones,5 benzofurans,6 furans,7 indoles,8 furopyridines,9 cyclic 
4 
carbonates,10 2,3-dihydropyrroles and pyrroles,11 pyrilium salts and isochromenes,12 
bicyclic P-lactams,13 2//-bcnzopyrans,14 naphthalenes and 2-naphthols,15 chromones,16 
isoindolin-l-ones17 and bcnzo[/;]sclcnophcncs.18 
We recently reported the synthesis of numerous highly substituted isoxazoles through 
the cyclization of various 2-alkyn-l-one O-methyl oximes (eq l)19 by a variety of 
electrophiles. The yields of the desired Z-O-methyl oximes from the ynones are generally 
good, and these compounds are easily isolated by column chromatography on silica gel. 
We now report the full details of our work on the ICl-induced cyclization of 2-alkyn-l-
one O-methyl oximes, which provides a very efficient synthesis of 4-iodoisoxazoles. 
Numerous examples are reported. The resulting 4-iodoisoxazoles are readily elaborated 
by conventional palladium-catalyzed processes to afford highly substituted isoxazoles, 
including valdecoxib. 
E-X = l2, ICI, Br2, PhSeBr 
Results and Discussion 
The requisite ynones can be easily prepared (Scheme 1) by the palladium/copper-
catalyzed Sonogashira coupling of an acid chloride with a terminal acetylene20 or by Pd-
catalyzed carbonylative coupling of terminal acetylenes with aryl iodides.21 The ynones 
can also be prepared by allowing a lithium acetylide to react with an aldehyde, followed 
by oxidation of the resulting secondary alcohol.22 In addition, ynones can be 
conveniently prepared by the treatment of silyl acetylenes with an acid chloride in the 
presence of aluminum chloride.23 
Scheme 1 
0 H = R2 
^ cat. PdCI2(PPh3)2 1) Li — R2 0 
R' CI A cat. Cul, Et3N o 2) M n 0 2 or PCC R H 
I M S — R2 R > \ cat. Pd ,CO ^
 :
 ^ ^
 ArX 
R CI AICI3, CH2CI2 H = R2 X = halogen 
(R1 = Ar) 
The O-methyl oximes required in our isoxazole synthesis are readily prepared by 
stirring the ynone in the presence of methoxylamine hydrochloride, pyridine, and 
Na2SC>4 or MgSC>4 at room temperature using methanol as the solvent.24 Heating is 
sometimes required, especially when R1 is an aromatic ring bearing electron-donating 
groups. When R1 is a bulky group relative to the alkyne moiety, the desired Z isomer is 
the predominant product. However, if R1 is significantly less bulky, a mixture of isomers 
often results and the desired isomer must be separated by column chromatography. Upon 
preparation of the 2-alkyn-l-one O-methyl oximes 21 and 23, a 1:1 mixture of E.Z O-
methyl oximes, observable by 1H NMR spectroscopy, was obtained. Our attempts at 
separating these isomers on a silica gel column led to the unwanted E isomer exclusively 
(eq 2). The 1:1 mixture of E\Z O-methyl oximes 21 and 23 isomerized exclusively to 
their E isomers. This isomerization only occurred when R was either a proton or a 
methyl group, but was not observed in any other cases. Nevertheless, in the cases when R 
is equal to a proton (21) or methyl (23), the desired Z-O-methyl oxime could be isolated 
by utilizing a basic alumina column, although the yields were only modest. It was 
discovered that only the Z isomer cyclized when subjected to our usual IC1 cyclization 
conditions. Our attempts at simultaneous isomerization and cyclization of the E isomer 
were unsuccessful. Consequently, it is essential that the Z-O-methyl oxime isomer be 
employed in the cyclization process. 
N ^
0 M e
 Silica Gel MeCX 
Ph Ph 
21 R = H 
1:1 /E:Z 23 R = Me 
With the desired Z-O-methyl oximes in hand, we studied the scope of the cyclization 
methodology (Table 1). In our earlier studies, we discovered that using IC1 as the source 
of electrophilic iodine provided the best results for the formation of isoxazoles. I2 may 
also be used to induce the cyclization of compound 1. However, the reactions are slower 
and higher molar equivalents of I2 are required to achieve yields comparable to those of 
IC1 (Table 1, compare entries 1 and 2). 
Table 1. The Synthesis of 4-Iodoisoxazoles by Electrophilic Cyclizationa 
entry O-methyl oxime electrophile time (h) product yield (%) 
N 
Ph' 
„OMe Xk r 
Ph I 
R 
1 R = Ph (1) 3.012C 1.0 (2) 77 
2 1.2 IC1 0.5 86 
3 R = Me (3) 1.2 IC1 0.75 (4) 99 
4 R = n-Bu (5) 1.2 IC1 0.75 (6) 91 
5 R = ?-Bu (7) 1.2 IC1 0.75 (8) 90 
R = — 4 co2Et ( 9 ) 1 .2 IC1 0 . 5 ( 1 0 ) 8 7 
7 
7 R = - H T V o M e (11) 1.2 IC1 0.5 (12) 89 
8 (13) 1.2 IC1 0.5 (14) 82 
OMe . 0 Ph 
16 R = - ( " ) (29) 1.2 IC1 0.5 (30) 93 
Me 
MeQ 
R ^ R I 
~Ph 
9 ( 1 5 ) 1 2 m 1 0
 (16> 94 
1 0 R =
 ~ Q ^ c f 3 ( 1 7> ] - 2 I C 1 1 0 (18) 93 
1 1 R = ( 1 9 ) 2
-
2 I C 1 6 0
 (20> 98 
12 R = H (21) 1.2 IC1 0.5 (22) 83 
13 R = Me (23) 1.2 IC1 0.75 (24) 79 
14 R = «-C6H13 (25) 1.2 IC1 0.75 (26) 94 
15 R = ;-Bu (27) 1.2 IC1 0.75 (28) 100 
1 7 R =
 — y j ( 3 1 ) L 2 I C 1 1 0 ( 3 2 ) 8 9 
MeO 
18 R = Y Y ° ) ( 3 3 ) L 2 I C 1 1 0 (34> 8 2 
19 R = (35) 1.2 IC1 0.5 (36) 86 
20 R = | 
N 
Me 
(37) 1.2 IC1 0.5 
21 R = ( T ^ (39) 3.0 IC1 3.0 
(38) 
(40) 
55 
68 
X5Me 
22 
t-Bu 
23 
MeO-
MeO' 
(41) 
(43) 
1.2 IC1 2.0 
1.2 IC1 1.0 
MeO 
OMe 
87 
I (44) 96 
a
 All reactions were carried out in CH2CI2 (10 mL/mmol) at room temperature using 0.25 mmol of starting 
material unless otherwise specified. b Isolated yields after column chromatography. c The reaction was 
carried out in CH3CN. 
When the terminus of the alkynyl moiety was substituted with aliphatic substituents 
ranging from compact to bulky, the yields were excellent (entries 3-5). Furthermore, the 
introduction of substituents on the aryl group, has little effect on the yield of the reaction. 
The electron-withdrawing group CChEt (9) and the electron-donating group OMe (11), 
both in the para position of the phenyl ring, did not significantly change the reaction 
yields compared to the parent system (entries 6 and 7). Furthermore, substituting the 
alkynyl unit with a thiophene heterocycle (13) lowered the yield only slightly (entry 8). 
The effect of changing the substituents in the 1 position of the 2-alkyn-l-one O-
methyl oxime was also studied. The para electron-withdrawing groups in compounds 15 
and 17 provided the corresponding isoxazoles 16 and 18 in excellent yields (entries 9 and 
10). The electron-donating group NMe2 in the para position of compound 19 required a 
dramatic increase in reaction time and 2.2 mole equivalents of IC1 had to be used to 
achieve an excellent yield of 20. 1.2 Mole equivalents of IC1 provided only a trace of 20 
9 
and the reaction suffered from low conversion. No further iodinated products were 
observed in the reaction. 
Other substituents in the 1 position of the 1-alkynone were generally quite successful. 
For example, compounds 21 and 23, as the pure Z-isomers, afforded the expected product 
with only a slight decrease in yields (entries 12 and 13) using our standard procedure, 
while compound 25 provided an excellent yield of 26 (entry 14). Introducing a bulky t-
Bu group (27) into the alkynone provided a quantitative yield of the desired isoxazole 28 
(entry 15). Compounds 29 and 31 introduce steric bulk at the ortho positions of the 
parent phenyl rings. This did not hinder the reaction and high yields of the isoxazole 
products 30 and 32 were obtained using short reaction times (entries 16 and 17). Thus, 
steric effects appear to be minimal in this process. It is noteworthy that compound 31 
cyclized exclusively to the desired 5-endo dig isoxazole product 32 and the possible 6-
exo dig chromone oxime product was not observed, even though we have successfully 
cyclized closely related ketones to the corresponding chromones (Scheme 2). 
Introduction of the oxygen-containing heterocycles 33 and 35 into the alkynone also 
provided isoxazoles in good yields (entries 18 and 19). The nitrogen-containing 
heterocycles 37 and 39 also afforded the desired isoxazoles, although the yields were 
10 
only modest (entries 20 and 21). The cyclization of compound 39 required the use of 3 
equivalents of IC1, as well as an increased reaction time. Compound 41 was synthesized 
to study the effect of having two sterically bulky t-Bu substituents present in the same 
substrate. The reaction required a slight increase in time. Nevertheless, isoxazole 42 was 
obtained in a very good yield (entry 22). The highly substituted aryl group of O-methyl 
oxime 43 also provided an excellent yield of isoxazole 44 (entry 23). Scaled up reactions, 
including multi-gram preparations of compounds 2, 4, and 44, did not affect the yield or 
outcome of the methodology. This is important to note in cases where one wishes to 
produce a large quantity of product for use in total synthesis or library generation. 
To demonstrate the value of the 4-iodoisoxazole products generated in this 
methodology, a number of reactions were carried out utilizing the iodine handle. We 
reasoned that we could approach the highly potent COX-2 inhibitor 4-(5-methyl-3-
phenyl-4-isoxazolyl)benzenesulfonamide (valdecoxib) (46)25 ' lg by a Suzuki-Miyaura 
cross-coupling of isoxazole 4 with the appropriate boronic acid ester.26 Using our 
isoxazole methodology to prepare 4 and a Suzuki-Miyaura coupling with the 
commercially available benzenesulfonamide-4-boronic acid pinacol ester, we were able 
to develop a very efficient route to valdecoxib (Scheme 3). Starting with ynone 45, O-
methyl oxime 3 was obtained in a 92% yield. Compound 3 was subjected to our IC1 
cyclization conditions to afford isoxazole 4 in nearly a quantitative yield. After several 
protocols were screened, Suzuki cross-coupling was best accomplished using 5 mol % 
PdCl2 catalyst, 1.4 equiv of KHC0 3 in 4:1 DMF:H 20 at 85 °C for 3 h to provide 
valdecoxib (46) in an 81% isolated yield, which constitutes a 74% overall yield from 
ynone 45. 
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Scheme 3 
0
 M'OMe 
Ph 
NH 2 OMe*HCI (J 2 I CI n ' 0 V " c h 3 
MeOH, Pyridine Ph CH2CI2 
4 5
 C H 3 M g S 0 4 3 CH3 9 9 O / O P H 4 1 
92% 
0 . . 0 
JL 
5% PdCI2 
1.4 K H C 0 3 
4:1 DMF:H 2 0 V 85 °C, 3 h 1 
SO 2NH 2 81% (74% overall) 
Ph | 
This synthetic route to valdecoxib provides a high overall yield and utilizes very mild 
reaction conditions compared to those previously reported. Earlier reports on the 
synthesis of valdecoxib required the use of strong bases, such as «-BuLi,lg'25'27 or the 
preparation of boronic acids in situ using air and water sensitive triisopropyl borate (i-
PrO)3B. These previous processes also suffer from poor overall yields. In addition to the 
aforementioned advantages of this synthesis, one may construct many analogues of 
valdecoxib by choosing from the wide array of commercially available starting materials 
that are appropriate for this methodology. 
Other palladium-catalyzed methodology has also proven useful for further elaboration 
of these iodoisoxazoles. For example, we were able to convert 4-iodo-3,5-
diphenylisoxazole (2) to the corresponding methyl ester by allowing 2 to react in the 
presence of catalytic amounts of Pd(OAc)2 plus a ferrocene ligand, carbon monoxide and 
methanol to afford methyl ester 47 in a 51% yield (eq 3).28 Reduction of compound 2 to 
3,5-diphenylisoxazole was an observed minor side product. In addition, we were able to 
convert 4-iodo-5-methyl-3-phenylisoxazole (4) to the corresponding phenethylamide by a 
12 
similar approach using a modified literature procedure.29 By allowing compound 4 to 
react in the presence of catalytic amounts of P d C h f P P h ^ , carbon monoxide and 2-
phenethyl amine, we were able to obtain 48 cleanly in good yield (eq 4). 
u ' ° y - P h 3% Pd(OAc)2, CO \ j T 
Ph 
Ph I 
2 
6% DPPF 
4:1 DMF:MeOH 
51% 
Ph y - O M e 
0 
47 
(3) 
5% PdCI2(PPh3)2, CO 
.0 
Ph I 
4 
DMF, PhCH 2CH 2NH 2 
79 % 
K CH3 NH (4) 
0 
48 
Ph 
Additionally, we were able to affect Heck and Sonogashira cross-couplings on 4-
iodo-5-methyl-3-phenylisoxazole (4) (Scheme 4). By allowing compound 4 to react 
under standard Sonogashira30 conditions in the presence of 1.2 equiv of phenyl acetylene, 
alkyne 49 was obtained in a good yield. Also, allowing compound 4 to react under 
Heck31 reaction conditions in the presence of /V-acryloylmorpholinc, provided the desired 
a,P-unsaturated amide 50 in excellent yield. 
Scheme 4 
1.2 Ph- -H 
1% PdCI2(PPh3)2 
2% Cul 
* 
Et2NH, DMF 
74% 
.0 
v r 
CH; 
Ph I 
°\ / — \ 
= r \ j > 
5% Pd(OAc)2 
1 
DMF, TBAC, N a 2 C 0 3 
93% 
^CH3 
Ph 
49 50 0 
Unfortunately, the palladium-catalyzed carbonylative cyclization32 of isoxazole 4 
failed and reduction of the starting material was the only observed product (eq 5). 
13 
64 
cat. Pd(PCy3)2, CO 
H- • 
DM F, CsPiv 
110 °C 0 
Conclusions 
3,4,5-Trisubstituted isoxazoles have been generated in high yields under mild 
reaction conditions by the electrophilic cyclization of Z-O-methyl oximes of 2-alkyn-l-
ones. Our methodology tolerates a wide variety of functional groups, including 
heterocycles and sterically cumbersome substrates. This process can be scaled up to 
provide multi-gram quantities of the desired product without sacrificing the yield or 
outcome of the methodology. One can construct libraries of highly substituted isoxazoles 
by invoking the appropriate starting materials in an orderly fashion. Furthermore, the 
iodine handle of the products provides an opportunity for further functionalization, as 
demonstrated by the ester and amide products 47 and 48, the Sonogashira product 49 and 
the Heck product 50. 
General. The 'H and 13C NMR spectra were recorded at 300 and 75.5 MHz or 400 and 
100 MHz respectively. Thin layer chromatography was performed using commercially 
prepared 60-mesh silica gel plates, and visualization was effected with short wavelength 
UV light (254 nm). All melting points are uncorrected. All reagents were used directly as 
obtained commercially unless otherwise noted. The following starting materials were 
made according to literature procedures: l,3-diphenylprop-2-yn-l-one, l-phenyl-2-
butyn-1 -one,33 4,4-dimethyl-1 -phenylpent-1 -yn-3-one, /V-mcthyl-3-
indolecarboxaldehyde,34 1 -phenylnon-1 -yn-3-one,35 2,2,6,6-tetramethylhept-4-yn-3-
one,36 l-(furan-2-yl)-3-phenylprop-2-yn-l-one37 and l-(4-chlorophenyl)-3-phenylprop-
Experimental Section 
14 
2-yn-l-one. Compounds 1-4, 7, 8, 21, 22, 25-28, 37 and 38 have been reported in our 
previous communication. 
General procedure for the preparation of alkynones from acyl chlorides. To a 25 
mL flask were added Cul (0.05 mmol), PdChfPPh .^ (0.01 mmol) and triethylamine (5 
mL). The flask was flushed with argon and the terminal acetylene (2.5 mmol) was added 
to the stirred suspension, followed by immediate dropwise addition of benzoyl chloride 
(3.25 mmol, 1.3 equiv). If the acid chloride is a solid, it was added as a THF solution. 
The resulting mixture was allowed to stir at room temperature overnight, water (5 mL) 
was added, and the aqueous layer was extracted with ethyl acetate. The organic layers 
were combined, dried and concentrated under reduced pressure. The residue was then 
purified by column chromatography on silica gel to afford the desired alkynone. 
l-Phenylhept-2-yn-l-one. Purification by flash chromatography (20:1 hexanes/EtOAc) 
afforded 381 mg (82%) of the product as a yellow oil with spectral properties identical to 
those previously reported.38 
Ethyl 4-(3-oxo-3-phenylprop-l-ynyl)benzoate. Purification by flash chromatography 
(20:1 hexanes/EtOAc) afforded 570 mg (86%) of the product as a pale yellow solid: mp 
54-56 °C; JH NMR (CDC13 400 MHz) 8 1.42 (t, J = 12 Hz, 3H), 4.39-4.44 (q, J = 7.0 
Hz, 2H), 7.54 (t, / = 7.6 Hz, 2H), 7.66 (t, / = 7.4 Hz, 1H), 7.74-7.76 (d, / = 8.4 Hz, 2H), 
8.1 (t, / = 8.2 Hz, 2H), 8.22-8.23 (d, / = 7.2 Hz, 2H); 13C NMR 8 14.5, 61.7, 88.7, 91.5, 
124.6, 128.9, 129.8 (2 carbons), 132.3, 133.0, 134.6, 136.8, 165.8, 177.9; HRMS Calcd 
for C I 8 H I 4 0 3 : 278.0943. Found: 278.0947. 
3-(4-Methoxyphenyl)-l-phenylprop-2-yn-l-one. Purification by flash chromatography 
(10:1 hexanes/EtOAc) afforded 470 mg (84%) of the product as a colorless solid: mp 
121-122 °C (lit. 81-85 °C)39 with spectral properties identical to those previously 
reported.40 
15 
l-Phenyl-3-(thiophen-2-yl)prop-2-yn-l-one. Purification by flash chromatography 
(20:1 hexanes/EtOAc) afforded 413 mg (78%) of the product as a yellow oil with spectral 
properties identical to those previously reported.41 
3-Phenyl-l-[4-(trifluoromethyl)phenyl]prop-2-yn-l-one. Purification by flash 
chromatography (20:1 hexanes/EtOAc) afforded 413 mg (79%) of the product as a 
colorless solid: mp 75-77 °C (lit. 70-72 °C) with spectral properties identical to those 
previously reported.42 
3-Phenyl-1 -otolylprop-2-yn-1 -one. Purification by flash chromatography (20:1 
hexanes/EtOAc) afforded 440 mg (80%) of the product as a pale yellow liquid with 
spectral properties identical to those previously reported.43 
4,4-Dimethyl-l-phenyl-2-pentyn-l-one. Purification by flash chromatography (40:1 
hexanes/EtOAc) afforded 428 mg (92%) of the product as a pale yellow oil with spectral 
properties identical to those previously reported.44 
l-(3,4,5-Trimethoxyphenyl)but-2-yn-l-one. A modified procedure was used. To a 25 
mL flask were added Cul (0.05 mmol), PdChfPPh.O2 (0.01 mmol) and triethylamine (5 
mL). The flask was flushed with argon and 3,4,5-trimethoxybenzoyl chloride (3.25 
mmol) in THF (5 mL) was added to the flask. The flask was flushed with propyne and a 
balloon of propyne gas was placed on the reaction flask. The resulting suspension was 
allowed to stir overnight. Purification by flash chromatography (4:1 hexanes/EtOAc) 
afforded 550 mg (94%) of the product as a pale yellow solid: mp 99-100 °C; 'H NMR 
(CDCI3 400 MHz) 8 2.17 (s, 3H), 3.94 (s, 9H), 7.41 (s, 2H); 13C NMR 8 4.6, 56.5, 61.2, 
79.1, 92.4, 107.1, 132.2, 143.6, 153.2, 177.2; HRMS Calcd for C I 3 H I 4 0 4 : 234.0892. 
Found: 234.0895. 
General procedure for the preparation of alkynones by the reaction of aldehydes 
with lithium acetylides, followed by oxidation with MnC>2. To a three-neck flask was 
added phenyl acetylene (11.2 mmol, 1.14 g) and anhydrous THF (7 mL). The stirred 
solution was cooled to 0 °C and flushed with argon. To the stirred solution, //-BuLi (2.5 
M in hexanes, 4.5 mL, 11.2 mmol) was added dropwise. The resulting mixture was 
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allowed to stir for 30 min at 0 °C. The aldehyde (9.3 mmol) in anhydrous THF (5 mL) 
was added dropwise and allowed to stir for 1 h at 0 °C. The solution was quenched with 
a satd aq NH4CI solution and extracted with ether. The organic layers were combined, 
dried and concentrated under reduced pressure. The residue was dissolved in chloroform 
(20 mL) and MnC>2 (27.9 mmol, 2.43 g) was added to the solution. The suspension was 
refluxed for 1 h, the solution was cooled and filtered through a pad of celite, and the 
filtrate was concentrated. The residue was purified by column chromatography on silica 
gel to afford the product. When the product was a solid, it was recrystallized from 
hexanes/EtOAc or hexanes/CH2Cl2 to afford spectroscopically pure product. 
l-(2,6-Dimethoxyphenyl)-3-phenylprop-2-yn-l-one. The residue was purified by 
column chromatography on silica gel to afford 2.37 g (96%) of the product as an orange 
oil: JH NMR (CDCI3 400 MHz) 8 3.83 (s, 6H), 6.57-6.59 (d, J = 8.4 Hz, 2H), 7.30-7.35 
(m, 3H), 7.38-7.42 (m, 1H), 7.52-7.55 (td, / = 6.8, 1.6 Hz, 2H); 13C NMR 8 56.1, 90.1, 
90.5, 104.3, 119.0, 120.6, 128.6, 130.5, 132.2, 133.0, 158.1, 178.5; HRMS Calcd for 
C17H14O3: 266.0943. Found 266.0947. 
3-Phenyl-l-(pyridin-3-yl)prop-2-yn-l-one. The residue was purified by column 
chromatography on silica gel to afford 1.19 g (62%) of the product as a brown solid: mp 
73-75 °C; JH NMR (CDCI3 400 MHz) 8 7.42-7.54 (m, 4H), 7.69-7.71 (dd, J = 8.2, 1.4 
Hz, 2H), 8.42-8.45 (m, 1H), 8.84-8.86 (dd, / = 4.8, 1.6 Hz, 1H), 9.45 (t, / = 0.8 Hz, 1H); 
13C NMR 8 86.4, 94.8, 119.6, 123.7, 128.9, 131.4, 132.3, 133.4, 136.3, 151.5, 154.3, 
176.5; HRMS Calcd for C14H9NO: 207.0684. Found: 207.0689. 
l-[4(Dimethylamino)phenyl]-3-phenylprop-2-yn-l-one. The residue was purified by 
column chromatography on silica gel to afford 2.13 g (92%) of the product as a bright 
yellow solid: mp 155-156 °C; JH NMR (CDCI3 400 MHz) 8 3.09 (s, 6H), 6.67-6.69 (d, J 
= 9.2 Hz, 2H), 7.40-7.45 (m, 3H), 7.65-7.67 (m, 2H), 8.10-8.12 (dd, / = 7.2, 2.0 Hz, 2H); 
13C NMR 8 40.3, 87.6, 91.3, 110.8, 121.0, 125.7, 128.7. 130.3, 132.2, 133.0, 154.3, 
176.2; HRMS Calcd for C17H15NO: 249.1154. Found: 249.1160. 
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l-(Benzo[<i][l,3]dioxol-5-yl)-3-phenylprop-2-yn-l-one. The residue was purified by 
flash chromatography on silica gel (1:1 hexanes:CHCl3) to afford 1.72 g (74%) of the 
product as a yellow oil with spectral properties identical to those previously reported.45 
General procedure for preparation of the O-methyl oximes. The alkynone (3.5 
mmol), methoxylamine hydrochloride (7.0 mmol, 579 mg), Na2SC>4 (7.0 mmol, 994 mg) 
and pyridine (1 mL) in methanol (10 mL) were stirred at room temperature. The addition 
of the co-solvent benzene was used in cases where the ynone showed poor solubility in 
methanol. In some cases the reaction required refluxing conditions to go to completion. 
The reaction was monitored by TLC until the reaction was complete. The mixture was 
diluted with water (25 mL) and extracted with EtOAc ( 3 x 5 mL). The organic layer was 
washed with brine, dried and evaporated. The residue was then purified by column 
chromatography on silica gel, unless otherwise stated, to afford the desired O-methyl 
oxime. 
(Z)-l-Phenylhept-2-yn-l-one O-methyl oxime (5). Purification by flash 
chromatography (40:1 hexanes/EtOAc) afforded 617 mg (82%) of the product as a pale 
yellow oil: JH NMR (CDC13 300 MHz) 8 0.93-0.98 (t, J = 7.3 Hz, 3H), 1.46-1.56 (m, 
2H), 1.63-1.68 (m, 2H), 2.52-2.57 (t, J = 8.2 Hz, 2H), 4.08 (s, 3H), 7.35-7.37 (m, 3H), 
7.82-7.85 (m, 2H); 13C NMR (CDC13) 8 13.8, 19.7, 22.3, 30.6, 71.7, 104.2, 126.7, 128.5, 
129.7, 134.1, 140.5; HRMS Calcd for C14H17NO: 215.1310. Found: 215.1314. 
(Z)-Ethyl 4-(3-oxo-3-phenylprop-l-ynyl)benzoate O-methyl oxime (9). Purification by 
flash chromatography (40:1 hexanes/EtOAc) afforded 904 mg (82%) of the product as a 
colorless oil: JH NMR (CDC13 300 MHz) 8 1.15 (s, 21H), 4.07 (s, 3H), 7.34-7.37 (m, 
3H), 7.84-7.88 (m, 2H); 13C NMR (CDC13) 8 11.4, 18.9, 63.2, 96.1, 105.6, 126.6, 128.6, 
129 .7 , 133 .8 , 140 .1 ; H R M S Calcd for C I 9 H I 7 N 0 3 : 3 0 7 . 1 2 0 8 . Found: 3 0 7 . 1 2 1 2 . 
(Z)-3-(4-Methoxyphenyl)-l-phenylprop-2-yn-l-one O-methyl oxime (11). 
Purification by flash chromatography (20:1 hexanes/EtOAc) afforded 677 mg (73%) of 
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the product as a pale yellow oil: JH NMR (CDCI3 300 MHz) 8 3.83 (s, 3H), 4.13 (s, 3H), 
6.88-6.91 (d, / = 8.9 Hz, 2H), 7.38-7.40 (m, 3H), 7.54-7.57 (d, / = 8.9 Hz, 2H) 7.90-7.93 
(m, 2H); 13C NMR (CDC13) 8 55.6, 63.3, 78.8, 101.9, 114.0, 114.3, 126.7, 128.6, 129.8, 
134 .0 , 134 .1 , 140 .4 , 160 .9 ; H R M S Calcd for C I 7 H I 5 N 0 2 : 2 6 5 . 1 1 0 3 . Found: 2 6 5 . 1 1 0 7 . 
(Z)-l-Phenyl-3-(thiophen-2-yl)prop-2-yn-l-one O-methyl oxime (13). Purification by 
flash chromatography (20:1 hexanes/EtOAc) afforded 523 mg (62%) of the product as a 
pale yellow oil: JH NMR (CDCI3 400 MHz) 8 4.13 (s, 3H), 7.02-7.05 (m, 1H), 7.38-7.41 
(m, 5H), 7.86-7.90 (m, 2H); 13C NMR (CDC13) 8 63.4, 83.7, 94.7, 121.7, 126.7, 127.6, 
128 .7 , 129 .6 , 130 .0 , 133 .6 , 134 .3 , 140 .0 ; H R M S Calcd for C M H U N O S : 2 4 1 . 0 5 6 1 . 
Found: 2 4 1 . 0 5 6 6 . 
(Z)-l-(4-Chlorophenyl)-3-phenylprop-2-yn-l-one O-methyl oxime (15). Purification 
by flash chromatography (6:1 hcxancs/CHCh) afforded 621 mg (69%) of the product as 
a colorless solid: mp 52-54 °C: JH NMR (CDCI3 400 MHz) 8 4.13 (s, 3H), 7.34-7.41 (m, 
5H), 7.59-7.62 (m, 2H), 7.83-7.86 (dt, J = 8.8, 2.0 Hz, 2H); 13C NMR (CDC13) 8 63.4, 
7 9 . 2 , 101 .7 , 121 .7 , 127 .9 , 128 .7 , 128 .8 , 129 .9 , 132 .2 , 132 .3 , 135 .8 , 139; H R M S Calcd for 
C I 6 H I 2 C 1 N O : 2 6 9 . 0 6 0 7 . Found: 2 6 9 . 0 6 1 1 . 
(Z)-3-Phenyl-l-[4-(trifhioromethyl)phenyl]prop-2-yn-l-one O-methyl oxime (17). 
Purification by flash chromatography (3:1 hexanes/ CHCI3) afforded 530 mg (50%) of 
the product as a tan solid: mp 41-43 °C; JH NMR (CDCI3 400 MHz) 8 4.17 (s, 3H), 7.36-
7.43 (m, 3H), 7.61-7.66 (m, 4H), 8.02-8.04 (dd, / = 8.0, 0.4 Hz, 2H); 13C NMR (CDC13) 
8 63.69, 79.10, 102.20, 121.65, 125.53, 125.57, 125.61, 125.65, 125.95, 126.95, 126.96, 
126.99, 128.75, 128.76, 128.77, 130.03, 132.39, 132.41, 132.42, 132.43, 137.15, 138.92 
(extra peaks due to C-F coupling); HRMS Calcd for C17H12F3NO: 303.0871. Found: 
303.0875. 
(Z)-l-[4(Dimethylamino)phenyl]-3-phenylprop-2-yn-l-one O-methyl oxime (19). 
Purification by flash chromatography (CHCI3) afforded 710 mg (73%) of the product as a 
yellow solid: mp 81-83 °C: 'HNMR (CDCI3 400 MHz) 8 2.99 (s, 6H), 4.10 (s, 3H), 6.69-
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6 . 7 1 (M, 2 H ) , 7 . 3 5 - 7 . 3 9 (M, 3 H ) , 7 . 6 0 - 7 . 6 2 (M, 2 H ) , 7 . 7 6 - 7 . 8 0 (M, 2 H ) ; 1 3 C N M R 
( C D C 1 3 ) 8 4 0 . 6 , 6 3 . 0 , 80 .2 , 100 .5 , 111 .9 , 122 .3 , 127 .8 , 128 .6 , 129 .5 , 132 .4 , 140 .3 , 151 .6 ; 
H R M S Calcd for C I 8 H I 8 N 2 0 : 2 7 8 . 1 4 1 9 . Found: 2 7 8 . 1 4 2 4 . 
(Z)-4-Phenylbut-3-yn-2-one O-methyl oxime (23). Purification by flash 
chromatography on basic alumina (hexanes) afforded 291 mg (48%) of the product as a 
colorless liquid: JH NMR (CDCI3 300 MHz) 8 2.13 (s, 3H), 3.97 (s, 3H), 7.34-7.36 (m, 
3H), 7.51-7.54 (m, 2H); 13C NMR (CDC13) 8 20.8, 62.5, 81.2, 99.3, 121.9, 128.6, 129.6, 
132.3, 137.8; HRMS Calcd for CnH„NO: 173.0841. Found: 173.0845. 
(Z)-3-Phenyl-l-otolylprop-2-yn-l-one O-methyl oxime (29). Purification by flash 
chromatography (20:1 hexanes/EtOAc) afforded 488 mg (56%) of the product as a 
yellow oil: JH NMR (CDCI3 400 MHz) 8 2.54 (s, 3H), 4.12 (s, 3H), 7.22-7.35 (m, 6H), 
7.52-7.55 (m, 3H); 13C NMR (CDC13) 8 21.1, 63.3, 80.9, 101.5, 122.0, 126.2, 128.7, 
129.4, 129.7, 129.8, 131.3, 132.3, 133.6, 137.1, 141.1; HRMS Calcd for C17H15NO: 
249.1154. Found: 249.1158. 
(Z)-l-(2,6-Dimethoxyphenyl)-3-phenylprop-2-yn-l-one O-methyl oxime (31). 
Purification by flash chromatography (CHCI3) afforded 630 mg (61%) of the product as a 
yellow solid: mp 144-146 °C: JH NMR (CDCI3 400 MHz) 8 3.83 (s, 6H), 4.11 (s, 3H), 
6.58-6.60 (d, / = 8.4 Hz, 2H), 7.27-7.33 (m, 4H), 7.49-7.51 (m, 2H); 13C NMR (CDC13) 8 
5 6 . 4 , 63 .1 , 81 .4 , 9 8 . 6 , 104 .4 , 112 .2 , 122 .4 , 128 .5 , 129 .3 , 131 .0 , 132 .4 , 135 .0 , 159 .0 ; 
H R M S Calcd for C I 8 H I 7 N 0 3 : 2 9 5 . 1 2 0 8 . Found: 2 9 5 . 1 2 1 2 . 
(Z)-l-(Benzo[<i][l,3]dioxol-5-yl)-3-phenylprop-2-yn-l-one O-methyl oxime (33). 
Purification by flash chromatography (1:1 hcxancs/CHCh) afforded 322 mg (53%) of the 
product as a pale yellow oil: JH NMR (CDCI3 400 MHz) 8 4.11 (s, 3H), 5.99 (s, 2H), 
6.82-6.84 (d, J = 8.0, 0.8 Hz, 1H), 7.36-7.45 (m, 5H), 7.59-7.61 (m, 2H); 13C NMR 
(CDC13) 8 63.1, 79.6, 101.1, 101.7, 106.4, 108.3, 121.8, 121.9, 128.1, 128.8, 132.4, 
139.6, 148.1, 149.3; HRMS Calcd for C17H13INO3: 279.0895. Found: 279.0900. 
(Z)-l-(Furan-2-yl)-3-phenylprop-2-yn-l-one O-methyl oxime (35). Purification by 
flash chromatography (20:1 hexanes/EtOAc) afforded 575 mg (73%) of the product as a 
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pale yellow oil: JH NMR (CDCI3 400 MHz) 8 4.14 (s, 3H), 6.47-6.48 (m, 1H), 6.82-6.83 
(d, J = 3.8 Hz, 1H), 7.34-7.40 (m, 3H), 7.49 (t, J = 0.8 Hz, 1H), 7.58-7.6 (m, 2H); 13C 
NMR (CDC13) 8 63.6, 78.2, 99.6, 111.8, 112.7, 121.6, 128.7, 130.0, 132.2, 132.4, 144.4, 
148.3; HRMS Calcd for C i 4 HnN0 2 : 225.0789. Found: 225.0793. 
(Z)-3-Phenyl-l-(pyridin-3-yl)prop-2-yn-l-one O-methyl oxime (39) Purification by 
flash chromatography (2:1 hexanes/EtOAc) afforded 471 mg (57%) of the product as an 
orange oil: JH NMR (CDCI3 300 MHz) 8 4.16 (s, 3H), 7.29-7.40 (m, 4H), 7.60-7.63 (m, 
2H) 8.16-8.20 (m, 1H), 8.62-8.64 (dd, J = 4.8, 1.6 Hz, 1H), 9.14-9.15 (dd, J = 2.3, 0.9 
Hz, 1H); 13C NMR (CDC13) 8 63.6, 78.7, 102.3, 121.6, 123.4, 128.7, 129.7, 130.1, 132.4, 
133.6 , 137.7 , 148 .3 , 150 .7 ; H R M S Calcd for C I 5 H I 2 N 2 0 : 2 3 6 . 0 9 5 0 . Found: 2 3 6 . 0 9 5 3 . 
(Z)-2,2,6,6-Tetramethylhept-4-yn-3-one O-methyl oxime (41). Purification by flash 
chromatography (40:1 hexanes/EtOAc) afforded 566 mg (83%) of the product as a pale 
yellow oil: JH NMR (CDCI3 400 MHz) 8 1.17 (s, 9H), 1.31 (s, 9H), 3.90 (s, 3H); 13C 
NMR (CDCI3) 8 28.35, 28.36, 30.9, 37.1, 62.3, 69.9, 110.9, 149.7; HRMS Calcd for 
CI2H2INO: 195.1623. Found: 195.1626. 
(Z)-l-(3,4,5-Trimethoxyphenyl)but-2-yn-l-one O-methyl oxime (43). Purification by 
flash chromatography (4:1 hexanes/EtOAc) afforded 838 mg (91%) of the product as a 
pale yellow solid: mp 99-100 °C; JH NMR (CDCI3 400 MHz) 8 2.21 (s, 3H), 3.87 (s, 
3H), 3.91 (s, 6H), 4.09 (s, 3H), 7.09 (s, 2H); 13C NMR (CDC13) 8 5.1, 56.3, 61.0, 63.1, 
70.8, 99.5, 103.9, 129.4, 139.6, 140.0, 153.1; HRMS Calcd for C14H17NO4: 263.1158. 
Found: 263.1162. 
General procedure for iodocyclization using IC1. To a stirred solution of the 
appropriate O-methyl oxime (0.25 mmol) in CH2C12 (2.5 mL) was added IC1 (1M in 
CH2C12, 1.2 equiv) dropwise and the solution was allowed to stir at room temperature. 
The reaction was monitored by TLC to establish completion. The excess IC1 was 
removed by washing with a satd aq soln of Na 2 S 2 0 3 . The aqueous solution was then 
extracted with CH2C12 ( 3 x 5 mL). The combined organic layers were dried over 
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anhydrous MgS04 and concentrated under a vacuum to yield the crude product, which 
was purified by flash chromatography on silica gel using hexanes/EtOAc or 
hexanes/CHCl3 as the eluent. 
5-Butyl-4-iodo-3-phenylisoxazole (6). The product was obtained as a pale yellow oil; 
JH NMR (CDCI3 300 MHz) 8 0.97 (t, / = 7.3 Hz, 3H), 1.37-1.49 (m, 2H), 1.72-1.80 (m, 
2H), 2.88 (t, J = 7.6 Hz, 2H), 7.47-7.49 (m, 3H), 7.76-7.78 (m, 2H); 13C NMR (CDC13) 8 
13.9, 22.4, 27.1, 29.5, 57.5, 128.7 (2 carbons), 129.0, 130.1, 162.9, 175.0; HRMS Calcd 
for C13H14INO: 327.0120. Found: 327.0126. 
Ethyl 4-(4-iodo-3-phenylisoxazol-5-yl)benzoate (10). The product was obtained as a 
colorless solid: mp 151-153 °C; JH NMR (CDCI3 300 MHz) 8 1.43 (t, J = 1.2 Hz, 3H), 
4.39-4.46 (q, J =1.1 Hz, 2H), 7.51-7.54 (m, 3H) 7.76-7.80 (m, 2H), 8.16-8.22 (m, 4H); 
13C NMR (CDC13) 8 14.6, 57.8, 61.6, 127.8, 128.7, 128.8, 129.2, 130.1, 130.4, 131.2, 
132.4, 165.2, 166.0, 168.0; HRMS Calcd for C I 8 H I 4 I N 0 3 : 419.0019. Found: 419.0026. 
4-Iodo-5-(4-methoxyphenyl)-3-phenylisoxazole (12). The product was obtained as a 
colorless solid: mp 153-155 °C; JH NMR (CDCI3 300 MHz) 8 3.88 (s, 3H), 7.02-7.05 (m, 
2H), 7.47-7.52 (m, 3H), 7.76-7.80 (m, 2H), 8.03-8.06 (dd, / = 9.1, 0.8 Hz, 2H); 13C NMR 
(CDC13) 8 54.9, 55.7, 114.4, 120.0, 128.7, 129.1, 129.2, 129.6, 130.2, 161.6, 164.9, 
1 6 9 . 1 ; H R M S Calcd for C I 6 H I 2 I N 0 2 : 3 7 6 . 9 9 1 3 . Found: 3 7 6 . 9 9 1 8 . 
4-Iodo-3-phenyl-5-(thiophen-2-yl)isoxazole (14). The product was obtained as a 
yellow solid: mp 118-120 °C; JH NMR (CDCI3 300 MHz) 8 7.20-7.23 (dt, J = 3.8, 1.2 
Hz, 1H), 7.49-7.54 (m, 3H), 7.56-7.81 (dd, / = 6.8, 1.2 Hz, 1H), 7.76-7.81 (m, 2H), 7.98-
8.00 (dd, J = 3.8, 1.2 Hz, 1H); 13C NMR (CDC13) 8 54.9, 55.7, 114.4, 120.0, 128.7, 
129.1, 129.2, 129.6, 130.2, 161.6, 164.9, 169.1; HRMS Calcd for Ci3H8INOS: 352.9371. 
Found: 352.9376. 
3-(4-Chlorophenyl)-4-iodo-5-phenylisoxazole (16). The product was obtained as a 
colorless solid: mp 165-167 °C; JH NMR (CDCI3 400 MHz) 8 7.48-7.53 (m, 5H), 7.72-
7.76 (td, / = 8.8, 2.2 Hz, 2H), 8.04-8.07 (m, 2H); 13C NMR (CDC13) 8 56.0, 127.3, 127.4, 
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128.0, 129.0, 129.1, 130.5, 131.1, 136.6, 164.0; HRMS Calcd for C15H9CIINO: 
380.9417. Found: 380.9425. 
4-Iodo-5-phenyl-3-[4-(trifluoromethyl)phenyl]isoxazole (18). The product was 
obtained as a pale yellow solid: mp 174-175 °C; JH NMR (CDCI3 400 MHz) 8 7.52-7.55 
(m, 3H), 7.77-7.79 (d, / = 8.0 Hz, 2H), 7.92-7.94 (d, / = 8.4 Hz, 2H), 8.06-8.08 (m, 2H); 
13C NMR (CDCI3) 8 55.72, 125.74, 125.78, 125.81, 125.85, 127.18, 128.01, 128.02, 
1 2 8 . 0 3 , 1 2 9 . 0 5 , 1 2 9 . 0 6 , 1 2 9 . 6 5 , 1 2 9 . 6 7 , 1 3 1 . 1 9 , 163 .87 , 1 6 9 . 7 3 (extra peaks due to C-F 
coupling); H R M S Calcd for C I 6 H 9 F 3 I N O : 4 1 6 . 9 6 8 1 . Found: 4 1 4 . 9 6 8 6 . 
4-Iodo-3-[4(dimethylamino)phenyl]-5-phenylisoxazole (20). The product was obtained 
as a pale yellow solid: mp 148-149 °C; JH NMR (CDCI3 400 MHz) 8 3.04 (s, 6H), 6.80-
6.82 (d, / = 8.8 Hz, 2H), 7.49-7.53 (m, 3H), 7.72-7.74 (td, / = 7.0, 2.1 Hz, 2H), 8.05-8.07 
(m, 2H); 13C NMR (CDC13) 8 40.5, 56.6, 111.9, 127.7, 128.0, 128.8, 128.9, 130.0, 130.7, 
151 .5 , 164 .6 , 168 .7 ; H R M S for C I 7 H I 5 I N 2 0 : 3 9 0 . 0 2 2 9 . Found: 3 9 0 . 0 2 3 4 . 
4-Iodo-3-methyl-5-phenylisoxazole (24). The product was isolated as a pale yellow oily 
solid: mp 31-34 °C; JH NMR (CDCI3 300 MHz) 8 2.35 (s, 3H), 7.48-7.50 (m, 3H), 8.01-
8.05 (m, 2H); 13C NMR (CDC13) 8 12.8, 58.0, 127.4, 127.5, 128.9, 130.7, 163.2, 167.5; 
H R M S for C I O H 8 I N O : 2 8 4 . 9 6 5 1 . Found: 2 8 4 . 9 6 5 4 . 
4-1 odo-5-ph en yl-3-otolyl isoxazole (30). The product was obtained as a pale yellow 
solid: mp 84-86 °C; JH NMR (CDCI3 400 MHz) 8 2.31 (s, 3H), 7.28-7.34 (m, 4H), 7.38-
7.41 (m, 1H), 7.50-7.54 (m, 3H), 8.12-8.13 (m, 2H); 13C NMR (CDC13) 8 20.3, 58.8, 
126 .0 , 127 .4 , 127 .7 , 128 .7 , 129 .0 , 130 .2 , 130 .4 , 130 .7 , 131 .0 , 137 .7 , 166 .9 , 168 .2 ; H R M S 
Calcd for C I 6 H I 2 I N O : 3 6 0 . 9 9 6 4 . Found: 3 6 0 . 9 9 6 8 . 
3-(2,6-Dimethoxyphenyl)-4-iodo-5-phenylisoxazole (32). The product was obtained as 
a yellow solid: mp 141-143 °C; JH NMR (CDC13 400 MHz) 8 3.78 (s, 6H), 6.65-6.67 (d, 
J = 8.4 Hz, 2H), 7.42 (t, / = 8.4 Hz, 1H), 7.47-7.52 (m, 2H), 8.12-8.15 (m, 2H); 13CNMR 
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( C D C 1 3 ) 8 5 6 . 3 , 6 0 . 7 , 104 .7 , 106 .7 , 127 .6 , 127 .8 , 128 .9 , 130 .6 , 132 .1 , 159 .1 , 162 .6 , 
167 .5 ; H R M S Calcd for C I 7 H I 4 I N 0 3 : 4 0 7 . 0 0 1 9 . Found: 4 0 7 . 0 0 2 6 . 
3-(Benzo[d][l,3]dioxol-5-yl)-4-iodo-5-phenylisoxazole (34). The product was obtained 
as a colorless solid: mp 126-128 °C; JH NMR (CDC13 400 MHz) 8 6.05 (s, 2H), 6.93-
6.95 (dd / = 8.0, 0.4 Hz, 1H), 7.25-7.26 (m, 1H), 7.30-7.33 (dd, J = 8.2, 1.8 Hz, 1H), 
7.51-7.54 (m, 3H), 8.04-8.06 (m, 2H); 13C NMR (CDC13) 8 56.4, 101.8, 108.7, 109.5, 
122 .5 , 123 .6 , 127 .5 , 128 .0 , 129 .0 , 130 .9 , 148 .0 , 149 .4 , 164 .5 , 169 .2 ; H R M S Calcd for 
C I 6 H I O I N 0 3 : 3 9 0 . 9 7 0 5 . Found: 3 9 0 . 9 7 1 2 . 
3-(Furan-2-yl)-4-iodo-5-phenylisoxazole (36). The product was obtained as an orange 
solid: mp 50-53 °C; JH NMR (CDC13 400 MHz) 8 6.37-6.38 (d, J = 3.6 Hz, 1H), 7.34-
7.35 (d, J = 3.6 Hz, 1H), 7.52-7.54 (m, 4H), 8.02-8.05 (m, 2H); 13C NMR (CDC13) 8 
5 2 . 3 , 108 .4 , 114 .9 , 126 .9 , 128 .1 , 129 .0 , 131 .2 , 139 .5 , 142 .9 , 155 .7 , 169 .6 ; H R M S Calcd 
for C I 3 H 8 I N 0 2 : 3 3 6 . 9 6 0 0 . Found: 3 3 6 3 . 9 6 0 6 . 
3-(4-Iodo-5-phenylisoxazol-3-yl)pyridine (40). The product was obtained as a pale 
yellow solid: mp 144-146 °C; JH NMR (CDC13 300 MHz) 8 7.44-7.49 (m, 1H), 7.54-7.56 
(m, 3H), 8.06-8.15 (m, 3H), 8.76-8.77 (dd, / = 4.9, 1.6 Hz, 1H), 9.07 (d, / = 1.5 Hz, 1H); 
13C NMR (CDC13) 8 55.8, 123.5, 125.3, 127.1, 128.0, 129.1, 131.2, 136.6, 149.8, 151.3, 
162.7, 169.7; HRMS Calcd for Ci 4H 9 IN 20: 347.9760. Found: 347.9765. 
3,5-Di-/f/7-butyl-4-iodoisoxazole (42). The product was obtained as a colorless solid: 
mp 106-108 °C; JH NMR (CDC13 400 MHz) 8 1.47 (s, 9H), 1.49 (s, 9H); 13C NMR 
(CDC13) 8 28.4, 28.5, 33.8, 34.6, 50.6, 169.4, 177.6; HRMS Calcd for CnHiglNO: 
307.0433. Found: 307.0437. 
4-Iodo-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole (44). The product was obtained 
as a colorless solid: mp 148-150 °C; JH NMR (CDC13 400 MHz) 8 2.56 (s, 3H), 3.91 (s, 
3H), 3.93 (s, 6H), 7.06 (s, 2H) ; 13C NMR (CDC13) 8 13.2, 56.4, 57.9, 61.1, 105.8, 124.0, 
139.6, 153.4, 162.4, 171.7; H R M S Calcd for C I 3 H I 4 I N 0 4 : 374.9968. Found: 374.9971. 
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Procedure for the Suzuki-Miyaura cross-coupling to form 4-(5-methyl-3-phenyl-4-
isoxazolyl)benzenesulfonamide (valdecoxib) (46). To a 4-dram vial was added 4-iodo-
5-methyl-3-phenylisoxazole (0.25 mmol, 71 mg), benzenesulfonamide-4-boronic acid 
pinacol ester (0.35 mmol, 99 mg), KHC0 3 (0.35 mmol, 35 mg) and PdCl2 (0.0125 mmol, 
2.2 mg) in 4:1 DMF:H 20 (2.5 mL). The solution was stirred for 5 min at room 
temperature and flushed with argon and then heated to 80 °C for 2 h. The product was 
concentrated under reduced pressure and isolated by column chromatography on silica 
gel (2:3 hexanes/EtOAc) to afford 4-(5-methyl-3-phenyl-4-
isoxazolyl)benzenesulfonamide (valdecoxib) (46) as a colorless solid: mp 160-162 °C 
(lit.25a 155-157 °C, lit.46 172-173 °C) with spectral properties identical to those previously 
reported.25''46 
Procedure for the palladium-catalyzed carbonylative esterification to form methyl 
3,5-diphenylisoxazole-4-carboxylate (47). To a 4-dram vial was added 4-iodo-3,5-
diphenylisoxazole (0.44 mmol, 152 mg), Pd(OAc)2 (0.0132 mmol, 2.8 mg), DPPF (0.028 
mmol, 14.8 mg) in 4:1 DMF:H 20 (1.25 mL). The reaction mixture was evacuated and 
back-filled with carbon monoxide three times. A balloon of carbon monoxide was 
attached to the vial, which was heated to 55 °C for 18 h. The solution was allowed to 
cool and was diluted with ethyl acetate (20 mL). The organic layer was washed with 
water and brine, dried and concentrated. The residue was purified by column 
chromatography using 10:1 hexanes/EtOAc to afford the compound as a colorless solid: 
mp 94-96 °C; JH NMR (CDC13 400 MHz) 8 3.72 (s, 3H), 7.48-7.54 (m, 6H), 7.65-7.67 
(m, 2H), 7.67-7.93 (dd, J = 7.8, 1.8 Hz, 2H); 13C NMR (CDC13) 8 52.2, 108.2, 127.0, 
128 .5 (2 peaks), 128 .7 , 128 .8 , 128 .9 , 129 .1 , 130 .1 , 131 .5 , 163 .1 , 163 .2 , 172 .7 ; H R M S 
Calcd for C I 7 H I 3 N 0 3 : 2 7 9 . 0 8 9 5 . Found: 2 7 9 . 0 8 9 9 . 
Procedure for the palladium-catalyzed carbonylative amidation to form N-
phenethyl-5-methyl-3-phenylisoxazole-4-carboxamide (48). A modified literature 
procedure was used. To a 4-dram vial was added 4-iodo-5-methyl-3-phenylisoxazole 
(0.17 mmol, 48 mg), PdCl2(PPh3)2 (0.0085 mmol, 6 mg), 2-phenethyl amine (0.25 mL) 
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in DMF (1 mL). The reaction mixture was evacuated and back-filled with carbon 
monoxide three times. A balloon of carbon monoxide was placed on the vial, which was 
heated to 80 °C for 18 h. The solution was allowed to cool and was diluted with ethyl 
acetate (20 mL). The organic layer was washed with water and brine, dried and 
concentrated. The residue was purified by column chromatography using 4:1 
hexanes/EtOAc to afford the compound as a colorless solid: mp 145-146 °C; JH NMR 
(CDCls 400 MHz) 8 1.51 (s, 3H), 2.71 (t, / = 6.8 Hz, 2H), 3.51-3.56 (q, / = 6.8 Hz, 2H), 
5.41 (br s, 1H), 6.96-6.98 (dd, J = 12, 1.6 Hz, 2H), 7.20-7.26 (m, 3H), 7.39-7.50 (m, 
5H); 13C NMR (CDC13) 8 13.2, 35.2, 40.7, 111.2, 126.8, 128.3, 128.7, 128.9, 129.1, 
129.3, 130.6, 138.5, 160.3, 161.7, 174.3; HRMS Calcd for C19H18N2O2: 306.1368. 
Found: 306.1374. 
Procedure for the Sonogashira coupling to form 5-methyl-3-phenyl-4-
(phenylethynyl)isoxazole (49). To a 4-dram vial was added 4-iodo-5-methyl-3-
phenylisoxazole (0.5 mmol, 142 mg), phenyl acetylene (0.6 mmol, 61.2 mg), 
PdCl2(PPh3)2 (0.005 mmol, 3.5 mg), Cul ( 0.01 mmol, 1.9 mg), DMF (1.5 mL) and 
Et2NH (1.85 mL). The solution was stirred for 5 minutes at room temperature and 
flushed with argon and then heated to 50 °C for 6 h. The solution was allowed to cool and 
was diluted with ethyl acetate (20 mL). The organic layer was washed with water and 
brine, dried and concentrated. The residue was purified by column chromatography 
using 10:1 hexanes/EtOAc to afford the compound as a brown solid: mp 98-100 °C; JH 
NMR (CDCI3 400 MHz) 8 2.58 (s, 3H), 7.35 (t, J = 4.2 Hz, 3H), 7.46-7.51 (m, 5 H), 
8.09-8.12 (dd, J = 12, 4.2 Hz, 2H); 13C NMR (CDC13) 8 12.3, 78.4, 95.1, 99.5, 122.9, 
127 .7 , 128 .6 , 128 .7 , 128 .8 , 130 .3 , 131 .6 , 161 .3 , 173 .1 ; H R M S Calcd for C I 8 H I 3 N O : 
2 5 9 . 0 9 9 7 . Found: 2 5 9 . 1 0 0 1 . 
Procedure for the Heck coupling to form (£')-3-(5-methyl-3-phenylisoxazol-4-yl)-l-
morpholinoprop-2-en-l-one (50). To a 4-dram vial was added 4-iodo-5-methyl-3-
phenylisoxazole (0.25 mmol, 71 mg), /V-acryloylmorpholinc (1.0 mmol, 141 mg), 
PdOAc2 (0.0132 mmol, 2.8 mg), TBAC (0.25 mmol, 69 mg), Na 2 C0 3 (0.625 mmol, 66 
26 
mg) and DMF (1 mL), which was then heated to 85 °C for 24 h. The solution was 
allowed to cool and was diluted with ethyl acetate (20 mL). The organic layer was 
washed with water and brine, dried and concentrated. The residue was purified by 
column chromatography using 1:1 hexanes/EtOAc to afford the compound as a yellow 
oil; JH NMR (CDC13 400 MHz) 8 2.59 (s, 3H), 3.27 (br s, 2H), 3.60 (br s, 2H), 3.68 (br s, 
4H), 6.28-6.33 (d, J = 15.3 Hz, 1H), 7.46-7.51 (m, 4H), 7.53-7.58 (m, 2H); 13C NMR 
(CDC13) 8 12.3, 42.5, 46.0, 66.8, 111.7, 118.5, 128.9, 129.0, 129.2, 130.0, 130.8, 161.8, 
165.1, 169.3; HRMS Calcd for C17H18N2O3: 298.1317. Found: 298.1321. 
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CHAPTER 2. Solution Phase Synthesis of a Diverse Library of Highly Substituted 
Isoxazoles 
Based on a paper submitted to the Journal of Combinatorial Chemistry 
Jesse P. Waldo,^ Saurabh Mehta,' Benjamin Neuenswander,* Gerald H. Lushington,* 
Richard C. Larock, 
Department of Chemistry, Iowa State University, Ames, IA 50011, and the University of 
Kansas NIH Center of Excellence in Chemical Methodologies and Library Development, 
Lawrence, Kansas 66047 
Abstract 
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The iodocyclization of O-methyloximes of 2-alkyn-l-ones affords 4-iodoisoxazoles, 
which undergo various palladium-catalyzed reactions to yield 3,4,5-trisubstituted 
isoxazoles. The palladium-catalyzed processes have been adapted to parallel synthesis 
utilizing commercially available boronic acid, acetylene, styrene and amine sublibraries. 
Accordingly, a diverse 51-member library of 3,4,5-trisubstituted isoxazoles has been 
generated. 
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Introduction 
Low molecular weight nitrogen-containing heterocycles are securing their place 
among the most highly recognized pharmacophores.1 Among them, the isoxazole 
scaffold is of particular interest, since it is known to exhibit a broad range of biological 
activity.2 Isoxazoles have also had a significant impact as intermediates in the synthesis 
of various natural products.3 Consequently, isoxazoles are prized as potential drug 
candidates and biological probes. There have been several reports relating to the 
synthesis of functionalized isoxazoles by combinatorial techniques,4 although the use of 
4-iodoisoxazoles as the key intermediate for library generation is thus far unreported. 
Many of the reported libraries have been limited to the preparation of disubstituted 
isoxazoles. Additionally, functionalization at the C4 position of the isoxazole core, with 
respect to library generation, has previously met with limited success. Until recently, 
restricted access to 4-haloisoxazoles by a route involving mild reaction conditions, has 
prevented them from being an important intermediate for library generation. The 
halogenation of isoxazoles at the C4 position generally requires the use of high 
temperatures and harsh acids.5 
Previous work in our laboratory has demonstrated that the electrophilic cyclization of 
Z-2-alkyn-l-one O-methyl oximes (1), using IC1, provides a mild and selective route to 
3,5-disubstituted-4-iodoisoxazoles (2) (Scheme l).6 The requisite 2-alkyn-l-ones (3) 
required for this methodology can be readily synthesized by established chemistry 
utilizing commercially available starting materials (Scheme 2).7 
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We have previously demonstrated the significance of this methodology by reporting 
individual examples of Sonogashira,8 Suzuki-Miyaura,9 Heck,10 and carbonylative 
amidation cross-coupling reactions,11 which provide the corresponding 3,4,5-
trisubstituted isoxazoles in good yields, including the highly potent COX-2 inhibitor 
valdecoxib (4) (Scheme 3).12 With optimized conditions in hand for each of these 
processes, we wished to adapt these reactions to library generation. Herein, we report the 
success of this objective. 
Scheme 3 
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Results and Discussion 
Our 4-iodoisoxazole synthesis has previously been demonstrated to tolerate, but not 
be limited to, alkyl and aryl groups at the R or R2 positions of the isoxazole core. 
During our initial study, we found that employing of Z-O-methyloximes was essential to 
the success of our methodology, since the corresponding .E-O-methyloximes proved 
ineffective in the electrophilic cyclization process. Since bulky groups at the R1 position 
provided the highest yields of the necessary Z-O-methyloximes required for our 4-
iodoisoxazole synthesis, R1 was restricted to aryl groups for library generation. Since R2 
substituents had less of an effect on the outcome of our methodology, there was no need 
to adhere to strict guidelines when choosing R2. Accordingly, we chose a subset of 
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various 4-iodoisoxazoles which could be synthesized from readily available starting 
materials (Figure 1). 
1(3} 1{4} 
Figure 1. 4-Iodoisoxazole sublibrary. 
Isoxazoles 1(1-4} were selected because their synthesis is straightforward and the 
oxygen heteroatoms provide desired polarity in the resulting library. 
The alkyne sublibrary, used for Sonogashira cross-coupling, was chosen based on 
commercially available, heteroatom-containing acetylenes that could provide hydrogen 
bond donors and/or acceptors (Figure 2). 
A small styrene sublibrary for Heck cross-coupling was chosen to demonstrate 
vinylic functionalization. However, only a few functionally diverse styrenes were 
available from commercial sources (Figure 3). We avoided the use of better Michael 
acceptors, such as acrylates or acrylonitriles, since the resulting Heck products would 
also be excellent Michael acceptors and thus undesirable for subsequent pharmaceutical 
applications. 
38 
o 
N-
O 
2{1} 
2{4} 
o < ; 
2(7} 
x
 -N e x ? 
2{2} 2{3} 
MeHN 
2{8} 2{9} 
Figure 2. Terminal acetylene sublibrary. 
/ / 
3(3} 3{4} 
Figure 3. Styrene sublibrary. 
Commercially available boronic acids, for Suzuki-Miyaura cross-coupling, were 
chosen based on their diverse functionality (Figure 4). 5-Indoleboronic acid 4(1} was 
chosen because the resulting cross-coupling products could generate druglike scaffolds 
with potentially positive physiochemical properties. Arylboronic acids 4(3} and 4(6} 
were chosen because the resulting cross-coupling products would contain fluorine atoms. 
Organofluorine compounds are of considerable interest because of their versatile 
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applications in industry and medicine.13 Other boronic acids within the sublibrary were 
chosen because they contain heterocycles and polar functionality that would incorporate 
druglike moieties in the resulting cross-coupling products. 
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Figure 4. Boronic acid sublibrary. 
Primary amines were chosen as a sublibrary for palladium-catalyzed amide 
formation, because the resulting nitrogen-containing products would enable us to make 
compounds with potentially attractive druglike features, including molecular weight, 
solubility and molecular polarizability. Amines 5(1-11} were chosen to represent 
compounds found in natural products and derivatives of substances known to possess 
biological activity (Figure 5). 
To ease the transition from our isoxazole methodology to library generation, we 
wished to preserve the protocols we had originally employed for the cross-coupling of 4-
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iodoisoxazoles with terminal acetylenes, styrenes, boronic acids and amines.6b With these 
preliminary findings, we proceeded to prepare a diverse library of 3,4,5-trisubstituted 
isoxazoles as outlined in Scheme 3. The crude products were analyzed by LC/MS, 
followed by purification by preparative HPLC. 
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Figure 5. Primary amine sublibrary. 
Table 1. Library Data for Compounds 6(1-13} 
NH, 
MeO oMe 
6{1-9} 6(10-13} 
compound R yielda (%) purityb (%) 
6(1} 2-ethylphthalimide 40 94 
6(2} 2-pyridinyl 30 97 
6(3} 1 -amino-1 -cyclohexyl 42 95 
6(4} 4-H2NC6H4 62 99 
6(5} 1 -methyl-1 //-imidazo-5 -yl 83 95 
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6(6} CH2OH 67 97 
6(7} 1-hydroxy-1-eye lohexyl 59 99 
6(8} 3-thiophenyl 75 97 
6(9} 2-(iV-methyl)propyl 50 97 
6(10} 4-AcOC6H4 60 94 
6(11} 4-H2NC6H4 67 93 
6(12} 3-0 2NC 6H 4 73 95 
6(13} 4-H02CC6H4 8 87 
a
 Isolated yield after preparative HPLC. 
b UV purities determined at 214 nm after preparative HPLC. 
The results of the library synthesis are summarized in Tables 1-3. The crude products 
were subjected to preparative HPLC and purities in the range of 87-100% were achieved 
after purification. Most of the reactions proceeded well, with the exception of the Heck 
reaction of 4-vinylbenzoic acid. In the Suzuki-Miyaura reaction of boronic acids 4(5} 
and 4(7}, poor or no yield of the desired product was observed. Palladium-catalyzed 
amide formation using carbon monoxide and primary amines proceeded smoothly and 
provided the corresponding amides in satisfactory yields with high purities. Out of a total 
of 54 palladium-catalyzed processes attempted, only three failed completely. 
Table 2. Library Data for Compounds 6(14-45} 
6(14-20} 6(21-27} 6(28-35} 6(36-43} 
compound Ar yielda (%) purity" (%) 
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Isolated yield after preparative HPLC. 
'UV purities determined at 214 nm after preparative HPLC. 
Table 2. Library Data for Compounds 6(44-54} 
compound R yielda (%) purity0 (%) 
6(44} 
6(45} 
6(46} 
6(47} 
(CH2)2OH 
( C H 2 ) 3 - N O 
( C H 2 ) 3 - N ^ N 
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(CH2)2Ph 
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< C K > 
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H 
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6(51} 4 0 " 
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6(53} C H 2 ^ O n ^ C H 3 80 99 
O 
-N' 
6 ( 5 4 ) ( C H 2 ) 3 ~ X 69 99 
1
 Isolated yield after preparative HPLC. 
'UV purities determined at 214 nm after preparative HPLC. 
Because of our interest in synthesizing heterocycles for use in high-throughput 
screening projects, an in silico evaluation of library members was carried out to 
determine their agreement with Lipinski's14 "rule of five" and Veber's rules.15 Molecular 
weight, clog P, number of hydrogen bond donors and acceptors, and the number of 
rotatable bonds were either specified or calculated for each of the library members using 
the SYBYL16 program (Table 4). Most of the isoxazole library members were highly 
Lipinski compliant. In fact, 96% of the library members are entirely compliant with 
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Lipinski rules and only compound 6(31} had multiple violations, including molecular 
weight and clog P. 
Table 4. In silico parameters for gauging oral availability / drug-likeness 
Mean St. Dev. Range 
Clog P 3.13 1.40 -0.01-6.87 
Mol. Weight 380.8 46.4 292.3 -518.5 
H-Bond Acceptors 6.00 1.13 3 - 9 
H-Bond Donors 0.92 0.73 0 - 2 
Rotatable Bonds 5.14 1.67 2 - 8 
Conclusion 
In conclusion, the preparation and subsequent palladium-catalyzed reactions of 4-
iodoisoxazoles with various cross-coupling partners has allowed for simple construction 
of a 51-member library of 3,4,5-trisubstituted isoxazoles. The average yield of the library 
was 49% and the average purity after preparative HPLC was 96%. 
Experimental 
General. The lU and 13C NMR spectra were recorded at 300 and 75.5 MHz or 400 and 
100 MHz respectively. Chemical shifts are reported in parts per million (ppm) downfield 
from TMS. Thin layer chromatography was performed using commercially prepared 60-
mesh silica gel plates, and visualization was effected with short wavelength UV light 
(254 nm). All reagents were used directly as obtained commercially unless otherwise 
noted. THF and CH2CI2 were distilled from sodium/benzophenone or CaH2 respectively, 
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under an atmosphere of argon prior to use. All glassware and stirring bars were oven 
dried prior to use. 
HPLC analysis was carried out using an XBridge MS C-18 column (5 |_iM, 4.6 x 150 
mm) with gradient elution (5% CH3CN to 100% CH3CN) on a Waters Alliance 2795 
Separation Module with a Waters 2996 Photodiode Array UV detector and a 
Waters/Micromass LCT Premier (TOF) detector. Purification was carried out using an 
XBridge MS C-18 column (5 (iM, 19 x 150 mm) with gradient elution (a narrow CH3CN 
gradient was chosen based on the targets retention time from LCMS analysis of the crude 
sample) on a Mass Directed Fractionation instrument with a Waters 2767 sample 
manager, a Waters 2525 HPLC pump, a Waters 2487 dual X absorbance detector, and a 
Waters/Micromass ZQ (quadrupole) detector. Fractions were triggered using an MS 
and/or UV threshold determined by an LCMS analysis of the crude sample. One of three 
aqueous mobile phases were chosen for both analysis and purification to promote the 
targets neutral state (water, 0.05% formic acid or pH 9.8 ImM HC02NH4) . High 
resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Premier 
(TOF instrument). 
Iodoisoxazoles 1(1} and 1 {4} were prepared by procedures described earlier.6b 
Procedure for the preparation of l-(benzo[d][l,3]dioxol-5-yl)-3-(thiophen-3-yl)prop-
2-yn-l-one. To a 100 mL flask were added Cul (0.22 mmol, 41.9 mg), PdCl2(PPh3)2 
(0.12 mmol, 84.2 mg) and triethylamine (40 mL). The flask was flushed with argon and 
3-ethynylthiophene (11.0 mmol, 1.19 g, 1.08 mL) was added to the stirred suspension, 
followed by immediate dropwise addition of piperonyloyl chloride (10.8 mmol, 3.0 g) as 
a solution in THF (8 mL). The resulting mixture was allowed to stir at room temperature 
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overnight, filtered through a plug of silica gel, and concentrated under reduced pressure. 
Purification by column chromatography on silica gel using (4:1 hexanes/EtOAc) afforded 
2.49 g (90%) of the product: JH NMR (CDC13, 300 MHz) 8 6.07 (s, 2H), 6.88-6.90 (d, J 
= 8.2 Hz, 1H), 7.28-7.30 (td, J = 0.6, 5.0 Hz, 1H), 7.35-7.37 (dd, J = 2.9, 5.0 Hz, 1H), 
7.57-7.58 (d, J = 1.7 Hz, 1H), 7.81-7.87 (m, 2H); 13C NMR 8 87.12, 87.88, 102.26, 
108.11, 108.34, 119.52, 126.36, 127.28, 130.32, 132.11, 133.77, 148.32, 152.96, 176.18; 
HRMS Calcd for C i 4 H 8 0 3 S: 256.0194. Found: 256.0195. 
Procedure for the preparat ion of l-(benzo[d][l,3]dioxol-5-yl)but-2-yn-l-one. A 
modified procedure was used. To a 100 mL flask were added Cul (0.43 mmol, 81.9 mg), 
PdCl2(PPh3)2 (0.22 mmol, 154.4 mg) and triethylamine (50 mL). The flask was flushed 
with argon and piperonyloyl chloride (21.7 mmol, 4.0 g) as a solution in THF (10 mL) 
was added to the flask. The flask was flushed with propyne and a balloon of propyne gas 
was placed on the reaction flask. The resulting suspension was allowed to stir overnight, 
filtered through a plug of silica gel, and concentrated under reduced pressure. Purification 
by flash chromatography (4:1 hexanes/EtOAc) afforded 3.72 g (91%) of the product: 1H 
NMR (CDC13, 400 MHz) 8 2.14 (s, 3H), 6.06 (s, 2H), 6.85-6.87 (d, / = 8.1 Hz, 1H), 
7.53-7.54 (d, J = 1.7 Hz, 1H), 7.79-7.81 (dd, J = 1.7, 8.2 Hz, 1H); 13C NMR 8 4.50, 
78.97, 91.86, 102.22, 108.04, 108.48, 127.33, 132.12, 148.23, 152.84, 176.52; HRMS 
Calcd for C H H 8 0 3 : 188.0473. Found: 188.0476. 
General procedure for preparat ion of the O-methyl oximes. The alkynone (7.0 
mmol), methoxylamine hydrochloride (14.0 mmol, 1.16 g), N a 2 S 0 4 (14.0 mmol, 1.99 g) 
and pyridine (2 mL) in methanol (20 mL) were stirred at room temperature. Benzene 
was added as a co-solvent in cases where the alkynone showed poor solubility in 
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methanol. In some cases, the reaction required refluxing conditions to reach completion. 
The reaction was monitored by TLC until the reaction was complete. The mixture was 
diluted with water (25 mL) and extracted with EtOAc ( 3 x 5 mL). The organic layer was 
washed with brine, dried and evaporated. The residue was then purified by column 
chromatography on silica gel to afford the desired O-methyl oxime. 
Z-l-(Benzo[<i][l,3]dioxol-5-yl)-3-(thiophen-3-yl)prop-2-yn-l-one O-methyl oxime. 
Purification by flash chromatography (4:1 hexanes/EtOAc) afforded 1.64 g (82%) of the 
product: JH NMR (CDC13, 400 MHz) 8 4.09 (s, 3H), 5.98 (s, 2H), 6.81-6.83 (d, J = 8.5 
Hz, 1H), 7.24-7.25 (t, J = 2.0 Hz, 1H), 7.30-7.32 (m, 1H), 7.40-7.42 (m, 2H), 7.66-7.67 
(d, J = 2.0 Hz, 1H); 13C NMR 8 63.20, 79.33, 96.23, 101.57, 106.32, 108.19, 120.92, 
121.67, 125.88, 127.94, 130.08, 131.04, 139.52, 148.01, 149.17; HRMS Calcd for 
C15H11NO3S: 285.0460. Found: 285.0463. 
Z-l-(Benzo[<i][l,3]dioxol-5-yl)prop-2-yn-l-one O-methyl oxime. Purification by flash 
chromatography (4:1 hexanes/EtOAc) afforded 1.32 g (87%) of the product: 'H NMR 
(CDCI3, 400 MHz) 8 2.17 (s, 3H), 4.05 (s, 3H), 5.96 (s, 2H), 6.77-6.70 (d, J = 8.5 Hz, 
1H), 7.34-7.36 (d, / = 5.4 Hz, 2H); 13C NMR 8 5.08, 63.11, 70.96, 99.32, 101.59, 106.38, 
108.11, 121.71, 128.29, 139.88, 147.97, 149.13; HRMS Calcd for C i 2 HnN0 3 : 217.0739. 
Found: 217.0744. 
General procedure for iodocyclization using IC1. To a stirred solution of the 
appropriate O-methyl oxime (2.5 mmol) in CH2CI2 (25 mL) was added IC1 (1M in 
CH2C12, 1.2 equiv) dropwise and the solution was allowed to stir at room temperature. 
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The reaction was monitored by TLC to establish completion. The excess IC1 was 
removed by washing with a satd aq soln of Na 2 S 2 0 3 . The aqueous solution was then 
extracted with CH2CI2 (3 x 15 mL). The combined organic layers were dried over 
anhydrous MgS0 4 and concentrated under a vacuum to yield the crude product, which 
was purified by flash chromatography on silica gel using hexanes/EtOAc as the eluent. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-iodo-5-(thiophen-3-yl)isoxazole. Purification by flash 
chromatography (4:1 hexanes/EtOAc) afforded 804 mg (81%) of the product: 'H NMR 
(CDCI3, 400 MHz) 8 6.05 (s, 2H), 6.93-6.95 (d, / = 8.1 Hz, 1H), 7.25-7.26 (apparent 
doublet merged with CDCI3, 1H), 7.29-7.32 (dd, / = 1.6, 8.0 Hz, 1H), 7.46-7.48 (dd, J = 
3.0, 5.1 Hz, 1H), 7.81-7.82 (m, 1H), 8.28-8.29 (m, 1H); 13C NMR 8 55.59, 101.71, 
108.66, 109.41, 122.28, 123.48, 126.33, 126.68, 126.84, 128.24, 147.93, 149.33, 164.13, 
165.96; HRMS Calcd for Ci 4H 8IN0 3S: 396.9270. Found: 396.9278. 
3-(Benzo[d][l,3]dioxol-5-yl)-4-iodo-5-methylisoxazole. Purification by flash 
chromatography (4:1 hexanes/EtOAc) afforded 732 mg (89%) of the product: 1H NMR 
(CDCI3, 400 MHz) 8 2.53 (s, 3H), 6.03 (s, 2H), 6.92-6.90 (d, / = 8.1 Hz, 1H), 7.25-7.26 
(apparent doublet merged with CDCI3, / = 1.6 Hz, 1H), 7.30-7.33 (dd, / = 1.6, 8.0 Hz, 
1H); 13C NMR 8 13.22, 58.12, 101.71, 108.67, 108.99, 122.57, 123.04, 148.00, 149.32, 
162.49, 171.60; HRMS Calcd for CnH 8 IN0 3 : 328.9549. Found: 329.9555. 
General procedure for Sonogashira coupling. To a 4-dram vial was added the 
appropriate 4-iodoisoxazole (0.25 mmol), the acetylene (0.30 mmol), PdCl2(PPh3)2 
(0.0025 mmol, 1.8 mg), Cul (0.005 mmol, 1.0 mg), DMF (1.5 mL) and Et2NH (1.85 mL). 
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If the acetylene is a solid, it was added as a solution in THF. The solution was stirred for 
5 minutes at room temperature and flushed with argon and then heated to 50 °C until 
TLC revealed complete conversion of the starting material. The solution was allowed to 
cool and was diluted with ethyl acetate (20 mL). The organic layer was washed with 
water and brine, dried and concentrated. The residue was purified by preparative HPLC. 
General procedure for Heck coupling. To a 4-dram vial was added the appropriate 4-
iodoisoxazole (0.25 mmol, 71 mg), the styrene (1.0 mmol), Pd(OAc)2 (0.0132 mmol, 2.8 
mg), W-BU4NC1 (0.25 mmol, 69 mg), Na 2 C0 3 (0.625 mmol, 66 mg) and DMF (1 mL), 
which was then heated to 85 °C for 24 h. The solution was allowed to cool and was 
diluted with ethyl acetate (20 mL). The organic layer was washed with water and brine, 
dried and concentrated. The residue was purified by preparative HPLC. 
General procedure for Suzuki-Miyaura cross-coupling. To a 4-dram vial was added 
the appropriate 4-iodoisoxazole (0.25 mmol), the boronic acid (0.35 mmol), KHCO3 
(0.35 mmol, 35 mg) and PdCl2 (0.0125 mmol, 2.2 mg) in 4:1 DMF:H20 (2.5 mL). The 
solution was stirred for 5 min at room temperature and flushed with argon and then 
heated to 80 °C until TLC revealed complete conversion of the starting material. The 
residue was concentrated under reduced pressure and isolated preparative HPLC. 
General procedure for the palladium-catalyzed carbonylative amidation. A 
modified literature procedure was used. To a 2-dram vial was added the appropriate 4-
iodoisoxazole (0.17 mmol, 48 mg), PdCl2(PPh3)2 (0.0085 mmol, 6.0 mg), DMF (1 mL) 
and the amine (0.25 mL) if liquid or (0.5 mmol) if solid. The reaction mixture was 
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stirred for 2 minutes at room temperature and flushed with carbon monoxide. A balloon 
of carbon monoxide was placed on the vial, which was heated to 80 °C for 18 h. The 
solution was allowed to cool and the solvent was removed by a stream of nitrogen. The 
residue was purified by preparative HPLC. 
Characterization data for a representative 20 compounds 
4-(4-Phthalimidoylbut-l-ynyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole 6{1}. 
Yield = 40%; JH NMR (CDC13, 400 MHz) 8 2.43 (s, 3H), 2.84-2.88 (t, J = 7.0 Hz, 2H), 
3.87 (s, 3H), 3.87 (s, 6H), 3.92-3.96 (t, J = 7.0 Hz, 2H), 7.25 (s merged with CDC13, 2H), 
7.70-7.72 (dd, J = 2.6, 5.4 Hz, 2H), 7.81-7.83 (dd, J = 2.8, 5.6 Hz, 2H); 13C NMR 8 
11.85, 19.5, 36.63, 56.13, 60.93, 71.67, 91.69, 98.80, 104.53, 123.36, 123.80, 131.86, 
134.20, 153.26, 160.85, 168.00, 173.42 (1 peak missing due to overlap); HRMS Calcd 
for C25H26N306: 464.1821 [M + NH4]+. Found: 464.1844. 
MeO OMe 
,0, ^Me 
MeO 
4-(4-Aminophenylethynyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole 6{4}. Yield 
= 62%; JH NMR (CDC13, 400 MHz) 8 2.58 (s, 2H), 3.87 (s, 6H), 3.90 (s, 3H), 6.61-6.65 
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(td, J = 2.2, 8.8 Hz, 2H), 7.27-7.31 (td, J = 2.2, 8.4 Hz, 2H), 7.44 (s, 2H); 13C NMR 8 
12.11, 56.14, 60.94, 76.06, 95.82, 99.59, 104.60, 111.77, 114.76, 124.06, 132.81, 139.44, 
147.12, 153.31, 160.63, 172.59; HRMS Calcd for C 2 IH 2 IN 2 04: 365.1501 [M + H]+. 
Found: 365.1510. 
5-Methyl-4-(l-methyl-l//-imidazol-5-ylethynyl)-3-(3,4,5-trimethoxyphenyl)-
isoxazole 6{5}. Yield = 83%; JH NMR (CDC13, 400 MHz) 8 2.60 (s, 3H), 3.70 (s, 3H), 
3.87 (s, 6H), 3.90 (s, 3H), 7.35 (s, 2H), 7.44-4.70 (m, 2H); 13C NMR 8 12.36, 32.28, 
56.35, 61.09, 76.87, 85.54, 98.87, 104.93, 123.67, 128.57, 128.69, 132.28, 139.96, 
153.55, 160.86, 173.74; HRMS Calcd for Ci9H2oN304: 354.1554 [M + H]+. Found: 
354.1559. 
4-(3-Hydroxyprop-l-ynyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole 6{6}. Yield 
= 67%; JH NMR (CDC13, 400 MHz) 8 1.94 (br s, 1H), 2.53 (s, 3H), 3.90 (s, 3H), 3.92 (s, 
6H), 4.52 (s, 2H), 7.33 (s, 2H); 13C NMR 8 12.04, 51.59, 56.18, 60.95, 75.08, 93.48, 
98.44, 104.64, 123.61, 139.59, 153.35, 160.90, 173.67; HRMS Calcd for C I 6 H I 8 N 0 5 : 
304.1185 [M + H]+. Found: 304.1204. 
MeO OMe 
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.0, Me 
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l-((5-Methyl-3-(3,4,5-trimethoxyphenyl)isoxazol-4-yl)ethynyl)cyclohexanol 6{7}. 
Yield = 59%; ' H N M R (CDC13, 400 MHz) 8 1.25-1.34 (m, 1H), 1.53-1.77 (m, 8H), 1.96-
2.00 (m, 2H), 2.11 (br s, 1H), 2.53 (s, 3H), 3.90 (s, 3H), 3.93 (s, 6H), 7.31 (s, 2H); 13C 
NMR 8 12.03, 23.36, 25.10, 40.08, 40.96, 56.30, 60.94, 69.26, 73.37, 98.65, 99.16, 
104.81, 123.81, 139.70, 153.38, 160.68, 173.57 (1 peak missing due to overlap); HRMS 
Calcd for C 2 iH 26N0 5 : 372.1811 [M + H]+. Found: 372.1832. 
5-Methyl-4-(thiophen-3-ylethynyl)-3-(3,4,5-trimethoxyphenyl)isoxazole 6{8}. Yield = 
75%; JH NMR (CDC13, 400 MHz) 8 2.59 (s, 3H), 3.88 (s, 6H), 3.90 (s, 3H), 7.15-7.17 
(dd, / = 1.0, 5.0 Hz, 1H), 7.32-7.34 (dd, / = 3.0, 5.0 Hz, 1H), 7.41 (s, 2H), 7.50-7.51 (dd, 
J = 1.2, 2.8 Hz, 1H); 13C NMR 8 12.17, 56.13, 60.95, 77.95, 90.20, 99.08, 104.64, 
121.59, 123.83, 125.93, 129.01, 129.53, 139.59, 153.36, 160.71, 173.19; HRMS Calcd 
for C I 9 H I 8 N0 4 S: 356.0957 [M + H]+.Found: 356.0961. 
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OAc 
4-(£'-2-(4-Acetoxyphenyl)ethenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)-isoxazole 
6{ 10}. Yield = 60%; JH NMR (CDC13, 400 MHz) 8 2.31 (s, 3H), 2.60 (s, 3H), 3.85 (s, 
6H), 3.91 (s, 3H), 6.68-6.72 (d, / = 16.4 Hz, 1H), 6.76-6.80 (d, / = 16.4 Hz, 1H), 6.89 (s, 
2H), 7.07-7.09 (d, J = 8.8 Hz, 2H), 7.41-7.43 (d, J = 8.4 Hz, 2H); 13C NMR 8 12.41, 
21.14, 56.26, 60.98, 105.76, 112.46, 116.65, 122.02, 124.60, 127.04, 131.30, 134.66, 
139.21, 150.32, 153.51, 161.44, 166.43, 169.46; HRMS Calcd for C23H24N06: 410.1604 
[M + H]+. Found: 410.1628. 
5-Methyl-4-(£'-2-(3-nitrophenyl)ethenyl)-3-(3,4,5-trimethoxyphenyl)isoxazole 6{12}. 
Yield = 73%; JH NMR (CDC13, 400 MHz) 8 2.64 (s, 3H), 3.86 (s, 6H), 3.92 (s, 3H), 
6.75-6.79 (d, / = 16.4 Hz, 2H), 6.87 (s, 2H), 6.96-7.00 (d, / = 16.4 Hz, 2H), 7.50-7.54 (t, 
J = 8.0 Hz, 1H), 7.67-7.69 (d, / = 8.0 Hz, 1H), 8.10-8.12 (m, 1H), 8.27-8.28 (t, / = 2.0 
Hz, 1H); 13C NMR 8 12.53, 56.28, 61.00, 105.86, 111.92, 119.71, 120.52, 122.40, 124.30, 
129.41, 129.80, 131.84, 138.70, 139.43, 148.78, 153.62, 161.50, 167.14; HRMS Calcd 
for C42H44N5Oi2: 810.2987 [2M + NH4]+. Found: 810.2996. 
55 
MeO 
M e u
 OMe COoEt 
4-(4-Ethoxycarbonyl-3-fluorophenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)-
isoxazole 6{16}. Yield = 53%; JH NMR (CDCI3, 400 MHz) 8 1.39-1.43 (t, / = 7.2 Hz, 
3H), 2.48 (s, 3H), 3.69 (s, 6H), 3.87 (s, 3H), 4.39-4.44 (q, / = 7.2 Hz, 2H), 6.63 (s, 2H), 
7.02-7.08 (m, 2H), 7.95-7.98 (t, / = 7.8 Hz, 1H); 13C NMR 8 11.90, 14.42, 56.18, 61.09, 
61.73, 76.89, 105.80, 114.21, 118.24, 118.30, 118.40, 118.47, 123.69, 125.67, 125.70, 
132.55, 132.56, 137.38, 137.47, 139.47, 153.49, 160.65, 160.83, 163.24, 164.07, 164.11, 
167.57 (extra peaks due to C-F splitting); HRMS Calcd for C22H23FN06: 416.1509 [M + 
H]+. Found: 416.1533. 
4-(3-Fluoro-4-methoxyphenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole 6{ 19}. 
Yield = 58%; JH NMR (CDC13, 400 MHz) 8 2.43 (s, 3H), 3.68 (s, 6H), 3.86 (s, 3H), 3.92 
(s, 3H), 6.69 (s, 2H), 6.92-7.02 (m, 3H); 13C NMR 8 11.52, 55.94, 60.91, 105.49, 113.54, 
113.56, 114.46, 114.47, 117.65, 117.84, 123.23, 123.31, 124.11, 126.17, 126.20, 139.03, 
147.27, 147.38, 150.98, 153.17, 160.60, 166.82 (extra peaks due to C-F splitting); HRMS 
Calcd for C2 0H2IFNO5: 374.1404 [M + H]+. Found: 374.1424. 
56 
MeO 
M e u OMe C 0 2 M e 
4-(3-Methoxycarbonyl-5-nitrophenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)-
isoxazole 6{20}. Yield = 44%; JH NMR (CDCI3, 400 MHz) 8 2.51 (s, 3H), 3.67 (s, 6H), 
3.86 (s, 3H), 3.98 (s, 3H), 6.60 (s, 2H) 8.23-8.24 (t,J= 1.4 Hz, 1H), 8.26-8.27 (t, / = 2.0 
Hz, 1H), 8.83-8.84 (m, 1H); 13C NMR 8 11.89, 53.17, 56.19, 61.05, 105.85, 113.34, 
123.31, 123.68, 128.45, 132.55, 133.25, 136.43, 139.69, 148.62, 153.58, 160.78, 164.54, 
167.92; HRMS Calcd for C42H44N5O16: 874.2783 [2M + NH4]+. Found: 874.2822. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(l//-indol-5-yl)-5-methylisoxazole 6{21}. Yield = 24%; 
JH NMR (CDCI3, 400 MHz) 8 2.42 (s, 3H), 5.92 (s, 3H), 6.55-6.56 (m, 1H), 6.67-6.69 
(d, / = 8.0 Hz, 1H), 6.93-7.00 (m, 3H), 7.25-7.27 (apparent doublet merged with CDCI3, 
J =2.0 Hz, 1H), 7.38-7.40 (d, / = 8.4 Hz, 1H), 7.49 (t, / = 0.6 Hz, 1H), 8.38 (s, 1H); 13C 
NMR 8 11.72, 101.31, 102.95, 108.47, 108.87, 111.56, 116.64, 122.26, 122.88, 123.49, 
124.32, 125.08, 128.32, 135.40, 147.73, 148.55, 161.01, 166.63; HRMS Calcd for 
C19H15N2O3: 319.1083 [M + H]+. Found: 319.1100. 
H 
57 
O OMe 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(3-fluoro-4-methoxyphenyl)-5-methyl-isoxazole 6{26}. 
Yield = 46%; JH NMR (CDCI3, 400 MHz) 8 2.41 (s, 3H), 3.93 (s, 3H), 5.93 (s, 2H), 
6.75-6.77 (d, / = 8.0 Hz, 1H), 6.88-7.03 (m, 4H), 7.22-7.28 (m, 1H); 13C NMR 8 11.54, 
56.22, 101.30, 108.47, 108.62, 113.54, 113.56, 113.69, 114.51, 117.45, 117.64, 122.19, 
122.23, 122.64, 122.67, 125.83, 125.87, 147.75, 148.66, 151.00. 153.45, 160.64, 166.63 
(extra peaks due to C - F splitting); HRMS Calcd for C I 8 H I 5 F N 0 4 : 328.0985 [M + H]+. 
Found: 328.1004. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(l//-indol-5-yl)-5-(thiophen-3-yl)isoxazole 6{28}. Yield 
= 79%; JH NMR (CDCI3, 400 MHz) 8 5.91 (s, 2H), 6.56-6.57 (m, 1H), 6.65-6.67 (d, / = 
8.4 Hz, 1H), 6.95-6.98 (dd, / = 1.6, 8.0 Hz, 1H), 7.03-7.04 (d, / = 1.6 Hz, 1H), 7.08-7.11 
(dd, / = 1.6, 8.4 Hz, 1H), 7.15-7.16 (dd, / = 1.4, 5.0 Hz, 1H), 7.20-7.22 (dd, / = 3.0, 5.0 
Hz, 1H), 7.28-7.30 (t, / = 2.8 Hz, 1H), 7.44-7.48 (m, 2H), 7.59-7.60 (t, / = 0.8 Hz, 1H), 
8.35 (br s, 1H); 13C NMR 8 101.34, 103.26, 108.50, 108.79, 112.14, 115.36, 121.84, 
122.86, 123.09, 123.33, 124.63, 124.73, 125.18, 125.88, 126.11, 128.67, 129.36, 135.86, 
H 
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147.75, 148.65, 161.76, 162.75; HRMS Calcd for C22H15N2O3S: 387.0803 [M + H]+. 
Found: 387.0816. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(6-methoxypyridin-3-yl)-5-(thiophen-3-yl)isoxazole 
6{29}. Yield = 81%; JH NMR (CDCI3, 400 MHz) 8 3.98 (s, 3H), 5.96 (s, 2H), 6.73-6.75 
(d, / = 7.6 Hz, 1H), 6.80-6.82 (dd, / = 0.8, 8.4 Hz, 1H), 6.87-6.89 (dd, / = 1.6, 8.0 Hz, 
1H), 6.93-6.94 (d, / = 1.6 Hz, 1H), 7.16-7.17 (dd, / = 1.2, 5.2 Hz, 1H), 7.29-7.31 (dd, / = 
2.8, 8.4 Hz, 1H), 7.52-7.53 (dd, / = 1.2, 3.2 Hz, 1H), 8.08-8.09 (dd, / = 0.6, 1.4 Hz, 1H); 
13C NMR 8 53.65, 101.36, 108.54, 108.63, 110.64, 111.44, 119.29, 122.33, 122.75, 
125.12, 125.46, 126.59, 128.49, 140.67, 147.84, 148.30, 148.79, 161.74, 163.06, 164.06; 
HRMS Calcd for C20H15N2O4S: 379.0753 [M + H]+. Found: 379.0761. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(4-ethoxycarbonyl-3-fluorophenyl)-5-(thiophen-3-
yl)isoxazole 6{30}. Yield = 73%; JH NMR (CDC13, 400 MHz) 8 1.41-1.45 (t,J= 7.0 Hz, 
3H), 4.41-4.47 (q, / = 7.1 Hz, 2H), 5.99 (s, 2H), 6.74-7.76 (d, / = 8.0 Hz, 1H), 6.83-6.85 
(dd, / = 1.8, 8.2 Hz, 1H), 6.92-6.93 (d, J =1.6 Hz, 1H), 7.08-7.18 (m, 3H), 7.32-7.34 (dd, 
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J = 3.0, 5.0 Hz, 1H), 7.55-7.56 (dd, / = 1.2, 3.2 Hz, 1H), 7.98-8.02 (t, J = 7.8 Hz, 1H); 
13C NMR 8 14.53, 61.88, 101.66, 108.80, 108.81, 119.19, 119.42, 122.12, 122.99, 
125.70, 125.85, 126.49, 126.52, 127.01, 128.28, 133.10, 137.55, 148.15, 149.20, 161.50, 
163.13, 163.53 (extra peaks due to C-F splitting); HRMS Calcd for C23H17FNO5S: 
438.0812 [M + H]+. Found: 438.0840. 
3-(Benzo[<i][l,3]dioxol-5-yl)-4-(6-(dimethylamino)pyridin-3-yl)-5-(thiophen-3-
yl)isoxazole 6{32}. Yield = 85%; JH NMR (CDCI3, 400 MHz) 8 3.15 (s, 3H), 5.97 (s, 
2H), 6.55-6.57 (dd, J = 0.4, 8.8 Hz, 1H), 6.75-6.77 (d, J = 8.4 Hz, 1H), 6.97-6.99 (dd, 
1.8, 8.2 Hz, 1H), 7.01-7.02 (d, / = 1.6 Hz, 1H), 7.24-7.26 (dd, / = 1.2, 5.2 Hz, 1H), 7.29-
7.34 (m, 2H), 7.56-7.57 (dd, / = 1.2, 2.8 Hz, 1H), 8.08-8.09 (dd, / = 0.8, 2.4 Hz, 1H); 13C 
NMR 8 38.25, 101.47, 106.00, 108.70, 108.89, 111.71, 113.29, 122.97, 124.98, 125.80, 
126.51, 129.07, 139.30, 147.94, 148.83, 149.44, 159.01, 162.08, 163.04 (1 peak missing 
due to overlap); HRMS Calcd for C21H18N3O3S: 329.1069 [M + H]+. Found: 329.1089. 
N 
H 
60 
3-(Furan-2-yl)-4-(l//-indol-5-yl)-5-phenylisoxazole 6{35}. Yield = 75%; JH NMR 
(CDCI3, 400 MHz) 8 5.98-5.99 (dd, / = 0.8, 3.6 Hz, 1H), 6.25-6.27 (dd, / = 1.8, 3.4 Hz, 
1H), 6.58-6.60 (m, 1H), 7.14-7.17 (dd, / = 1.4, 8.2 Hz, 1H), 7.28-7.33 (m, 4H), 7.46-7.58 
(m, 4H), 7.65 (t, J = 0.8 Hz, 1H), 8.42 (br s, 1H); 13C NMR 8 103.07, 111.09, 111.97, 
112.00, 115.02, 121.23, 122.80, 124.26, 125.05, 126.74, 127.82, 128.50, 128.57, 129.63, 
135.81, 143.49, 144.24, 154.89, 165.07; HRMS Calcd for C21H15N2O2: 327.1136 [M + 
H]+. Found: 327.1156. 
4-(4-Ethoxycarbonyl-3-fluorophenyl)-3-(furan-2-yl)-5-phenylisoxazole 6{37}. Yield = 
64%; JH NMR (CDCI3, 400 MHz) 8 1.44-1.46 (t, / = 7.2 Hz, 3H), 4.44-4.48 (q, / = 7.2 
Hz, 2H), 6.36-6.37 (dd, J = 0.6, 3.4 Hz, 1H), 6.40-6.41 (dd, / = 1.8, 3.4 Hz, 1H), 7.17-
7.20 (dd, / = 1.4, 11.0 Hz, 1H), 7.22-7.24 (dd, / = 1.4, 7.8 Hz, 1H), 7.33-7.7.45 (m, 3H), 
7.48-7.51 (m, 3H), 8.02-8.05 (t, J = 7.8 Hz, 1H); 13C NMR 8 14.30, 61.67, 111.35, 
111.92, 119.07, 119.30, 126.31, 126.34, 126.76, 127.02, 128.93, 130.47, 132.77, 137.06, 
143.26, 144.15, 153.88, 160.67, 163.27, 164.06, 166.17 (extra peaks due to C-F 
splitting); HRMS Calcd for C44H36F2N3O8: 772.2465 [2M + NH4]+. Found: 772.2476. 
C 0 2 E t 
61 
A^-(2-(Thiophen-2-yl)ethyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)isoxazole-4-
carboxamide 6{49}. Yield = 79%; JH NMR (CDC13, 400 MHz) 8 2.69 (s, 3H), 2.94-
2.97 (t, / = 6.6 Hz, 2H), 3.55-3.60 (q, / = 6.8 Hz, 2H), 3.84 (s, 6H), 3.90 (s, 3H), 5.74 (br 
s, 1H), 6.59-6.60 (m, 1H), 6.73 (s, 2H), 6.83-6.96 (dd, / = 3.6, 5.2 Hz, 1H), 7.10-7.11 
(dd, / = 1.2, 5.2 Hz, 1H); 13C NMR 8 12.97, 29.58, 40.68, 56.25, 60.96, 105.92, 110.99, 
123.21, 124.11, 125.24, 126.97, 139.64, 140.47, 153.68, 160.04, 161.54, 174.03; HRMS 
Calcd for C2oH23N205S: 403.1328 [M + H]+. Found: 403.1343. 
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CHAPTER 3. Room Temperature ICl-Induced Dehydration/iodination of l-Acyl-5-
hydroxy-4,5-dihydro-l//-pyrazoles. A Selective Route to Substituted l-Acyl-4-iodo-
l//-pyrazoles 
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Abstract 
o 
Me-^O Me^O 
NH2NHCOCH3_ ICI, L i 2 C0 3 _ R1. 
2 toluene, 80 °C \ — \ CH2CI2 
N. 
HO-\ \\ 
R I 
R1 = Ar, alkyl, vinylic R - Ar 
R2 = Ar, alkyl, vinylic r 2 = Ar< 
A number of new functionally-substituted l -acyl-5-hydroxy-4,5-dihydro-1H-
pyrazoles have been prepared in moderate to excellent yields from the corresponding 2-
alkyn-l-ones. The resulting dihydropyrazoles undergo dehydration and iodination in the 
presence of IC1 and Li2C03 at room temperature to provide l -acyl-4-iodo-1 //-pyrazolcs. 
Introduction 
Pyrazoles and derivatives have attracted considerable attention due to the wide 
variety of biological activities they exhibit, including hypoglycemic, antimicrobial, 
amoebicidal, anti-bacterial, anti-inflammatory, antipyretic and analgesic activities.1 
Specifically, 5-hydroxy-4,5-dihydro-1 //-pyrazoles are known to possess anti-
inflammatory and analgesic activity.2 Pyrazoles exhibit analgesic,3 antimicrobial,4 anti-
67 
inflammatory,5 anti-hypertensive,6 and hypoglycemic7 activities, and appear promising 
as potential antiprotozoal and cytotoxic agents,8 and CB1 cannabinoid receptor 
antagonists as appetite suppressants for the treatment of obesity.9 
We recently reported the synthesis of highly substituted isoxazoles by the 
electrophilic cyclization of 2-alkyn-l-one O-methyl oximes (Scheme l).10 The requisite 
ynone O-methyl oximes were prepared by stirring the ynone in the presence of 
methoxylamine hydrochloride, pyridine and Na2SC>4 or MgSC>4 at room temperature 
using methanol as the solvent.11 
Scheme 1 
E-X = l2 , ICI, Br2, PhSeBr 
We reasoned that an analogous synthetic strategy could be applied towards the 
synthesis of highly substituted pyrazoles. We envisioned that 2-alkyn-l-one N,N-
dimethylhydrazones (1) would react in the presence of an electrophile to afford 
substituted 1-methylpyrazoles (Scheme 2). However, this synthetic strategy was 
unsuccessful, because we were unable to prepare the requisite hydrazones, and thus an 
alternative route to 4-halopyrazoles was ultimately developed. We wish herein to report 
our results on that project. 
Scheme 2 
68 
0 ,NMe 2 V® 
NH2NMe2 N E-X M ' N N - - R 2 
R2 
R1 // 
R1 
Results and Discussion 
The preparation of dimethylhydrazones, such as 1, is not as straightforward as was 
first anticipated. The reaction of 1,1-dimethylhydrazine with l,3-diphenylprop-2-yn-l-
one (4) in ethanol at reflux has been reported to afford 3-(2,2-dimethylhydrazinyl)-l,3-
diphenylprop-2-en-l-one (5) (eq l).12 
0 0 NHNMe 2 
X ^ N M e ^
 (1 ) 
EtoH i y i y 
Ph reflux ^ ^ ^ ^ 
4 5 
We have found that when 4 was allowed to react with 1,1-dimethylhydrazine and a 
catalytic amount of acetic acid in methanol at reflux, l-methyl-3,5-diphenylpyrazole (6) 
was the major product isolated in a 51% yield (eq 2). None of the desired hydrazone 
product was observed. To our surprise, reactions at room temperature still afforded 
pyrazole 6 in modest yields. A similar result has been reported when compound 5 was 
heated in the presence of acetic anhydride. Once again, one of the two methyl groups of 
the hydrazine was also eliminated to afford 6.13 
Me 
NH 2 NMe 2 ^ N ' N y . P h ( 2 ) 
MeOH 
% AcC 
51% 
10 OH
 p h -
These results do not provide a particularly useful route to 1-substituted pyrazoles, 
since it has been reported that mono-substituted hydrazines react with 2-alkyn-l-ones to 
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afford pyrazoles regioselectively in good yields.14 The latter reaction occurs by 1,4-
addition of the mono-substituted hydrazine to the alkynone, followed by dehydration to 
form the substituted pyrazole. In the same study, when 2,4-dinitrophenylhydrazine was 
employed, 1,2-addition dominated, resulting in the formation of 2-alkyn-l-one 
hydrazones 7 and 8 (eq 3). 
2,4-DNP (3) 
Hydrazones of 2-alkyn-l-ones have also been reported when mono-substituted 
hydrazines are allowed to react with alkynones bearing sterically bulky silanes on the 
alkyne terminus and a proton or methyl group on the carbonyl moiety (eq 4).15 
O N ,NHR 
Me ^ 
R 3 = Me3, f-BuPh2 
R = H, Me, Ph 
NH-JNHR 
Me' (4) 
'SiRa 
This prompted us to employ a bulky triisopropylsilyl group on the alkyne terminus to 
form the desired alkynone hydrazones. When alkynone 9 was subjected to 1,1-
dimethylhydrazine in ethanol at reflux, no reaction was observed. Only when the 
solution was heated to 150 °C by microwave irradiation did conversion of 9 occur slowly, 
but dimethylhydrazone 10 was not observed (eq 5). Presumably, the diminished 
reactivity of l-phenyl-3-(triisopropylsilyl)prop-2-yn-l-one (9) towards 1,2-addition of 
70 
the 1,1-dimethylhydrazine, as compared to 3-silylalkynones bearing a proton or methyl at 
the 1-position, is due to the ketone bearing an aromatic ring. 
O NH 2NMe 2 N - N M e 2 
-H- ^ JJ (6) 
P h
 ^ EtOH Ph 
T I P S
 150 °C ^ T I P S 
mw 
9 10 
Given that the preparation of A^,A^-dimethylhydrazones by the addition of 1,1-
dimethylhydrazine to alkynones is not at this stage apparently a very general reaction, we 
explored indirect routes towards their synthesis. Hydrazonyl chloride 11, prepared in two 
steps from benzoyl chloride,16 failed to react with Li and Mg acetylides to provide the 
desired dimethylhydrazone (12) (eq 6). The analogous coupling of alkynyl Grignard 
reagents with imidoyl chlorides has been reported.17 Surprisingly, refluxing 11 in the 
presence of lithium phenylacetylide in THF provided no reaction. 
K , 'NMe 2 M Ph N 2 N  / / II 
A P h " ^ (®) 
Ph CI M = Li, MgBr r n 
Ph 
11 12 
The palladium-catalyzed cross-coupling of terminal acetylenes with imidoyl chlorides 
has been reported.18 When compound 11 was subjected to Sonogashira cross-coupling 
conditions in the presence of phenyl acetylene at room temperature, no reaction occurred. 
However, when the temperature was increased to 50 °C, pyrazole 6 was isolated in a 55% 
yield (Scheme 3). A similar result has been reported when copper and silver acetylides 
are allowed to react with /V-substitutcd hydrazonyl bromides to give 1,3,5-trisubstituted 
pyrazoles.19 Our attempts at copper-free cross-coupling conditions resulted in no reaction 
of l l . 2 0 
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When acyl and aroyl hydrazine derivatives were first allowed to react with alkynones, 
the products were originally assigned an open chain form. Since then, their structures 
have been reassigned and a small number of 5-hydroxy-4,5-dihydro-1 //-pyrazoles have 
been reported by the reaction of hydrazine derivatives with alkynones.21 To the best of 
our knowledge, the analogous reaction using acetylhydrazine has not been reported. 5-
Hydroxy-4,5-dihydro-1 //-pyrazoles have also been prepared by the reaction of hydrazine 
derivatives with 3-alkoxyalk-2-en-l-ones.22 The synthesis of 5-hydroxy-4,5-dihydro-1H-
pyrazoles from alkynones is attractive due to the many ways one can selectively 
synthesize alkynones from commercially available starting materials.23 
A literature search revealed that iodine has been used as a Lewis acid for the facile 
dehydration of aldoximes to nitriles.24 We envisioned that the dehydration of /V-acyl-5-
hydroxy-4,5-dihydro-1 //-pyrazoles, followed by iodination, could provide a selective 
route to substituted l-acyl-4-pyrazoles. Thus, we synthesized l-acetyl-5-hydroxy-3,5-
diphcnyl-4,5-dihydro-1 //-pyrazolc (13) as the model system for optimization of this 
process. The use of and carbonate bases, such as K2CO3, Li2C03 and Na2C03, in 
CH2CI2 or CH3CN provided no reaction of 13. We then shifted our attention to the use of 
IC1. IC1 has been established as the most Lewis acidic of the halogens.25 We were 
pleased to find that 1.2 equiv of IC1 in the presence of 2 equiv of Na2C03 in CH2CI2 
provided complete conversion of 13 to the corresponding 1 -acctyl-3,5-diphcnyl-1H-
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pyrazole (14) (60% yield) and 1 -acctyl-4-iodo-3,5-diphcnyl-1 //-pyrazole (15) (30% 
yield) (eq 7). 
O ^ M e M e - ^ O M e - ^ O 
base 
N
p h solvent H Ph \' Ph 
13 14 15 
In order to increase the solubility of the inorganic base, CH3CN and MeN02 were 
screened as solvents under the same reaction conditions. However, this provided messy 
reaction mixtures and provided none of the desired product. Among carbonate bases 
screened, using CH2C12 as the solvent in the presence of IC1, Li2C03 provided the best 
results. The use of Li2CC>3 nearly reversed the product ratio, compared with Na2CC>3, 
providing a 13% yield of 14 and a 52% yield of 15, although the reaction took two days 
to reach completion. Omitting Li2C03 from the reaction, led to the formation of 
deacylated pyrazole products, presumably due to the formation of HC1. The optimal 
reaction conditions thus far developed involve stirring 0.25 mmol of the dihydropyrazole 
13, 3 equiv of IC1 and 2 equiv of Li2C03 in 2.5 mL of CH2C12 at room temperature, 
which affords a 95% yield of 15. 
With optimized conditions in hand, we synthesized a number of l-acyl-5-hydroxy-
4,5-dihydro-1 //-pyrazoles from the corresponding 2-alkyn-l-ones (Table 1). In most 
cases, preparation of the 1 -acyl-5-hydroxy-4,5-dihydro-1 //-pyrazoles proceeded 
smoothly in good yield by simply heating the appropriate alkynone in the presence of 2 
equiv of acetylhydrazine in toluene at 80 °C. When R1 is a phenyl group, the reaction 
proceeds satisfactorily in most cases. Both the parent system and one containing an 
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electron-deficient aryl group gave the desired dihydropyrazoles 16 and 17 in good yields 
(Table 1, entries 1 and 2). Substituting an //-butyl group on the terminus of the alkyne 
moiety was also tolerated well and provided 18 in a good yield (Table 1, entry 3). Only 
when R2 = 1-cyclohexenyl did the reaction afford only a modest yield of compound 19 
(Table 1, entry 4). 
When the 1 position of the 2-alkyn-l-one was substituted with a 2-naphthyl group, 
the reaction gave a yield of 20 comparable to that of the parent system (Table 1, compare 
entries 1 and 5). Halogens in the para position of the aromatic ring, including F, CI, Br 
and trifluoromethyl, provided good yields of the desired 5-hydroxy-4,5-dihydro-1H-
pyrazoles 21, 22, 23 and 24 respectively (Table 1, entries 6-9). The presence of an 
electron-withdrawing cyano group in the para position also gave a good yield of 25 
(Table 1, entry 10). Electron-rich aryl groups, including p-t-Bu, 3,4-0CH2CH20-, and 
3,4,5-trimethoxy phenyl groups also worked well and provided good yields of 26, 27, and 
28 respectively (Table 1, entries 11-13). The highly electron-rich benzene ring 
containing a />Me2N group provided only a modest yield of 29 and the reaction required 
a four fold increase in reaction time (Table 1, entry 14). A methyl group in the ortho 
position of the benzene ring provided a slightly lower yield of 30 and required a longer 
reaction time compared to that of the parent system (Table 1, compare entries 1 and 15). 
A 3-pyridyl substituent provided an excellent yield of 31 (Table 1, entry 16). The 
reaction also tolerated a vinylic group in the R1 position, affording cinnamyl derivative 
32 (Table 1, entry 17). Thus, this approach to 1 -acyl-5-hydroxy-4,5-dihydro-1H-
pyrazoles appears to be quite general. 
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Table 1. Synthesis of l-Acetyl-5-hydroxy-4,5-dihydro-l//-pyrazoles.a 
entry R1 R2 product yield (%)' 
1 Ph Ph 16 77 
2 />Et02CC6H4 17 86 
Ph 
3 Ph n-Bu 18 60 
Ph ^ 19 47 
p-BrC6H 4 
/?-CF3C6H 4 
b 
2-naphthyl Ph 20 79 
Ph 21 95 
P-FC6H4 
p-C1C6H4 Ph 22 78° 
Ph 23 72 
Ph 24 96 
10 Ph 25 71 
p- NCC6H4 
75 
11 Ph 26 65 
12 r Ph 27 71 
1 3
 \ j CH3 2 8 78 
MeO' 
OMe 
14 Ph 29 53d 
p-Me2NC6H 4 
15 o-MeC6H4 Ph 3 Q 64d 
16 ^ Ph 31 93 
N 
17 I r ^ Ph 32 68 
a) All reactions were carried out using 1.0 mmol of alkynone, 2.0 mmol of acetylhydrazine in toluene (5 
mL) at 80 °C for 6 h unless otherwise specified, b) Isolated yields after column chromatography, c) X-ray 
crystallographic data are available for this compound in the supporting information, d) The reaction 
required 24 h to reach completion. 
With the desired l-acetyl-5-hydroxy-4,5-dihydropyrazole derivatives in hand, we 
studied the scope of the ICl-induced dehydration/iodination process (Table 2). Under our 
optimized conditions, pyrazole 33 was obtained in an excellent yield (Table 2, entry 1). 
Substitution of the phenyl ring in the R2 group by an electron-withdrawing C0 2 Et group 
afforded a slightly lower yield of 34 as compared to the parent system (Table 2, compare 
entries 1 and 2). Replacing the aryl moiety with an alkyl group also led to the desired 
pyrazole 35 in an excellent yield (Table 2, entry 3). Unfortunately, introducing a vinylic 
group m theR 2 position led to only a low yield of the desired pyrazole 36 (Table 2, entry 
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4). Pyrazole 36 was observed by 'H NMR spectroscopy. However, inseparable 
impurities alongside the product could not be removed by column chromatography. The 
lower yield may be attributed to the generation of HC1 in the reaction mixture, which 
may cause unwanted side reactions with the 1-cyclohexenyl group or perhaps the IC1 is 
reacting directly with the carbon-carbon double bond. 
We have also studied the effect of varying the nature of the R1 group, while retaining 
R2 as a phenyl group. When R is a 2-naphthyl group, the reaction proceeded smoothly 
and gave an excellent yield of the pyrazole 37, which is comparable to the yield of the 
parent system (Table 2, compare entries 1 and 5). Phenyl groups bearing an F, CI or Br in 
the 4-position all provided the corresponding 4-iodopyrazoles 38, 39 and 40 respectively 
in good yields (Table 2, entries 6-8). The structure of compound 39 has been confirmed 
by X-ray analysis. The presence of a CF3 group in the 4-position of the aromatic ring also 
provided the desired 4-iodopyrazole 41 in a good yield (Table 2, entry 9). Introducing an 
electron-withdrawing CN group into the 4-position of the phenyl group of R1 provided 
only a modest yield of 4-iodopyrazole 42 and a dramatic increase in the required reaction 
time was noted (Table 2, entry 10). Increasing the amount of IC1 only provided a modest 
increase in yield and the results were within experimental error. Electron-rich aromatic 
rings, including 4-/-BuC6H4 and 3,4-methylenedioxyphenyl, provided good yields of 43 
and 44 respectively (Table 2, entries 11 and 12). To examine the effect of steric bulk on 
the benzene ring, we employed compound 30 under our optimized reaction conditions. 
The reaction proceeded, although an increased reaction time was required and only a 
moderate yield of 45 was obtained. Unfortunately, 45 could not be separated from its 
non-halogenated counterpart (Table 2, entry 13). When R1 was a /?-Me2NCeH4 or 3-
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pyridyl group, the reaction provided none of the desired 4-iodopyrazoles (Table 2, entries 
14 and 15). Despite employing 10 equiv of IC1, 31 failed to react. This observation may 
be a result of the basic nitrogen atoms tying up the Lewis acidic IC1, preventing it from 
effecting the desired dehydration reaction. Additional equivalents of IC1 were not 
attempted in the case of compound 29 because of the likelihood of an unwanted side 
reaction caused by iodination of the /?-Me2NCeH4 moiety through electrophilic aromatic 
substitution. Compound 28 was subjected to our dehydration conditions in order to study 
the effect of an electron-rich ring in the R1 position and a sterically compact group in the 
R2 position. This reaction suffered from extended reaction times and the corresponding 
pyrazole, minus an iodine moiety, was detected as the major side product by 'H NMR 
spectroscopy, along with 4-iodopyrazole 46 (Table 2, entry 16). 
0
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Table 2. Synthesis of l-Acetyl-4-iodopyrazoles.a 
entry R1 R2 time (h) product yield (%)b 
Ph Ph 0.75 33 95 
/>Et0 2CC 6H 4 1 34 75 
Ph 
3 Ph n-Bu 0.75 35 97 
4 Ph ^ 0.75 36 37° 
78 
5 2-naphthyl Ph 0.75 37 96 
6 p-FC6H4 Ph 1 38 84 
7 p-C1C6H4 Ph 1 39 87 
P - C F 3 C 6 H 4 
Ph 24 
d 
8 Ph 1 40 82 
p-BrC6H4 
Ph 1 41 71 
10 Ph 12 42 561 
P - N C C 6 H 4 
11 Ph 1 43 90 
p-t- B U C 6 H 4 
12 Ph 1 44 93 
0 ' 
13 o-MeC6H4 Ph 12 45 60f 
14 Ph 24 
p- Me2NC6H4 
CH3 12 46 41 f 
a) Unless otherwise stated, all reactions were carried out in CH2C12 (10 mL/mmol) at room temperature 
using 2.0 equiv of Li 2C0 3 and 3.0 equiv of IC1. b) Isolated yields after column chromatography, c) Yield 
determined by NMR spectroscopy, d) X-ray crystallographic data are available for this compound in the 
supporting information, e) Four equiv of IC1 were used, f) Yield determined by NMR spectroscopy. Non-
halogenated pyrazole is the major side product. 
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The advantage of this methodology is that 1 -acyl-4-iodo-3,5-disubstitutcd-1H-
pyrazoles can be synthesized selectively from the corresponding alkynones under mild 
reaction conditions. To the best of our knowledge, the iodination of 1-acylpyrazoles has 
not been reported, although bromination has.26 Aryl iodides generally react more readily 
than their bromine counterparts in the presence of palladium catalysts due to more facile 
oxidative addition. l-Acyl-4-halopyrazoles have demonstrated their importance as 
intermediates for palladium-catalyzed Sonogashira cross-coupling reactions leading to 
compounds of pharmacological interest. 27 Also, the palladium-catalyzed Heck28 cross-
coupling of l-acyl-4-halopyrazoles has been demonstrated. In addition, another 
advantage of this methodology is the fact that the acylation of pyrazoles often gives a 
mixture of /V-acylatcd products,13'29 leading to unwanted and often inseparable product 
mixtures, where our process eliminates this problem. We believe that this approach to 
substituted pyrazoles should be quite useful in synthesis, considering the many ways one 
can transform the resulting iodine functional group by catalytic methods other than those 
described above. 
Conclusions 
A number of new 1 -acctyl-5-hydroxy-4,5-dihydro-1 //-pyrazoles have been 
synthesized in good to excellent yields from 2-alkyn-l-ones. 3,5-Disubstituted-l-acyl-4-
iodo-1//-pyrazoles have been synthesized in moderate to excellent yields by a novel 
dehydration/iodination of l-acetyl-5-hydroxy-4,5-dihydro-l//-pyrazoles under mild 
reaction conditions. Our methodology is fairly general and provides a selective route to 
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1-acyl-4-iodopyrazoles. To the best of our knowledge, this is the first report of an IC1-
induced dehydration of a heterocyclic derivative that provides iodinated pyrazoles. 
Experimental Section 
General. The 'H and 13C NMR spectra were recorded at 300 and 75.5 MHz or 400 
and 100 MHz respectively. Thin layer chromatography was performed using 
commercially prepared 60-mesh silica gel plates, and visualization was effected with 
short wavelength UV light (254 nm). All melting points are uncorrected. All reagents 
were used directly as obtained commercially unless otherwise noted. THF and CH2C12 
were distilled from sodium/benzophenone or CaH2 respectively, under an atmosphere of 
argon prior to use. All glassware and stirring bars were oven dried prior to use. The high-
resolution mass spectra were recorded using EI at 70 eV. The following starting materials 
were made according to literature procedures: l,3-diphenylprop-2-yn-l-one,23a 1-phenyl-
2-butyn-l-one,30 l-(4-chlorophenyl)-3-phenylprop-2-yn-l-one,31 ethyl 4-(3-oxo-3-
phenylprop-1 -ynyl)benzoate,10a 3 -phenyl-1 - [4-(trifluoromethyl)phenyl]prop-2-yn-1 -
one,10a 3-phenyl-1 -otolylprop-2-yn-1 -one,10a 1 -(3,4,5-trimethoxyphenyl)but-2-yn-1 -
one,10a 3-phenyl-1 -(pyridin-3-yl)prop-2-yn-1 -one,10a 1 -[4-(dimethylamino)phenyl]-3-
phenylprop-2-yn-l-one,10a l-(benzo[d][l,3]dioxol-5-yl)-3-phenylprop-2-yn-l-one,10a 3-
(cyclohex-1 -enyl)-1 -phenylprop-2-yn-1 -one,10b 4-(3-phenylpropynoyl)benzonitrile,32 1 -
(4-bromophenyl)-3-phenylprop-2-yn-l-one33 and l-(naphthalen-2-yl)-3-phenylprop-2-
1 34 yn-l-one. 
General procedure for the preparation of alkynones from acetyl chlorides. To a 25 
mL flask were added Cul (0.05 mmol), PdCl2(PPhs)2 (0.01 mmol) and triethylamine (5 
mL). The flask was flushed with argon and the terminal acetylene (2.5 mmol) was added 
to the stirred suspension, followed by immediate dropwise addition of benzoyl chloride 
(3.25 mmol, 1.3 equiv). If the acid chloride is a solid, it was added as a THF solution. 
The resulting mixture was allowed to stir at room temperature overnight, filtered through 
a plug of silica gel, and concentrated under reduced pressure. The residue was then 
purified by column chromatography on silica gel to afford the desired alkynone. 
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3-[(4-tert-Butyl)phenyl]-l-phenylpr op ynone. Purification by flash chromatography 
(20:1 hexanes/EtOAc) afforded 538 mg (82%) of the product with spectral properties 
identical to those previously reported. 
l-(4-Fluorophenyl)-3-phenylprop-2-yn-l-one. Purification by flash chromatography 
(20:1 hexanes/EtOAc) afforded 488 mg (87%) of the product with spectral properties 
identical to those previously reported.35 
General procedure for preparation of the l-acetyl-5-hydroxy-4,5-dihydro-l//-
pyrazoles. The alkynone (1.0 mmol), acetyl hydrazide (2.0 mmol, 148.2 mg) in toluene 
(5 mL) were heated to 80 °C with stirring. The reaction was monitored by TLC until the 
reaction was complete. The solution was concentrated under a vacuum to yield the crude 
product, which was purified by flash chromatography on silica gel using CH2Cl2/EtOAc 
as the eluent. 
l-Acetyl-3,5-diphenyl-5-hydroxy-4,5-dihydro-l//-pyrazole (16). The product was 
obtained as a colorless solid: mp 139-141 °C; JH NMR (CDC13, 300 MHz) 8 2.44 (s, 1H), 
3.33-3.39 (d, J = 18.3 Hz, 1H), 3.67-3.73 (d, J = 18.2 Hz, 1H), 5.12 (s, 1H), 7.29-7.43 
(m, 8H), 7.69-7.72 (m, 2H); 13C NMR (CDC13) 8 22.52, 50.74, 94.04, 124.11, 126.76, 
128.37, 129.01, 130.74, 131.36, 143.98, 152.84, 171.08 (1 peak missing due to overlap); 
HRMS Calcd for CI 7HI 6N 20 2 : 280.1212. Found: 280.1221. 
Ethyl-4-(l-acetyl-5-hydroxy-5-phenyl-4,5-dihydro-l//-pyrazol-3-yl)benzoate (17). 
The product was obtained as a pale yellow solid: mp 137-139 °C; lH NMR (CDC13, 400 
MHz) 8 1.41 (t, / = 7.1 Hz, 3H), 2.45 (s, 3H), 3.35-3.40 (d, / = 18.3 Hz, 1H), 3.69-3.73 
(d, / = 18.3 Hz, 1H), 4.37-4.42 (q, / = 7.2 Hz, 2H), 5.10 (s, 1H), 7.29-7.43 (m, 5H), 7.75-
7.77 (d, J = 8.4 Hz, 2H), 8.07-8.09 (d, J = 8.4 Hz, 2H); 13C NMR (CDC13) 8 14.49, 
22.50, 61.44, 94.15, 123.98, 126.48, 128.94, 130.04, 131.99, 135.26, 143.58, 151.65, 
166.04, 171.09; HRMS Calcd for C2 0H2oN204 : 352.1423. Found: 352.1411. 
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l-Acetyl-3-butyl-5-hydroxy-5-phenyl-4,5-dihydro-l//-pyrazole (18). The product was 
obtained as a yellow oil: JH NMR (CDC13, 300 MHz) 8 0.93 (t, J = 7.3 Hz, 3H), 1.35-
1.42 (m, 2H), 1.53-1.62 (m, 2H), 2.32 (s, 3H), 2.35 (t, / = 7.7 Hz, 2H), 2.88-2.94 (d, / = 
18.6 Hz, 1H), 3.23-3.30 (d, J = 18.5 Hz, 1H), 7.25-7.36 (m, 5H); 13C NMR (CDC13) 8 
13.93, 22.37, 22.55, 28.53, 30.12, 52.87, 93.31, 123.97, 128.11, 128.84, 144.12, 157.98, 
170.58; HRMS Calcd for CI5H20N2O2: 260.1525. Found: 260.1526. 
l-Acetyl-3-(l-cyclohexenyl)-5-hydroxy-5-phenyl-4,5-dihydro-l//-pyrazole (19). The 
product was obtained as a pale yellow oil: lH NMR (CDCI3, 300 MHz) 8 1.63-1.71 (m, 
4H), 2.18 (br s, 2H), 2.34 (s, 3H), 2.43 (br s, 2H), 3.07-3.13 (d, / = 17.8 Hz, 1H), 3.39-
3.45 (d, / = 17.9 Hz, 1H), 5.09 (s, 1H), 5.98-6.01 (m, 1H), 7.24-7.38 (m, 5H); 13C NMR 
(CDCI3) 8 22.13, 22.19, 22.28, 24.37, 26.15, 49.97, 93.49, 123.99, 128.06, 128.78, 
131.80, 134.08, 144.14, 154.86, 170.80; HRMS Calcd for CI7H20N2O2: 284.1525. 
Found: 284.1528. 
l-Acetyl-5-hydroxy-5-(2-naphthyl)-3-phenyl-4,5-dihydro-l//-pyrazole (20). The 
product was obtained as a pale yellow oily solid: lU NMR ( C D C I 3 , 400 MHz) 8 2.46 (s, 
3H), 3.38-3.42 (d, / = 18.3 Hz, 1H), 3.71-3.76 (d, / = 18.2 Hz, 1H), 5.31 (s, 1H), 7.36-
7.47 (m, 6H), 7.69-7.71 (m, 2H), 7.77-7.83 (m, 3H), 7.93-7.94 (d, / = 1.4 Hz, 1 H); 13C 
NMR (CDCI3) 8 22.49, 50.61, 93.99, 122.06, 122.95, 126.42, 126.56, 126.66, 127.72, 
128.49, 128.88, 129.03, 130.64, 131.20, 133.11, 133.18, 141.07, 152.81, 171.01; HRMS 
Calcd for C 2 I H I 6 N 2 0 (M+ - H 2 0 ) : 312.1263. Found: 312.1263. 
l-Acetyl-5-(4-fhiorophenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-pyrazole (21). The 
product was obtained as a yellow oil: lH NMR (CDCI3, 400 MHz) 8 2.43 (s, 3H), 3.29-
3.34 (d, / = 18.2 Hz, 1H), 3.67-3.71 (d, / = 18.2 Hz, 1H), 5.34 (br s, 1H), 6.99-7.04 (m, 
2H), 7.36-7.42 (m, 5H), 7.68-7.71 (m, 2H); 13C NMR (CDC13) 8 22.49, 50.73, 93.54, 
115.56, 115.78, 125.91, 125.99, 126.64, 128.89, 130.70, 131.09, 139.73, 139.76, 152.76, 
161.26, 163.72, 170.99 (extra peaks due to C-F splitting); HRMS Calcd for 
C I 7 H I 5 F N 2 0 2 : 298.1118. Found: 298.1108. 
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FIGURE 1: X-Ray Crystal Structure of Product 22. 
l-Acetyl-5-(4-chlorophenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-pyrazole (22). The 
product was obtained as a pale yellow solid: mp 138-140 °C; JH NMR (CDC13, 300 
MHz) 8 2.41 (s, 3H), 3.24-3.30 (d, / = 18.3 Hz, 1H), 3.62-3.68 (d, / = 18.3 Hz, 1H), 5.40 
(br s, 1H), 7.20-7.41 (m, 8H), 7.65-7.69 (m, 2H); 13C NMR (CDC13) 8 22.36, 50.57, 
93.22, 125.55, 126.54, 128.79, 130.59, 130.94, 133.82, 142.36, 152.61, 170.71 (1 peak 
missing due to overlap); HRMS Calcd for CI7HI5C1N202: 314.0822. Found: 314.0826. 
l-Acetyl-5-(4-bromophenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-pyrazole (23). The 
product was obtained as a pale yellow solid: mp 168-169 °C; lH NMR (CDC13, 300 
MHz) 8 2.43 (s, 3H), 3.29-3.36 (d, / = 18.3 Hz, 1H), 3.67-3.73 (d, / = 18.3 Hz, 1H), 5.13 
(br s, 1H), 7.27-7.32 (m, 2H), 7.40-7.51 (m, 5H), 7.68-7.72 (m, 2H); 13C NMR (CDC13) 8 
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22.43, 50.56, 93.53, 122.39, 126.00, 126.73, 129.00, 130.85, 131.06, 132.08, 143.04, 
152.83, 171.14; HRMS Calcd for Ci 7 Hi 3 BrN 2 0 (M+ - H 2 0) : 340.0211. Found: 
340.0200. 
l-Acetyl-5-hydroxy-3-phenyl-5-(4-(trifluoromethyl)phenyl)-4,5-dihydro-l//-
pyrazole (24). The product was obtained as a colorless solid: mp 169-171 °C; JH NMR 
( C D C 1 3 , 400 MHz) 8 2.46 (s, 3H), 3.32-3.37 (d, / = 18.3 Hz, 1H), 3.71-3.75 (d, / = 18.4 
Hz, 1H), 5.24 (s, 1H), 7.40-7.45 (m, 3H), 7.54-7.56 (d, / = 8.1 Hz, 2H), 7.61-7.64 (d, / = 
8.3 Hz, 2H), 7.70-7.72 (m, 2H); 1 3 C NMR ( C D C 1 3 ) 8 22.46, 50.62, 93.41, 115.51, 
124.66, 125.58, 125.85, 125.99, 126.02, 126.06, 126.10, 126.72, 126.74, 126.76, 126.77, 
129.01, 129.03, 129.04, 129.19, 130.37, 130.69, 130.92, 130.95, 147.68, 147.70,152.87, 
171.20 (extra peaks due to C-F splitting); HRMS Calcd for CI 8 HI 3 F 3 N 2 0 (M+ - H 2 0) : 
330.0988. Found: 330.0980. 
l-Acetyl-5-(4-cyanophenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-pyrazole (25). The 
product was obtained as a colorless solid: mp 179-180 °C; 'H NMR (CDC13, 400 MHz) 8 
2.44 (s, 3H), 3.30-3.35 (d, / = 18.4 Hz, 1H), 3.70-3.75 (d, / = 18.3, 1H), 5.19 (s, 1H), 
7.40-7.48 (m, 3H), 7.53-7.55 (d, / = 8.4 Hz, 2H), 7.65-7.67 (d, J = 8.3 Hz, 2H), 7.70-7.72 
(dd, J = 1.7, 7.6 Hz, 2H); 13C NMR (CDC13) 8 22.35, 50.47, 93.10, 112.18, 118.61, 
125.09, 126.70, 128.98, 130.72, 130.96, 132.80, 148.80, 152.81, 171.09; HRMS Calcd 
fo rCi 8 Hi 5 N 3 0 2 : 305.1164. Found: 305.1165. 
l-Acetyl-5-(4-?ert-butylphenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-pyrazole (26). 
The product was obtained as a pale yellow solid: mp 199-201 °C; JH NMR (CDC13, 400 
MHz) 8 1.29 (s, 9H), 2.44 (s, 3H), 3.33-3.37 (d, / = 18.2 Hz, 1H), 3.65-3.70 (d, / = 18.2 
Hz, 1H), 5.13 (s, 1H), 7.31-7.40 (m, 7H), 7.68-7.70 (m, 2H); 13C NMR (CDC13) 8 22.51, 
31.48, 34.66, 50.62, 93.99, 123.70, 125.78, 126.62, 128.84, 130.56, 131.29, 140.81, 
150.99, 152.78, 170.93; HRMS Calcd for C 2 iH 2 4 N 2 0 2 : 336.1838. Found: 336.1831. 
l-Acetyl-5-hydroxy-5-(3,4-methylenedioxyphenyl)-3-phenyl-4,5-dihydro-l//-
pyrazole (27). The product was obtained as a light brown solid: mp 138-140 °C; JH 
NMR (CDC13, 300 MHz) 8 2.43 (s, 3H), 3.30-3.36 (d, / = 18.3 Hz, 1H), 3.64-3.70 (d, / = 
18.3 Hz, 1H), 5.10 (br s, 1H), 5.93 (s, 2H), 6.75-6.78 (d, / = 8.1 Hz, 1H), 6.86-6.93 (m, 
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2H), 7.39-7.42 (m, 3H), 7.68-7.71 (m, 2H); 13C NMR (CDC13) 8 22.47, 50.67, 93.87, 
101.46, 105.04, 108.44, 117.38, 126.66, 128.91, 130.67, 131.24, 138.12, 147.55, 148.25, 
152.81, 11.06; HRMS Calcd for C I 8 H I 6 N 2 04: 324.1110. Found: 324.1120. 
l-Acetyl-5-hydroxy-3-methyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-l//-pyrazole 
(28). The product was obtained as a yellow solid: mp 108-111 °C; JH NMR (CDC13, 400 
MHz) 8 2.06, (s, 3H), 2.34 (s, 3H), 2.90-2.95 (d, / = 18.8 Hz, 1H), 3.23-3.27 (d, / = 18.8 
Hz, 1H), 3.82 (s, 3H), 3.84 (s, 6H), 5.16 (s, 1H), 6.57 (s, 2H); 13C NMR (CDC13) 8 16.08, 
22.29, 54.31, 56.10, 60.72, 93.41, 100.92, 137.42, 139.65, 153.38, 154.52, 170.44; 
HRMS Calcd for Ci5H2oN205: 308.1372. Found: 308.1364. 
l-Acetyl-5-(4-(A^,A^-dimethylamino)phenyl)-5-hydroxy-3-phenyl-4,5-dihydro-l//-
pyrazole (29). The product was obtained as an orange solid: mp 123-125 °C; JH NMR 
(CDC13, 300 MHz) 8 2.42 (s, 3H), 2.91 (s, 6H), 3.32-3.38 (d, J = 18.3 Hz, 1H), 3.64-3.70 
(d, J = 18.3, 1H), 5.08 (s, 1H), 6.67-6.70 (d, J = 9.0 Hz, 2H), 7.24-7.27 (d, J = 9.0 Hz, 
2H), 7.38-7.40 (m, 3H), 7.68-7.71 (m, 2H); 13C NMR (CDC13) 8 22.47, 40.59, 50.59, 
94.17, 112.48, 124.86, 126.58, 128.82, 130.45, 131.47, 131.55, 150.36, 152.76, 170.86; 
HRMS Calcd for C I 9 H 2 I N 3 0 2 : 323.1634. Found: 323.1622. 
l-Acetyl-5-hydroxy-5-(2-methylphenyl)-3-phenyl-4,5-dihydro-l//-pyrazole (30). The 
product was obtained as a pale yellow solid: mp 135-137 °C; lH NMR (CDC13, 400 
MHz) 8 2.36 (br s, 3H), 2.46 (s, 3H), 3.36-3.40 (d, / = 18.4 Hz, 1H), 3.70-3.74 (d, / = 
18.4 Hz, 1H), 5.21 (br s, 1H), 7.16-7.23 (m, 3H), 7.38-7.40 (m, 4H), 7.69-7.71 (m, 2H); 
13C NMR (CDCls) 8 20.87,22.45,49.08,94.26, 125.20, 126.05, 126.62, 128.42, 128.83, 
130.59, 131.13, 132.59, 134.57, 140.35, 153.41, 171.13; HRMS Calcd for C I 8 H I 8 N 2 0 2 : 
294.1368. Found: 294.1367. 
l-Acetyl-5-hydroxy-3-phenyl-5-(3-pyridinyl)-4,5-dihydro-l//-pyrazole (31). The 
product was obtained as a pale orange solid: mp 154-157 °C; *H NMR (CDC13, 300 
MHz) 8 2.43 (s, 3H), 3.52-3.38 (d, J = 18.3 Hz, 1H), 3.70-3.76 (d, / = 18.3 Hz, 1H), 5.79 
(br s, 1H), 7.24-7.28 (m, 1H), 7.39-7.43 (m, 3H), 7.67-7.75 (m, 3H), 8.51-8.52 (d, / = 3.6 
Hz, 1H), 8.67-8.68 (d, / = 1.5 Hz, 1H); 13C NMR (CDC13) 8 22.37, 50.69, 92.33, 123.42, 
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126.61, 128.86, 130.73, 130.88, 132.12, 139.32, 146.15, 149.27, 152.58, 170.86; HRMS 
Calcd for C16H15N3O2: 281.1164. Found: 281.1173. 
l-Acetyl-5-hydroxy-3-phenyl-5-styryl-4,5-dihydro-l//-pyrazole (32). The product was 
obtained as an orange oil: JH NMR (CDC13, 400 MHz) 8 2.42 (s, 3H), 3.39-3.43 (d, J = 
18.4 Hz, 1H), 3.52-3.57 (d, / = 18.4 Hz, 1H), 5.05 (br s, 1H), 6.54-6.58 (d, / = 16.0 Hz, 
1H), 6.71-6.75 (d, J = 16.0 Hz, 1H), 7.23-7.31 (m, 2H), 7.37-7.42 (m, 6H), 7.69-7.72 (m, 
2H); 13C NMR ( C D C 1 3 ) 8 22.57, 47.77, 92.56, 126.59, 127.01, 128.23, 128.70, 128.88, 
129.71, 130.33, 130.59, 131.27, 135.81, 152.99, 171.09; HRMS Calcd for C I 9 H I 8 N 2 0 2 : 
306.1368. Found: 306.1374. 
General procedure for dehydration/iodination of l-acetyl-5-hydroxy-4,5-dihydro-
1 //-pyrazoles using IC1. The appropriate l-acetyl-5-hydroxy-4,5-dihydro-l//-pyrazole 
(0.25 mmol) and finely powdered O2CO3 (0.5 mmol) in C H 2 C I 2 (2.5 mL) were allowed 
to stir vigorously for 5 min. at room temperature. To the vigorously stirred slurry, in the 
absence of light, was added a freshly prepared solution of IC1 (1M in C H 2 C I 2 , 3.0 equiv) 
slowly and the solution was allowed to stir at room temperature. The reaction was 
monitored by TLC to establish completion. The excess IC1 was removed by washing with 
a satd aq soln of Na2S203. The aqueous solution was then extracted with C H 2 C I 2 ( 3 x 5 
mL). The combined organic layers were dried over anhydrous MgSC>4 and concentrated 
under a vacuum to yield the crude product, which was purified by flash chromatography 
on silica gel using hexanes/EtOAc as the eluent. 
l-Acetyl-4-iodo-3,5-diphenyl-l//-pyrazole (33). The product was obtained as an off 
white solid: mp 86-88 °C; JH NMR (CDCI3, 300 MHz) 8 2.75 (s, 3H), 7.34-7.38 (dd, / = 
3.8, 7.4 Hz, 2H), 7.44-7.53 (m, 6H), 7.90-7.93 (m, 2H); 13C NMR (CDC13) 8 23.08, 
71.67, 128.39, 128.59, 128.91, 129.36, 129.54, 129.82, 131.37, 131.88, 148.09, 154.28, 
169.37; HRMS Calcd for Ci7Hi3IN20: 388.0073. Found: 388.0073. 
l-Acetyl-3-(4-(ethoxycarbonyl)phenyl)-4-iodo-5-phenyl-l//-pyrazole (34). The 
product was obtained as an off white solid: mp 105-107 °C; 'H NMR (CDCI3, 300 MHz) 
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8 1.41-1.45 (t, / = 7.2 Hz, 3H), 2.76 (s, 3H), 4.39-4.46 (q, / = 7.2 Hz, 2H), 7.35-7.38 (m, 
2H), 7.48-7.50 (m, 3H), 8.02-8.05 (dd, / = 1.8, 6.6 Hz, 2H), 8.16-8.19 (td, / = 1.8, 6.9 
Hz, 2H); 13C NMR (CDC13) 8 14.53, 23.06, 61.37, 71.30, 128.44, 128.79, 129.48, 
129.78, 131.11, 131.23, 136.11, 148.38, 153.19, 166.39, 169.28 (1 peak missing due to 
overlap); HRMS Calcd for C20H17IN2O3: 460.0284. Found: 460.0292. 
1 -Acetyl-3-butyl-4-iodo-5-phenyl-1 //-pyrazole (35). The product was obtained as a 
pale yellow oil: JH NMR (CDCI3, 300 MHz) 8 0.97-1.02 (t, J = 7.3 Hz, 3H), 1.41-1.53 
(m, 2H), 1.68-1.78 (m, 2H), 2.64-2.69 [(m (a singlet merged with a triplet) 5H)], 7.30-
7.45 (m, 5H); 1 3 C NMR ( C D C I 3 ) 8 14.09, 22.71, 23.10, 28.58, 30.43, 74.14, 128.26, 
129.18, 129.72, 131.37, 146.84, 157.05, 169.28; HRMS Calcd for C I 5 H I 7 I N 2 0 : 
368.0386. Found: 368.0382. 
l-Acetyl-4-iodo-5-(naphthalen-2-yl)-3-phenyl-lH-pyrazole (37). The product was 
obtained as a yellow oil: JH NMR (CDCI3, 400 MHz) 8 2.75 (s, 3H), 7.41-7.56 (m, 6H), 
7.88-7.95 (m, 6H); 1 3 C NMR ( C D C I 3 ) 8 23.09, 72.03, 126.56, 127.07, 127.08, 127.96, 
128.06, 128.53, 128.59, 128.68, 128.91, 129.49, 129.55, 131.86, 132.98, 133.51, 147.95, 
154.40, 169.34; HRMS Calcd for C 2 I H I 5 I N 2 0 : 438.0229. Found: 438.0237. 
l-Acetyl-3-(4-fluorophenyl)-4-iodo-5-phenyl-l//-pyrazole (38). The product was 
obtained as a pale yellow oil: JH NMR (CDCI3, 400 MHz) 8 2.75 (s, 3H), 7.15-7.19 (t, J 
= 8.7 Hz, 2H), 7.34-7.37 (m, 2H), 7.46-7.52 (m, 3H), 7.90-7.92 (dd, / = 1.8, 7.6 Hz, 2H); 
13C NMR ( C D C I 3 ) 8 23.16, 72.13, 115.56, 115.78, 127.24, 127.27, 128.15, 128.66, 
128.91, 129.65, 131.77, 131.88, 131.96, 147.13, 154.36, 162.07, 164.54, 169.55 (extra 
peaks due to C-F splitting); HRMS Calcd for C I 7 H I 2 F I N 2 0 : 405.9978. Found: 405.9973. 
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FIGURE 2: X-Ray Crystal Structure of Product 39. 
l-Acetyl-3-(4-chlorophenyl)-4-iodo-5-phenyl-l//-pyrazole (39). The product was 
obtained as a pale yellow solid: mp 128-130 °C; JH NMR (CDC13, 300 MHz) 8 2.74 (s, 
3H), 7.28-7.32 (td, / = 2.1. 8.7 Hz, 2H), 7.43-7.50 (m, 5H), 7.89-7.92 (m, 2H); 13C NMR 
(CDCls) 8 23.04, 71.97, 128.63, 128.76, 128.88, 129.64, 129.71, 131.29, 131.67, 135.49, 
146.87, 154.41, 169.46; HRMS Calcd for CI7HI2C1IN20: 421.9683. Found: 421.9691. 
l-Acetyl-3-(4-bromophenyl)-4-iodo-5-phenyl-l//-pyrazole (40). The product was 
obtained as a pale yellow solid: mp 134-137 °C; JH NMR (CDC13, 400 MHz) 8 2.74 (s, 
3H), 7.23-7.25 (d, / = 8.5 Hz, 2H), 7.47-7.49 (m, 3H), 7.50-7.62 (m, 2H), 7.89-7.91 (dd, 
/ = 1.9, 7.7 Hz, 2H); 13C NMR (CDC13) 8 23.07, 71.93, 126.82, 128.62, 128.86, 129.63, 
130.19, 131.50, 131.64, 131.69, 146.86, 154.42, 169.43; HRMS Calcd for 
Ci7Hi2BrIN20: 465.9178. Found: 465.9186. 
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l-Acetyl-4-iodo-5-phenyl-3-(4-(trifluoromethyl)phenyl)-l//-pyrazole (41). The 
product was obtained as a colorless solid: mp 98-101 °C; 'H NMR (CDC13, 400 MHz) 8 
2.76 (s, 3H), 7.49-7.53 (m, 5H), 7.73-7.75 (d, J = 8.2 Hz, 2H), 7.90-7.92 (m, 2H); 13C 
NMR (CDC13) 8 22.97, 72.00, 125.37, 125.40, 125.44, 125.48, 128.12, 128.66, 128.85, 
128.89, 129.73, 130.31, 130.39, 131.08, 131.53, 135.07, 146.52, 154.59, 169.44 (extra 
peaks due to C-F splitting); HRMS Calcd for Ci8Hi2F3IN20: 455.9946. Found: 
455.9956. 
l-Acetyl-3-(4-cyanophenyl)-4-iodo-5-phenyl-l//-pyrazole (42). The product was 
obtained as a pale yellow solid: mp 170-172 °C; JH NMR (CDC13, 400 MHz) 8 2.76 (s, 
3H), 7.48-7.52 (m, 5H), 7.76-7.79 (m, 2H), 7.89-7.91 (m, 2H); 13C NMR ( C D C I 3 ) 8 
22.90, 72.04, 113.18, 118.66, 128.70, 128.87, 129.81, 130.80, 131.36, 132.19, 136.12, 
145.94, 154.72, 169.43; HRMS Calcd for Ci 8Hi 2 IN 30: 413.0025. Found: 413.0026. 
l-Acetyl-3-(4-tert-butylphenyl)-4-iodo-5-phenyl-l//-pyrazole (43). The product was 
obtained as a pale yellow oil: JH NMR (CDC13, 400 MHz) 8 1.37 (s, 9H), 2.74 (s, 3H), 
7.29-7.31 (dd, J = 2.0, 6.6 Hz, 2H), 7.46-7.51 (m, 5H), 7.90-7.93 (dd, / = 1.6, 7.9 Hz, 
2H); 13C NMR (CDC13) 8 23.20, 31.52, 35.02, 71.71, 125.26, 128.10, 128.13, 128.55, 
128.91, 129.47, 131.94, 148.21, 152.22, 154.30, 169.49; HRMS Calcd for C 2 iH 2 i IN 2 0: 
444.0699. Found: 444.0707. 
l-Acetyl-4-iodo-3-(3,4-methylenedioxyphenyl)-5-phenyl-l//-pyrazole (44). The 
product was obtained as a pale yellow solid: mp 101-103 °C; lH NMR (CDCI3, 400 
MHz) 8 2.76 (s, 3H), 6.03 (s, 2H), 6.81-6.92 (m, 3H), 7.47-7.49 (m, 3H), 7.88-7.92 (m, 
2H); 13C NMR ( C D C I 3 ) 8 23.15, 72.07, 101.61, 108.39, 110.26, 110.33, 123.90, 124.55, 
128.56, 128.85, 129.52, 131.84, 147.66, 148.51, 154.17, 169.39; HRMS Calcd for 
CI8HI3IN203 : 431.9971. Found: 431.9980. 
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Chapter 4. The Synthesis of Oxazolium Salts by Iodocyclization of Alkynamides. 
Efforts Towards Dequaternization 
Jesse P. Waldo and Richard C. Larock* 
Department of Chemistry, Iowa State University, Ames, IA 50011 
larock@iastate.edu 
Abstract 
O /TIPS 
J ^ l2 R V y T ' P S toluene, 230 ^ R ^ ° y n P S 
N + - \ or N J 
Me Me |- I 2:1 PhCI/sulfolane | 
150 °C 
R N i 
Oxazolium salts are readily prepared by the iodine-induced cyclization of alkynamides. 
These oxazolium iodide salts are highly stable and attempts at their dequaternization have 
been met with limited success. 
Introduction 
Oxazoles have become the focus of many synthetic efforts due to their wide 
occurrence in natural products.1 A number of compounds with the oxazole core have 
been examined as antitumor agents, antileukemia agents, antiviral agents, antifungal 
agents, ichthyotoxic agents, herpes simplex virus type 1 (HSV-1) inhibitors, serine-
threonine phosphatase inhibitors, antibacterial agents, antialgicidal agents, and peripheral 
analgesics.2 Oxazoles have also proven to be useful intermediates in the synthesis of a 
variety of biologically interesting scaffolds.3'4 Though an assortment of synthetic 
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methods for the construction of the oxazole core exist in the literature,5 the demand for 
facile syntheses of this important class of heterocycle still remain. 
The Larock group and others have studied electrophile-induced annulations of 
functionally substituted alkynes to form various heterocycles and carbocycles over the 
years, including bcnzo[/;]thiophcncs,6 isoquinolines and naphthyridines,7 isocoumarins 
8 9 10 11 12 13 
and a-pyrones, benzofurans, furans, indoles, furopyridines, cyclic carbonates, 
2,3-dihydropyrroles and pyrroles,14 pyrilium salts and isochromenes,15 bicyclic P-
lactams,16 2//-benzopyrans,17 naphthalenes and 2-naphthols,18 chromones,19 isoindolin-
1-ones,20 benzo[£>]selenophenes21 and isoxazoles.22 
With convenient copper-catalyzed approaches to alkynamides presently available,23 
we reasoned that their electrophilic cyclization should afford oxazoles (Scheme 1). 
Scheme 1 
X H 15% C U S 0 4 * 5 H 2 0 5 ^ T I P S E-X 
+ B r ^ ^ T I P S ^ V F 
Me 30% 1,10-phenanthroline
 E 
2 K3PO4, toluene 
75 °C 
The proposed mechanism for the formation of an oxazole from an alkynamide is 
outlined in Scheme 2. This involves coordination of the electrophile to the triple bond, 
which leads to cation 1, followed by intramolecular nucleophilic attack by the oxygen of 
the amide to provide intermediate 2, and subsequent demethylation by the counterion to 
afford the oxazole. 
Scheme 2 
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This chapter describes our efforts to synthesize new oxazolium iodides and oxazoles 
by the electrophilic cyclization of alkynamides. 
Results and Discussion 
To examine the electrophilic cyclization process, we prepared the alkynamide 3 by 
the copper-catalyzed cross-coupling of /V-mcthylbcnzamidc with l-bromo-2-
(triisopropylsilyl)acetylene (eq 1). 
O 15% C U S 0 4 * 5 H 2 0 O TIPS 
y 30% 1,10-phenanthroline y 
P h ^ N H + Br = TIPS • P h ^ N ^
 m 
i K3PO4, toluene i I 1 ) 
M e
 2 days, 75 °C M e 
86% 3 
With alkynamide 3 in hand, we employed iodine electrophiles in the electrophilic 
cyclization process using C H 2 C I 2 as the solvent. IC1 proved unsuccessful as an 
electrophile, providing only adducts arising from IC1 addition across the triple bond. 
However, I2 showed promise as an electrophile. Complete conversion of the alkynamide 
was observed when stirring at room temperature for 12 h in C H 2 C I 2 . The resulting 
product was extremely polar and could not be isolated by column chromatography on 
silica gel. The compound was finally isolated pure by crystallization from methanol. 
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Unfortunately, 1H NMR spectroscopic analysis revealed that the /V-mcthyl group was still 
present in the product. As expected the /V-mcthyloxazolium iodide salt 4 is apparently 
formed, but fails to undergo demethylation to the desired oxazole under our reaction 
conditions (eq 2). This assumption is based on four pieces of information: (i) the 
formation of a highly polar molecule as judged by silica gel TLC, (ii) the mass of the 
isolated compound was higher than the theoretical mass of the parent oxazole, (iii) a 
downfield shift of the N-Mq protons24 in the 1H NMR spectrum relative to the /V-mcthyl 
alkynamide, and (iv) mass spectroscopic analysis indicating a loss of methyl iodide in 
addition to a peak at m/z = 427. The proposed structure of oxazolium salt 4 was 
ultimately proven by x-ray crystallography (Figure 1). 
(2) 
4 
C2 
C12 
C10 
Figure 1. ORTEP diagram of 4 
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With success in the electrophilic cyclization process, we focused our attention on 
demethylation of the oxazolium salt 4 (Table 1). Our initial efforts at demethylating 4 
focused on increasing the amount of iodide ion in the reaction mixture. We reasoned that 
an increase in the concentration of the nucleophilic counter ion could promote 
demethylation of 4 and lead to oxazole 5. Thus, Lil was employed under various reaction 
conditions using C H 2 C I 2 , C H 3 C N and DMF as solvents at various temperatures (Table 1, 
entries 1-6). Unfortunately, these reactions did not provide any significant amount of 5. 
Organic bases, such as pyridine and DABCO, were also employed in attempts to 
dequaternize 4 (Table 1, entries 7 and 8). However, these experiments did not produce 
any oxazole 5, although oxazolium bromides, tosylates and perchlorates have been 
dequaternized in the presence of refluxing pyridine.25 Sodium sulfide and sodium 
thiophenoxide26 were examined as nucleophiles in the dequaternization process, which 
led to 100% conversion of 4, but the only products isolated from these reactions appeared 
to be ring-opened products (Table 1, entries 9 and 10). Similar results have been reported 
in the literature when sodium hydrosulfide was allowed to react with /V-mcthyl 
oxazolium salts.27 
It has been reported in the literature that heating oxazolium salts to temperatures of 
230 °C in toluene leads to oxazole products. Our attempts at thermal demethylation of 4 
led to the desired 4-iodo-2-phenyl-5-(triisopropylsilyl)oxazole (5), but in only a modest 
yield (Table 1, entry 11). Adding pyridine to remove the dissociated methyl iodide did 
not improve the outcome of the demethylation (Table 1, entry 12). Use of the inorganic 
silver bases Ag 2 C0 3 and AgOAc in ethanol led to complete conversion of 4, but the 
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products were inseparable mixtures of 5, its desilylated counterpart, and another 
unidentifiable compound (Table 1, entries 13 and 14). 
Triphenylphosphine has been reported to act as an alkyl halide scavenger in 
dequaternization reactions.28 It has been suggested that dequaternization occurs by 
nucleophilic attack of the counterion and that the PPI13 serves to absorb the alkyl halide, 
thus preventing the reverse reaction from taking place. When compound 4 was heated to 
150 °C in DMF in the presence of PPI13, no conversion of 4 was observed (Table 1, entry 
15). When the solvent was changed to 2:1 PhCl/sulfolane under similar reaction 
conditions, 5 was isolated in a 68% yield (Table 1, entry 16). Unfortunately, this 
procedure was not reproducible as high yields could not be achieved when the 
experiment was repeated. 
4
 — - IT 
5 1 
Table 1. Demethylation of 4-iodo-3-methyl-2-phenyl-5-(triisopropylsilyl)oxazolium 
iodide.a 
entry additive temp. (°C) solvent time (h) 5 % yield1 
1 Lil r l CH2C12 24 -
2 Lil reflux CH2C12 24 
3 Lil r.t. CH3CN 24 
4 Lil reflux CH3CN 24 
5 Lil reflux CH3CN 24 
F~ 
100 
Lil 
11 
Na2S 
10 NaSPh 
150 °C 
reflux 
8 DABCO r.t. 
r.t. 
r.t. 
230 
12 pyridine 230 
13 Ag 2 C0 3 80 
14 AgOAc 80 
15 PPh3 150 
16 PPh3 150 
DMF 12 
pyridine 12 
CH3CN 24 
CH3CN 6 
CH3CN 6 
toluene 0.15 
toluene 0.15 
EtOH 6 
EtOH 6 
DMF 0.15 
PhCksulfolane 0.15 
2:1 
0 
0d 
48e 
44e 
22f 
27f 
68 
a) Unless otherwise stated, all reactions were carried out using 0.25 mmol of the crude product 4 from the 
iodine-induced cyclization of 3. b) Isolated yield after column chromatography, c) No reaction, d) Ring-
opened products, e) The reaction was performed in a microwave reactor, f) Yield determined by NMR 
spectroscopy. 
Since the demethylation of 4 proved difficult, other alkynamides were synthesized in 
order to test different leaving groups on the nitrogen atom (Table 2). For reasons of atom 
economy and the ready availability of substituted primary benzamides from commercial 
sources, benzamide was examined as a model alkynamide precursor. However, 
benzamide did not prove to be a good cross-coupling partner here, and none of the 
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desired alkynamide was detected after 2 days of reaction (Table 2, entry 1). We felt that a 
t-Bu group might be promising, given that the Larock group has previously reported that 
acetylenic /-butylimincs cyclize readily in the presence of electrophiles to provide 
butylbenzamide was subjected to the alkyne cross-coupling conditions, none of the 
desired alkynamide product was observed (Table 2, entry 2). This result might be due to 
the steric bulk of the t-Bu group hindering the cross-coupling reaction. N-
(Trimethylsilyl)benzamide was also examined as a cross-coupling partner with alkynes, 
since it was felt that the longer C-Si bond length of a TMS group, compared with a t-Bu 
group, might allow for a successful cross-coupling. When R = TMS, the reaction 
proceeded to give complex mixtures with no sign of the desired alkynamide 8 (Table 2, 
entry 3). An /V-MOM benzamide did not undergo cross-coupling either and none of the 
desired alkynamide 9 was observed (Table 2, entry 4). This reaction may not have 
proceeded, because of unfavorable chelation of the copper with the MOM-protected 
amide. /V-Bcnzylbcnzamidc proved highly successful in the cross-coupling reaction and 
provided the corresponding alkynamide 10 in high yield (Table 2, entry 5). /V-(4-
Methoxybenzyl)benzamide reacted to form the desired ynamide 11, although the yield 
was poor (Table 2, entry 6). /V-Allylbcnzamidc proved to be an average coupling partner 
with the bromosilylacetylene and a moderate yield of alkynamide 12 was achieved (Table 
2, entry 7). 
isoquinolines in excellent yields under mild reaction conditions.7 When N-t-
A 
0 15% C U S 0 4 * 5 H 2 0 
30% 1,10-phenanthroline 
Ph NH + Br 
R 
TIPS 
K3PO4, toluene 
2 days, 75 °C R 
Table 2. Synthesis of alkynamides. a 
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entry R alkynamide yield (%)b 
l c H 6 0 
2 t- Bu 7 0 
3 TMS 8 0 
4 MOM 9 0 
5 Bn 10 87 
6 4-MeOC6H4CH2 11 43 
7 allyl 12 48 
a) Unless otherwise specified, the reaction was carried out using 7.33 mmol of the amide, 1.0 equiv of 1-
bromo-2-(triisopropylsilyl)acetylene, 15 mol % CuS0 4 , 5H 2 0, 30 mol % 1,10-phenanthroline, 1 equiv of 
K3PO4 in toluene (8 mL) at 75 °C for 2 days, b) Isolated yield after column chromatography, c) 3 Equiv of 
benzamide were used. 
Attempts at deprotecting alkynamides 10 and 11 using HBr or CAN29 (eerie 
ammonium nitrate) respectively to give alkynamide 6 did not provide any of the 
corresponding unprotected alkynamides. 
/V-Protcctcd alkynamides 10, 11, and 12 were subjected to our I2 cyclization 
conditions to form the corresponding oxazolium iodide salts 13, 14 and 15 respectively 
(eq 3). These iodocyclization reactions provided the expected oxazolium salts in good 
yields. 
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(3) 
EG 
13 Bn (94%) 
14 4-MeOC6H4CH2 (80%) 
15 allyl (64%) 
Oxazolium iodide 13 did not undergo deprotection in the presence of HBr, nor did 
oxazolium 14 undergo deprotection using CAN. Quaternary /V-allyl ammonium salts 
have been deprotected in the presence of water or an amine base.25 Our attempts at 
treating /V-allyl oxazolium iodide 15 with H2O, Et2NH or EhN at room temperature or 
reflux, did not provide any of the desired oxazole product. 
We speculate that these salts are extremely stable due to their conjugation with the 
lone pair of electrons on the oxygen atoms of the oxazolium ring, as well as the aromatic 
ring in the 2-position. To examine this hypothesis, we prepared alkynamide 16 by using 
the copper-catalyzed cross-coupling conditions (eq 4). We hoped that the diminished 
conjugation would destabilize the corresponding oxazolium salt. 
O 15% CUS04*5H20 O TIPS j i 30% 1,10-phenanthroline y 
M e ^ N H + Br = TIPS • M e ^ h T 
i K3PO4, toluene i (4) 
M e
 2 days, 75 °C M e 
85% 16 
When alkynamide 16 was subject to the iodine cyclization conditions, the reaction 
reached completion after 12 h. During the work-up, a soapy emulsion formed that could 
not be resolved. Presumably the emulsion is due to a less hydrophobic oxazolium salt, as 
compared with oxazolium iodides 4, 13, 14 and 15. Regardless, oxazolium iodide 17 
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could be isolated in a moderate yield by filtering the precipitate from the organic layer 
after the excess I2 was removed by washing with a saturated aqueous solution of 
Na 2 S 2 0 3 (eq 5). 
To our surprise, oxazolium iodide 17 did not undergo demethylation in the presence 
of PPI13 using a 2:1 PhCl/sulfolane solvent system at 150 °C. Increasing the temperature 
to 230 °C still did not provide any of the desired oxazole. 
Conclusions 
To date, the preparation of a variety of simple alkynamides has met with limited 
success.30 Most reports of alkynamide syntheses have focused on amide derivatives, 
such as sulfonamides, ureas, carbamates, cyclic carbamates and lactams.31 Thus, a wide 
variety of alkynamide starting materials are not available for our proposed oxazole 
synthesis. 
Our experience with synthesizing simple alkynamides has been limited to alkynes 
bearing bulky silyl groups. Our attempts at synthesizing alkynamides bearing aromatic 
rings on the alkyne terminus led primarily to homo-coupling products. The synthesis of 
alkynamides bearing non-silyl groups on the alkyne terminus, such as those derived from 
lactams and cyclic carbamates, have provided only modest yields of alkynamides.32 This 
includes efforts to employ Sonogashira cross-coupling reactions of terminal alkynamides 
with aryl halides.33 Efforts to generalize this synthesis of oxazoles by the eletrophilic 
cyclization of alkynamides will have to wait until a more general alkynamide synthesis 
TIPS 
(5) 
53% Me 
17 
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has been developed. The synthesis of alkynamides with a labile leaving group should be 
the focus of this research in the future, since the electrophilic cyclization of alkynamides 
leads to oxazolium salts. To the best of our knowledge, alkynamides bearing an N-H 
group have not been reported. Alternatively, allenamides34 might be examined as 
possible candidates for electrophilic cyclization to oxazoles. 
The electrophilic cyclization of alkynamides provides a convenient synthesis of 
oxazolium salts, rather than the desired oxazoles. Thus far, dequaternization has met with 
limited success and the conditions required are not mild. 
It should be noted that /V-alkyloxazolium salts have been shown to react with 
anhydrides, ammonia, and tris(trimethylsilyl)phosphine in the presence of KF, to 
generate pyroles,35 imidazoles,36 and 3-azaphospholes37 respectively. Thus, our approach 
to these oxazolium salts could prove useful for the synthesis of these other heterocyclic 
ring systems if we can make it more general. 
Experimental Section 
General. The lU and 13C NMR spectra were recorded at 300 and 75.5 MHz or 400 and 
100 MHz respectively. All melting points are uncorrected. Thin layer chromatography 
was performed using commercially prepared 60-mesh silica gel plates (Whatman K6F) 
and visualization was effected with short wavelength UV light (254 nm). High resolution 
mass spectra were recorded on a Kratos MS50TC double focusing magnetic sector mass 
spectrometer using EI at 70 eV. Toluene and CH2CI2 were distilled from CaH2. All 
reagents were used directly as obtained commercially unless otherwise noted. 
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General Procedure for the Preparation of Alkynamides. To a mixture of the 
appropriate amide (7.33 mmol), anhydrous K 3 P O 4 (7.33 mmol, 1.56 g ), CuS04*5H20 
(0.55 mmol, 137 mg), and 1,10-phenanthroline (1.09 mmol, 138 mg) in a 4 dram reaction 
vial was added l-bromo-2-(triisopropylsilyl)acetylene (3.67 mmol, 956 mg) in toluene (8 
mL). The reaction mixture was capped and heated in an oil bath at 75 °C for 48 h. The 
reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to 
room temperature and diluted with EtOAc, filtered through Celite, and concentrated 
under vacuum. The crude products were purified by flash column chromatography on 
silica gel using hexanes/EtOAc to afford the desired alkynamide. 
A^-Methyl-A^-[(triisopropylsilyl)ethynyl)]benzamide (3). The compound was isolated in 
an 86 % yield: JH NMR ( C D C I 3 400 MHz) 8 0.94 (s, 21H), 3.36 (s, 3H), 7.35-7.45 (m, 
3H), 7.78-7.80 (d, J = 6.5 Hz, 2H); 13C NMR (CDC13) 8 11.46, 18.74, 37.96, 70.07, 
100.35, 127.99, 128.79, 131.33, 133.78, 171.53; HRMS Calcd for Ci9H29NOSi: 
315.2018. Found 315.2024. 
A^-Benzyl-A^-[(triisopropylsilyl)ethynyl]benzamide (10). The compound was isolated in 
an 87 % yield: JH NMR (CDC13, 400 MHz) 8 0.87 (s, 21H), 4.87 (s, 2H), 7.30-7.46 (m, 
8H), 7.78-7.80 (d, J = 12 Hz, 2H); 13C NMR (CDC13) 8 11.43, 18.69, 53.13, 72.32, 
99.07, 128.01, 128.21, 128.72, 128.89, 129.19, 131.41, 133.83, 136.12, 171.02; HRMS 
Calcd for C25H33NOSi: 391.2331. Found 391.2338. 
A^-(4-Methoxybenzyl)-A^-[(triisopropylsilyl)ethynyl]benzamide (11). The compound 
was isolated in a 43 % yield: JH NMR (CDCI3, 400 MHz) 8 0.88 (s, 21H), 3.80 (s, 3H), 
4.80 (s, 2H), 6.86-6.89 (dd, / = 2.6, 8.9 Hz, 2H), 7.32-7.44 (m, 5H), 7.76-7.79 (d, / = 8.0 
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Hz, 2H); 13C NMR (CDC13) 5 11.40, 18.66, 52.62, 55.50, 72.30, 99.10, 114.07, 127.96, 
128.35, 128.84, 130.70, 131.32, 133.40, 159.70, 171.00; HRMS Calcd for C26H35N02Si: 
421.2437. Found 421.2443. 
A^-Allyl-A^-[(triisopropylsilyl)ethynyl]benzamide (12). The compound was isolated in a 
48 % yield: JH NMR (CDCI3, 400 MHz) 8 0.93 (s, 21H), 4.30-4.31 (d, / = 5.7 Hz, 2H), 
5.28-5.38 (m, 2H), 5.94-5.98 (m, 1H), 7.34-7.45 (m, 3H), 7.79-7.81 (d, / = 7.7 Hz, 2H); 
13C NMR ( C D C I 3 ) 8 11.45, 18.74, 52.01, 71.61, 98.88, 119.38, 127.99, 18.86, 131.40, 
131.55, 133.82, 170.90; HRMS Calcd for C2iH3iNOSi: 341.2177. Found 341.2182. 
A^-Methyl-A^-[(triisopropylsilyl)ethynyl]acetamide (16). The compound was isolated in 
an 85 % yield: JH NMR (CDCI3, 400 MHz) 8 1.08 (s, 21H), 2.34 (s, 3H), 3.14 (s, 3H); 
13C NMR ( C D C I 3 ) 8 11.53, 18.82, 22.44, 36.15, 70.06, 99.90, 172.53; HRMS Calcd for 
Ci4H27NOSi: 253.1862. Found 253.1865. 
General Procedure for the Preparation of Oxazolium Salts. To a stirred solution of 
the appropriate alkynamide (0.25 mmol) in CH2C12 (2.5 mL) was added finely divided I2 
(0.75 mmol, 191 mg) and the solution was allowed to stir at room temperature for 12 h. 
The reaction was monitored by TLC to establish completion. The excess I2 was removed 
by washing with a satd aq soln of Na 2 S 2 0 3 . The aqueous solution was then extracted 
with CH2C12 (3 x 20 mL). The combined organic layers were dried over anhydrous 
MgS0 4 and concentrated under a vacuum to yield the crude product, which was purified 
by recrystallization from MeOH or CH2Cl2/hexanes. 
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4-Iodo-3-methyl-2-phenyl-5-(triisopropylsilyl)oxazolium iodide (4). The compound 
was isolated in a 91 % yield: JH NMR (DMSO-d6, 400 MHz) 8 1.15-1.16 (d, / = 7.3 Hz, 
18H), 1.59-1.63 (m, 3H), 3.95 (s, 3H), 7.73-7.79 (m, 2H), 7.84-7.86 (s, 1H), 7.96-7.97 
(m, 2H); 13C NMR (DMSO-d6) 8 10.64, 18.13, 38.24, 99.83, 120.78, 129.49, 129.91, 
134.42, 157.42, 164.73; HRMS Calcd for Ci8H26INOSi: 427.0828 (M - Mel)+. Found 
427.0835. 
3-Benzyl-4-iodo-2-phenyl-5-(triisopropylsilyl)oxazolium iodide (13). The compound 
was isolated in a 94 % yield: JH NMR (CDC13, 400 MHz) 8 1.20-1.22 (d, J = 7.5 Hz, 
18H), 1.64-1.75 (m, 3H), 5.90 (s, 2H), 7.10-7.12 (m, 2H), 7.35-7.38 (m, 3 H), 7.50-7.54 
(t, / = 7.9 Hz, 2H), 7.65-7.68 (t, / = 7.6 Hz, 1H), 7.80-7.82 (dd, / = 1.3, 8.6 Hz, 2H); 13C 
NMR (CDCls) 8 11.40, 18.82, 54.32, 107.09, 120.73, 126.40, 128.98, 129.67, 129.97, 
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132.70, 134.83, 160.33, 165.83; HRMS Calcd for Ci8H26INOSi: 427.0828 (M -
PhCH2I)+. Found 427.0836. 
3-Allyl-4-iodo-2-phenyl-5-(triisopropylsilyl)oxazolium iodide (15). The compound 
was isolated in a 64 % yield: JH NMR (DMSO-d6, 400 MHz) 8 1.16-1.18 (d, J = 1A Hz, 
18H), 1.59-1.67 (m, 3H), 4.67 (br s, 2H), 5.38-5.42 (br d, / = 17.1 Hz, 1H), 5.52-5.55 (br 
d, / = 10.7 Hz, 1H), 6.13-6.21 (m, 1H), 7.76-7.80 (t, / = 7.7 Hz, 2H), 7.86-7.90 (t, / = 7.0 
Hz, 3H); 13C NMR (DMSO-d6) 8 10.71, 18.17, 52.65, 96.02, 119.81, 120.57, 129.49, 
129.71, 129.95, 134.78, 158.68, 165.99; HRMS Calcd for Ci8H26INOSi (M -
CH2CHCH2I)+: 427.0828. Found 427.0835. 
Procedure for the Demethylation of Oxazolium Iodide 10 to form 4-Iodo-2-phenyl-
5-(triisopropylsilyl)oxazole (5). To a microwave vial was added the crude oxazole salt 
10 (0.25 mmol), PPI13 (1 equiv) and 2:1 PhCl/sulfolane (2 mL). The microwave vial was 
capped and heated to 150 °C for 20 min. The solution was diluted with ethyl acetate (25 
mL) and the organic layer washed with water, brine and dried with magnesium sulfate. 
The organic layer was concentrated under vacuum and the residue purified by column 
chromatography (20:1 hexanes/EtOAc) to afford the product as a yellow oil: JH NMR 
(CDCI3, 400 MHz) 8 1.15-1.17 (d, J = 7.5 Hz, 18H), 1.54-1.65 (m, 3H) 7.45-7.47 (m, 
3H), 8.02-8.05 (m, 2H); 13C NMR (CDC13) 8 11.63, 18.86, 96.61, 126.69, 126.84, 
129.00, 130.93, 155.26, 166.50; HRMS Calcd for Ci8H26INOSi: 427.0828. Found 
427.0835. 
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Abstract 
O 
Fluoren-9-ones and derivatives are readily prepared in good yields by the annulation of in 
situ generated arynes by 2-haloarenecarboxaldehydes in the presence of a palladium 
catalyst. 
Introduction 
Recent groundbreaking work in the area of metal-catalyzed transformations of arynes, 
including the palladium-catalyzed cyclotrimerization of benzynes to form triphenylenes,1 
has provided novel new ways to rapidly construct fused aromatic poly cycles. The metal-
catalyzed cocyclization of arynes with alkynes has also been investigated.2 Additionally, 
metal-catalyzed carbonylative cycloadditions of arynes3 and the cocyclotrimerization of 
arynes with bicyclic alkenes4 and allenes5 have been reported. More recently, our group 
and others have synthesized fused polycyclic aromatics by palladium-catalyzed 
annulations of arynes with aryl halides.6 We have also reported a palladium-catalyzed, 
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three-component, sequential intermolecular coupling of aryl halides, alkynes, and 
arynes.7 
The construction of heterocycles and carbocycles by the palladium-catalyzed 
annulation of alkynes by functionally-substituted aryl halides has proven a powerful 
synthetic tool.8 Specifically, we have reported that 2-halobenzaldehydes can react with 
internal alkynes in the presence of a palladium catalyst to form substituted indenones in 
good yields.9 Analogous to that work, we recently reported the synthesis of fluoren-9-
ones by the palladium-catalyzed annulation of in situ generated benzynes by 2-
haloarenecarboxaldehydes.10 This provides a convenient synthesis of fluoren-9-ones, 
which are an important class of carbocycle, because of their important role in 
pharmaceutical applications,11 as photosensitizers,12 and their use as key intermediates in 
organic synthesis.13 A number of fluoren-9-one natural products, including dengibsin, 
dengibsinin and dendroflorin, have recently been reported to occur in the Asiatic orchid 
Dendrobium gibsonii Lindley (Figure l).14 We now wish to report the full details of our 
work on the palladium-catalyzed annulation of arynes by 2-haloarenecarboxaldehydes. 
OH OMe OH OMe 
Dengibsinin Dendroflorin 
Figure 1 
Results and Discussion 
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In our earlier study, it was found that the "optimal" conditions for our palladium-
catalyzed annulation of arynes by 2-haloarenecarboxaldehydes involves stirring 0.3 
mmol of the 2-iodobenzaldehyde (1), 1.5 mmol of the benzyne precursor 2-
(trimethylsilyl)phenyl triflate (2a), 1.5 mmol of CsF, 5 mol % Pd(dba)2 and 5 mol % P(o-
tolyl)3 ligand in 4 mL of 1:1 MeCN:toluene at 110 °C for 12 h. This affords the desired 
fluoren-9-one (3) in a 75% yield (eq 1). 
5 CsF 
5% Pd(dba)2 
5% P(o-tolyl)3 
(1) 
1:1 CH3CN/toluene 
110°C, 12 h 
75% 
To determine the scope and limitations of this chemistry, a number of new ortho-
haloarenecarboxaldehydes were required. However, many of the necessary starting 
materials were not readily accessible from commercial sources. The synthesis of ortho-
iodonaphthalenecarboxaldehyde starting materials was achieved by employing a useful 
variant of some of our earlier reported15 iodocyclization chemistry using appropriate 
benzylic-substituted propargylic diols, followed by oxidation of the resulting naphthalen-
1-ylmethanols by Mn0 2 (Scheme 1). The requisite diols are easily prepared by the 
reaction of the lithium acetylide dianion of propargyl alcohol with the corresponding 2-
arylacetaldehyde or 2-arylacetone in THF at 0 °C, followed by quenching with a 
saturated solution of aqueous NH4C1. 
Scheme 1 
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.0 1) 2 Li = ' 
THF, 0 °C to rt R1 
2) NH4CI (aq) 
OLi .OH 
2) Mn0 2 
1) ICI, NaHC0 3 
O H 
R1, R2, R3 = H, H, H (41%) R \ R2, R3 = H, H, H 20 (83%) 
= H, Me, H (54%) 
= H, Ph, H (45%) 
= Me, H, Me (38%) 
= H, Me, H 22 (47%) 
= H, Ph, H 24 (55%) 
= Me, H, Me 26 (70%) 
In addition to the ort/zohalonaphthalenecarboxaldehydes described above, we 
prepared 6-iodobenzothiophene-7-carboxaldehyde (28) by an analogous route starting 
from 2-(thiophen-3-yl)acetaldehyde (Scheme 2). The iodocyclization of the thiophene-
containing diol occurred selectively at the 2-position of the thiophene. The major side 
product appeared to arise by simple dehydration to an enynol product that did not cyclize. 
Scheme 2 
O H 
HO 28 
3 4 % 
The synthesis of 10-iodophenanthrene-9-carbaldehyde (30) was achieved by the 
iodocyclization of 3-(biphen-2-yl)prop-2-yn-l-ol, followed by oxidation with Mn0 2 (eq 
2).16 
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OH 
1) ICI, -78 °C 
2) M n 0 2 
76% 
H (2) 
30 
With a number of new r;r//zr;-iodoarcnccarboxaldchydcs in hand, we examined the 
scope of the fluoren-9-one synthesis (Table 1). When 2-iodobenzaldehyde (1) and 2-
bromobenzaldehyde (4) were allowed to react with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (2a) under our optimized conditions, fluoren-9-one (3) was 
isolated in good yields, although a two fold increase in reaction time was required for the 
reaction of 4 to reach completion (Table 1, compare entries 1 and 2). 5-Bromo-2-
iodobenzaldehyde (5) reacted selectively to afford the desired 2-bromofluoren-9-one (6) 
in good yield (Table 1, entry 3). 6-Fluoro-2-iodobenzaldehyde (7) reacted cleanly to 
provide l-fluorofluoren-9-one (8) in an 82% yield (Table 1, entry 4). The increased yield 
of 8 compared to the parent system is presumably due to the electron-withdrawing nature 
of the fluorine atom on the aromatic ring, which presumably facilitates the oxidative 
addition of Pd(0) to the carbon-iodine bond of 7. In addition, the fluorine atom may 
increase the electrophilicity of the aldehyde moiety, promoting the final cyclization step 
(see the later mechanistic discussion). On the contrary, the reaction of 2-iodo-4,5-
methylenedioxybenzaldehyde (9) with triflate 2a provided only a 50% yield of the 
desired fluoren-9-one 10 (Table 1, entry 5). This marked decrease in yield, as compared 
to the parent system, may be due to the electron-rich aromatic ring. Both 2-iodo-5,6-
methylenedioxybenzaldehyde (11) and 2-bromo-5,6-methylenedioxybenzaldehyde (13) 
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provided the corresponding fluoren-9-one 12. However, the aryl bromide gave a 
significantly reduced yield (Table 1, compare entries 6 and 7). The higher yield of 12 
from 11, as opposed to that of 10 from 9, might be explained by the electron-withdrawing 
inductive effect of the oxygen atoms of 11 being greater due to their proximity to the 
aldehyde group, thus making the aldehyde more electrophilic (Table 1, compare entries 5 
and 6). When 2-iodo-4,5-dimethoxybenzaldehde (14) was reacted with triflate 2, the 
desired fluoren-9-one 15 was obtained in a 53% yield (Table 1, entry 8). This result is in 
line with the reaction of triflate 2a with aldehyde 9. 2-Iodo-3,4,5-
trimethoxybenzaldehyde (16) provided 2,3,4-trimethoxyfluoren-9-one (17) in only a 
modest yield of 41% (Table 1, entry 9). The decrease in yield, compared with other aryl 
ethers is presumably due to a steric effect of the MeO group ortho to the iodine atom. 
Steric congestion around the carbon-iodine bond may hinder oxidative addition of 
palladium to the C-I bond. 
Table 1. Synthesis of Fluoren-9-ones by the Palladium-Catalyzed Annulation of Arynes 
by o-Haloarcnccarboxaldchydcs." 
5 CsF 
entry o-haloaldehyde aryne precursor product(s) % yield" 
O o 
1 1 2a 3 75 
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O 
H 
Br 2a 3 73
c 
Br-
H 
2a 6 61 
F O 
O 
o 
< 
o 
H 
H 
H 
Br 
O 
MeO 
MeO 
H 
11 
13 
14 
O 
2a 
2a 
8 82 
10 50 
12 72 
12 56 
2a MeO 
MeO 
\ 15 53 
MeO 
M e O ' ^ " I 
OMe 
H 16 2a MeO 
MeO 
\ 17 41 
OMe 
122 
123 
16 
17 
H 30 
32 
2a 
2a 
31 61 
O 
18 H 
O 
33 2a messy 
19 
MeCL / T M S 
2b 
MeO ^ OTf 
15 33d 
20 
21 
22 
M e ^ j ^ ^ T M S 
M e ^ ^ O T f ^ 
2c 
OMe 
•TMS 
2d 
OTf 
71 
73 
61£ 
23 
TMS 
OTf 
2e 19 trace 
+ 
21 50 
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a) Unless otherwise specified, all reactions were carried out using 0.3 mmol of the aldehyde, 1.5 mmol of 
the aryne precursor, 1.5 mmol of CsF, 5 mol % of Pd(dba)2 and 5 mol % of P(o-tol)3 in 4 mL of 1:1 
CH3CN/toluene at 110 °C for 12 h. b) Isolated yield after column chromatography on silica gel. c) The 
reaction required 24 h to reach completion and the yield was determined by GC-MS. d) The yield was 
determined by NMR spectroscopy, (e) The yield of the other isomer was 7% according to gas 
chromatographic analysis. 
In addition to benzaldehyde substrates, the annulation reaction has also been applied 
to 2-iodonaphthalene-l-carboxaldehydes. The annulation of triflate 2a by 1-
iodonaphthalene-2-carboxaldehyde (18) provided fluorenone derivative 19 in a 48% 
yield (Table 1, entry 10). A marked increase in the yield of fluorenone was observed 
when 2-iodonaphthalene-l-carboxaldehyde (20) was allowed to react with triflate 2a 
(Table 1, compare entries 10 and 11). The increase in yield of 21, compared to 
regioisomer 19, is apparently due to decreased steric crowding around the carbon-iodine 
bond, resulting in a more facile oxidative addition of the palladium moiety. Reactions of 
2-iodo-4-methylnaphthalene-l-carboxaldehyde (22) and 2-iodo-4-phenylnaphthalene-l-
carboxaldehyde (24) with triflate 2a proceeded smoothly, and provided the 
corresponding fluorenones 23 and 25 respectively in good yields (Table 1, entries 12 and 
13). 2-Iodo-3,7-dimethylnaphthalene-l-carboxaldehyde (26) afforded the desired 
compound 27 (Table 1, entry 14). However, the yield suffered, presumably due to steric 
hinderance in the vicinity of the carbon-iodine bond of 26. 6-Iodobenzothiophene-7-
carboxaldehyde (28) gave the corresponding thiophene-containing fluorenone 29 in a 
52% yield (Table 1, entry 15). When phenanthrene 30 was allowed to react with triflate 
2a, the desired fluoren-9-one derivative 31 was obtained in a 61% yield (Table 1, entry 
16). Naphthalene 32 was employed to see if this methodology could be extended to 6-
membered rings, but, unfortunately, triphenylene was observed as the major product of 
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this reaction, along with the reduced starting material naphthalene-1-carboxaldehyde 
(Table 1, entry 17). A double annulation was attempted by using diiododialdehyde 33. 
Unfortunately, the latter reaction provided a complex reaction mixture and none of the 
desired product was observed (Table 1, entry 18). A similar result was obtained when 
the reaction was performed using 0.3 mmol of diiododialdehyde 33, 3.0 mmol of 2-
(trimethylsilyl)phenyl triflate (2a), 3.0 mmol of CsF, 10 mol % Pd(dba)2 and 10 mol % 
P(o-tolyl)3 ligand in 8 mL of 1:1 CH3CN/toluene. 
In addition to the above reactions, which examined only the use of the benzyne 
precursor triflate 2a as an annulation partner, other aryne precursors have been examined 
in our methodology. 4,5-Dimethoxybenzyne precursor 2b was examined under our 
annulation conditions and gave the expected 2,3-dimethoxyfluoren-9-one (15), although 
the yield was poor (Table 1, entry 19). The low yield in this latter reaction may be 
attributed to the slower rate of generation of 4,5-dimethoxybenzyne from 2b, compared 
with the generation of benzyne from 2a, as has been suggested by earlier work in our 
group.6a'c However, when dimethylbenzyne precursor 2c was allowed to react with 2-
iodobenzaldehydes 1 and 7 under our optimized conditions, it provided the corresponding 
fluoren-9-one products 34 and 35 respectively in good yields (Table 1, entries 20 and 21). 
The reaction of 3-methoxybenzyne, generated from triflate 2d, exhibited good 
regioselectivity (Table 1, entry 22). The reaction gave rise to both isomeric 
methoxyfluoren-9-ones in approximately a 9:1 ratio as determined by gas 
chromatographic analysis. l-Methoxyfluoren-9-one (36) was the major product as 
determined by comparison of its *H and 13C NMR spectra with those of the known 
compound.17 The preference for regioisomer 36 over the other regioisomer can be 
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attributed to coordination of the methoxy group to the palladium in the biarylpalladium 
intermediate 37 (Figure 2).18 This regiochemistry also places the palladium on the 
inductively more thermodynamically stable carbanionic carbon. Intermediate 37 is also 
the product one would expect from the aryl moiety of the initial ArPdX adding to the 
most sterically accessible carbon of the aryne. As observed in the carbopalladation of 
alkynes,8 Pd presumably prefers to add to the more hindered end of the aryne, which is 
ortho to the methoxy group. 
O 
37 
Figure 2 
In addition to benzyne precursors, we have also examined the effect of naphthyne2c 
precursor 2e on the annulation process. We were pleased to find that one major 
regioisomer was formed in a 50% yield from the reaction of naphthyne precursor 2e with 
aldehyde 1 (Table 1, entry 23). This result is in agreement with the suggestion that the 
aryl moiety of the initial ArPdX adds to the more sterically exposed carbon of the aryne 
and that Pd prefers to add to the more hindered CI of naphthyne. 
In addition to the substrates illustrated in Table 1, we have also attempted to employ 
substituted 2-haloacrylaldehydes in this palladium-catalyzed annulation reaction to 
synthesize indenones.9 Unfortunately, reactions with 2-iodocyclohex-l-
enecarboxaldehyde and Z-3-iodo-3-phenylacrylaldehyde produced complex mixtures and 
only poor yields of indenones were achieved. Also, our attempts employing pyridine 
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substrates, such as 2-bromopyridine-3-carboxaldehyde, 4-bromopyridine-3-
carboxaldehyde and 2-fluoro-4-iodopyridine-3-carboxaldehyde, as starting materials did 
not lead to any formation of the desired fluoren-9-ones. This result is not surprising, since 
pyridine itself is known to react with benzynes to give novel polymers with o-phenylene 
and 2,3-dihydropyridine units in the main chain.19 
Based on previously reported palladium-catalyzed annulations of alkynes,8 
particularly the synthesis of indenones by the palladium-catalyzed coupling of internal 
alkynes with 2-haloarenecarboxaldehydes,9 we propose that this fluorenone synthesis 
proceeds as shown in Scheme 3. First, oxidative cyclization of Pd(0) occurs with the 
aryne generated from the silyl triflate to form palladacycle A.20 Oxidative addition of 1 
to this palladacycle forms Pd(IV) intermediate B. Reductive elimination gives rise to 
arylPd(II) intermediate C. Arylpalladium intermediate C can add across the aldehyde to 
produce a palladium(II) alkoxide D,21 which can undergo P-hydride elimination to 
produce the fluorenone product (path a). Alternatively, intermediate C can undergo 
oxidative addition of the aldehyde C-H bond to form palladium(IV) intermediate E,22 
followed by elimination of HI, and regeneration of the Pd(0) catalyst by further reductive 
elimination to the fluoren-9-one (path b). A similar mechanism involving the oxidative 
addition of an aldehyde to an organopalladium(II) intermediate has been proposed for the 
palladium-catalyzed reactions of obromobenzaldehyde with methyl acrylate.23 However, 
there does not appear to be any particular precedent favoring either of these paths. In 
addition, we cannot rule out the possibility that Pd(0) inserts directly into the C-I bond of 
1, followed by carbopalladation of the aryne, to give rise to intermediate C directly. This 
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pathway has been suggested by experiments in our earlier work on the synthesis of fused 
polycyclic aromatics by the palladium-catalyzed annulation of arynes by aryl halides.6a'c 
Scheme 3 
CsF 
In order to demonstrate the utility of 2-bromofluoren-9-one (6) generated by our 
methodology, we have elaborated the carbon-bromine bond by palladium-catalyzed, 
microwave-assisted Sonogashira24 and Suzuki-Miyaura25 cross-coupling reactions 
(Scheme 4). These reactions proceeded cleanly to give acetylenic fluoren-9-one 39 and 2-
(3,4,5-trimethoxyphenyl)fluoren-9-one (38) in high yields. 
Scheme 4 
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MeO 
38 
1.2 (HO)2B 
OMe 
\ ^ O M e 
OMe 
5% Pd(PPh3)4 
6:1 Et0H/H20 
Cs2C03 
mw, 110 °C, 10 min 
95% 
1.1 H-
OMe 
OMe 
2% PdCI2(PPh3)2 
4% Cul, 20% PPh3 
4:1 Et2NH/DMF 
mw, 120 °C, 15 min 
88% 
MeO 
Conclusions 
In summary, we have developed a novel synthesis of fluoren-9-ones, which involves 
the palladium-catalyzed annulation reaction of arynes by 2-haloarenecarboxaldehydes. 
This method provides an efficient synthesis of substituted fluoren-9-ones from readily 
available starting materials. Additionally, this methodology provides a route to fluoren-9-
ones that avoids the use of harsh oxidizing agents and strong mineral acids.26 Our process 
has been shown to be tolerant of benzaldehydes containing multiple halogens. The 
resulting halogenated 2-bromofluoren-9-one may be further elaborated by palladium-
catalyzed processes, such as Sonogashira and Suzuki-Miyaura cross-coupling reactions. 
Furthermore, this methodology has been extended to naphthalene derivatives of fluoren-
9-ones and has also been shown to work in the presence of a heterocycle. 
Experimental Section 
General. The lU and 13C NMR spectra were recorded at 300 and 75.5 MHz or 400 and 
100 MHz respectively. Thin layer chromatography was performed using commercially 
prepared 60-mesh silica gel plates (Whatman K6F), and visualization was effected with 
short wavelength UV light (254 nm) and/or a basic KMn0 4 solution [3 g of KMn0 4 + 20 
g of K 2 C 0 3 + 5 mL of NaOH (5%) + 300 mL of H 20] , All melting points are 
uncorrected. High resolution mass spectra were recorded on a Kratos MS50TC double 
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focusing magnetic sector mass spectrometer using EI at 70 eV. Toluene, CH2CI2 and 
MeCN were distilled from CaH2 under an atmosphere of argon prior to use and stored 
over 4A molecular sieves. Anhydrous CsF and Pd(dba)2 were stored in a glove box 
under an atmosphere of N2. All glassware and stirring bars were oven dried prior to use. 
All reagents were used directly as obtained commercially unless otherwise noted. 
Compounds 3 , 7-12, 18, 19, and 3 4 - 3 6 have been reported in our previous 
communication.10 
27 28 29 
Synthesis of Starting Materials. Compounds 14, 16 and benzyne precursors 2a-e 
were prepared according to literature procedures. 
Procedure for the Synthesis of 2-(Thiophen-3-yl)acetaldehyde. 2-(Thiophen-3-
yl)ethanol (20 mmol, 2.56 g) was dissolved in CH2C12 (200 mL) and cooled to 0 °C. PCC 
(26 mmol, 5.59 g) was added slowly. The solution was allowed to slowly warm to room 
temperature and stirred for 18 h. The resulting brown suspension was filtered through a 
plug of silica gel and the solvent concentrated to give the product as an orange oil. The 
resulting product was taken on to the next step immediately. The resulting aldehyde was 
unstable and should be used immediately. 
General Procedure for the Synthesis of Alkynediols. 
OLi 
1 )2 Li — ' 
THF, 0 °C to rt 
2) NH4CI (aq) 
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Propargyl alcohol (16.6 mmol, 930 mg, 0.98 mL) was dissolved in THF (100 mL) and 
cooled to 0 °C. Under an atmosphere of argon, //-BuLi (2.5 M in hexanes, 33.2 mmol, 
13.3 mL) was added slowly and the resulting solution allowed to stir at 0 °C for 1 h. A 
solution of the appropriate arylacetaldehyde or arylacetone (8.3 mmol) in THF (10 mL) 
was added slowly, and the solution was allowed to warm to room temperature over a 
period of 12 h. The solution was quenched with a satd aq N H 4 C I solution and extracted 
with EtOAc (3 x 20 mL). The organic layers were combined, dried (MgS04) and 
concentrated under reduced pressure. The crude products were isolated by flash column 
chromatography on silica gel (2:1 hexanes:EtOAc). 
5-Phenylpent-2-yne-l,4-diol. This compound was isolated as a pale yellow oil: *H NMR 
(CDCI3, 400 MHz) 8 2.94-2.95 (d, J = 6.6 Hz, 2H), 3.66 (br s, 2H), 4.16 (s, 2H), 4.52-
4.55 (t, / = 6.5 Hz, 1H), 7.21-7.30 (m, 5H); 13C NMR (CDC13) 8 44.0, 50.7, 63.2, 84.0, 
86.1, 127.0, 128.5, 129.8, 136.8; HRMS Calcd for C n H i 2 0 2 : 176.0837. Found: 
176.0840. 
5-Phenylhex-2-yne-l,4-diol. This compound was isolated as a pale yellow oil: *H NMR 
(CDCI3, 400 MHz) 8 1.39-1.38 (d, / = 7.1 Hz, 3H), 2.96-3.04 (m, 1H), 3.38-3.39 (d, / = 
5.3 Hz, 1H), 3.56 (br s, 1H), 4.12 (s, 2H), 4.45 (br s, 1H), 7.22-7.34 (m, 5H); 13C NMR 
( C D C I 3 ) 8 16.5, 45.9, 50.8, 67.2, 84.7, 85.5, 127.2, 128.5, 128.7, 142.3; HRMS Calcd for 
C12H14O2: 190.0994. Found: 190.0997. 
5,5-Diphenylpent-2-yne-l,4-diol. This compound was isolated as a colorless oil that 
solidified upon standing: mp 106-108 °C; JH NMR (DMSO-d6, 400 MHz) 8 3.97-3.99 (d, 
/ = 5.8 Hz, 2H), 4.12-4.14 (d, / = 9.0 Hz, 1H), 5.03-5.07 (m, 1H), 5.09-5.12 (t, / = 5.7 
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Hz, 1H), 5.61-5.63 (d, / = 6.1 Hz, 1H), 7.14-7.18 (m, 2H), 7.24-7.28 (t, / = 7.4 Hz, 4H), 
7.37-7.40 (t, / = 6.6 Hz, 4H); 13C NMR (DMSO-d6) 8 49.0, 57.9, 63.5, 84.7, 85.8, 126.0, 
126.3, 128.0, 128.1, 128.6, 128.7, 142.2, 142.3; H R M S Calcd for C I 7 H I 6 0 2 : 252.1150. 
Found: 252.1154. 
4-Methyl-5-/?-tolylpent-2-yne-l,4-diol. This compound was isolated as a pale yellow 
oil: JH NMR (CDC13, 400 MHz) 8 1.48 (s, 3H), 2.31 (s, 3H), 2.86-2.93 (m, 2H), 3.03 (br 
s, 1H), 3.13 (br s, 1H), 7.09-7.11 (d, / = 7.8 Hz, 2H), 7.17-7.19 (d, / = 7.9 Hz, 2H); 13C 
NMR (CDC13) 8 21.2, 29.3, 49.1, 50.8, 68.2, 82.8, 89.2, 128.9, 130.7, 133.2, 136.6; 
HRMS Calcd for C I 3 H I 6 0 2 : 204.1150. Found: 204.1174. 
5-(Thiophen-3-yl)pent-2-yne-l,4-diol. This compound was isolated as an orange oil: JH 
NMR (CDCI3, 400 MHz) 8 2.98-3.00 (d, J = 6.2 Hz, 2H), 3.73 (br s, 2H), 4.19 (s, 2H), 
5.49 (br s, 1H), 7.00-7.01 (d, / = 4.2 Hz, 1H), 7.09 (s, 1H), 7.23-7.28 (m, 1H); 13C NMR 
( C D C I 3 ) 8 38.4, 50.7, 62.6, 83.9, 86.3, 123.0, 125.6, 129.0, 137.0; HRMS Calcd for 
C 9 H 1 0 O 2 S : 182.0402. Found: 182.0404. 
General Procedure for the Electrophilic Cyclization of Alkynediols by IC1, Followed 
by Oxidation with M n 0 2 . A 1.2 mmol portion of the alkynediol, 2 equiv of NaHC03, 
and 8 mL of CH3CN were placed in a vial and stirred for 1 min at room temperature. 
Two equiv of IC1 in 2 mL of CH3CN was added dropwise to the vial. The reaction 
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mixture was stirred at room temperature for 10 min. The reaction mixture was then 
diluted with 25 mL of EtOAc and washed with 20 mL of satd aq Na2S2C>3. The organic 
layer was separated, and the aqueous layer was extracted with another 25 mL of EtOAc. 
The combined organic layers were dried over MgSC>4 and filtered. The solvent was 
evaporated under reduced pressure and the crude residue was filtered through a plug of 
silica gel rinsed with 25% EtOAc in hexanes. The solvent was evaporated under reduced 
pressure and the residue was dissolved in C H C I 3 (50 mL). The solution was cooled to 0 
°C and Mn02 (6.0 equiv based on the alkynediol) was added. The solution was warmed 
to room temperature and stirred for 18 h. The suspension was filtered through a plug of 
celite and the solvent evaporated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel using a gradient solvent system (40:1 
hexanes:EtOAc to 9:1 hexanes:EtOAc). 
2-Iodonaphthalene-l-carboxaldehyde (20). This product was isolated as a yellow solid: 
mp 77-79 °C; JH NMR (CDC13, 400 MHz) 8 7.55-7.59 (dt, / = 1.1, 7.5 Hz, 1H), 7.62-
7.67 (m, 2H), 7.80-7.82 (d, / = 8.1 Hz, 1H), 7.94-7.96 (d, / = 8.7 Hz, 1H), 9.01-9.03 (d, J 
= 8.7 Hz, 1H), 10.39 (s, 1H); 13C NMR (CDC13) 8 105.6, 124.2, 127.5, 128.5, 129.4, 
130.6, 131.7, 133.8, 135.1, 137.1, 199.0; HRMS Calcd for CnHylO: 281.9542. Found: 
281.9546. 
2-Iodo-4-methylnaphthalene-l-carboxaldehyde (22). This product was isolated as a 
yellow solid: mp 100-102 °C; JH NMR (CDCI3, 400 MHz) 8 2.60 (s, 3H), 7.53-7.61 (m, 
2H), 7.79 (s, 1H), 7.88-7.90 (d, / = 8.0 Hz, 1H), 9.06-9.08 (d, / = 8.4 Hz, 1H); 13C NMR 
( C D C I 3 ) 8 19.8, 106.8, 125.5, 124.6, 127.3, 128.9, 129.0, 131.5, 132.9, 137.9, 142.9, 
198.9; HRMS Calcd for C 1 2 H 9 I O : 295.9698. Found: 295.9704. 
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2-Iodo-4-phenylnaphthalene-l-carboxaldehyde (24). This product was isolated as a 
yellow solid: mp 123-125 °C; JH NMR (CDC13, 400 MHz) 8 7.38-7.49 (m, 6H), 7.60-
7.64 (t, / = 7.8 Hz, 1H), 7.83-7.85 (d, / = 8.3 Hz, 1H), 7.95 (s, 1H), 9.13-9.15 (d, / = 8.7 
Hz, 1H), 10.40 (s, 1H); 13C NMR (CDC13) 8 105.8, 124.5, 127.1, 127.6, 128.7, 128.8, 
129.3, 129.8, 130.0, 132.3, 132.4, 138.1, 138.4, 147.5, 199.0 (one carbon missing due to 
overlap); HRMS Calcd for C n H n I O : 357.9855. Found: 357.9561. 
2-Iodo-3,7-dimethylnaphthalene-l-carboxaldehyde (26). This product was isolated as 
a yellow solid: mp 63-65 °C; JH NMR (CDC13, 400 MHz) 8 2.51 (s, 3H), 2.60 (s, 3H), 
7.32-7.34 (d, J = 8.3 Hz, 1H), 7.58-7.60 (d, J = 8.3 Hz, 1H), 7.70 (s, 1H), 8.54 (s, 1H), 
10.39 (s, 3H); 13C NMR (CDC13) 8 22.5, 29.2, 111.9, 122.8, 127.5, 129.5, 130.1, 131.6, 
132.0, 132.6, 137.2, 138.5, 199.4; HRMS Calcd for Ci3HnIO: 309.9855. Found: 
309.9859. 
6-Iodothiophene-7-carboxaldehyde (28). This product was isolated as a brown solid: 
mp 102-105 °C; ' H N M R (CDC13, 400 MHz) 8 7.34-7.35 (d, / = 5.5 Hz, 1H), 7.54-7.56 
(d, J =5.5 Hz, 1H), 7.70-7.72 (d, J = 8.2 Hz, 1H), 7.89-7.91 (d, J = 8.2 Hz, 1H), 10.29 (s, 
1H); 13C NMR (CDC13) 8 99.6, 122.8, 128.6, 130.5, 131.0, 136.3, 140.1, 141.3, 196.4; 
HRMS Calcd for C9H5IOS: 287.9106. Found: 287.9110. 
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Procedure for the Cross-Coupling of 2-Iodobiphenyl and Propargyl Alcohol to form 
3-(Biphenyl-2-yl)prop-2-yn-l-ol. To a microwave vial were added 2-iodobiphenyl (1.79 
mmol, 0.5 g), propargyl alcohol (1.96 mmol, 110 mg), PdCl2(PPh3)2 (35.7 (imol, 25.1 
mg), Cul (71.6 (imol, 13.6 mg), PPh3 (0.36 mmol, 94.0 mg), DMF (0.5 mL) and Et2NH 
(1.5 mL). The vial was capped and the solution was heated in a microwave reactor for 10 
min at 100 °C. The solution was diluted with EtOAc (25 mL) and the organic layer 
washed with water and brine, and dried. The solvent was evaporated under reduced 
pressure and the product was purified by chromatography on a silica gel column to afford 
240 mg (64%) of the product as a yellow-orange oil: JH NMR (CDC13, 400 MHz) 8 1.88 
(br s, 1H), 4.28 (s, 2H), 7.24-7.28 (m, 1H), 7.33-7.41 (m, 5H), 7.52-7.57 (m, 3H); 13C 
NMR (CDCls) 8 51.7, 85.4, 90.2, 121.0, 127.2, 127.7, 128.1, 128.8, 129.7, 133.3, 140.5, 
144.0; HRMS Calcd for CI5HI20: 208.0888. Found: 208.0891. 
Procedure for the Cyclization of 3-(Biphenyl-2-yl)prop-2-yn-l-ol by IC1 and 
Oxidation by M n 0 2 to form 10-Iodophenanthrene-9-carbaldehyde (30). To a 
solution of 3-(biphenyl-2-yl)prop-2-yn-l-ol (0.96 mmol) in CH2C12 (10 mL) under N2 
was added IC1 (1.2 equiv) in CH2C12 (2 mL) at -78 °C. The reaction mixture was stirred 
at -78 °C for 0.5 h. The reaction mixture was then diluted with 25 mL of EtOAc and 
washed with 20 mL of satd aq Na 2 S 2 0 3 . The organic layer was separated, and the 
aqueous layer was extracted with another 25 mL of EtOAc. The combined organic layers 
were dried over MgS0 4 and filtered. The solvent was evaporated under reduced pressure, 
and the crude residue was filtered through a plug of silica gel and rinsed with 25% 
EtOAc in hexanes. The solvent was evaporated under reduced pressure and the residue 
was dissolved in CHC13 (50 mL). The solution was cooled to 0 °C and Mn0 2 (6.0 equiv) 
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was added. The solution was warmed to room temperature and stirred for 18 h. The 
suspension was filtered through a plug of celite and the solvent evaporated under reduced 
pressure. The residue was purified by column chromatography on silica gel using a 
gradient solvent system (40:1 hexanes:EtOAc to 9:1 hexanes:EtOAc) to afford 243 mg 
(76%) of the product as a yellow oil that solidified upon standing: mp 80-82 °C; JH NMR 
(CDCI3, 400 MHz) 8 7.34-7.41 (m, 5H) 7.43-7.47 (m, 2H) 7.50-7.54 (dt, / = 1.5, 7.5 Hz, 
1H), 9.26 (s, 1H); 13C NMR (CDC13) 8 106.5, 127.8, 128.1, 128.6, 128.8, 128.9, 130.7, 
130.8, 139.6, 140.2, 150.4, 185.9; HRMS Calcd for C15H9IO: 331.9698. Found: 
331.9700. 
General Procedure for the Palladium-Catalyzed Synthesis of Fluoren-9-ones. The 2-
iodoarenecarboxaldehyde (0.30 mmol), the 2-(trimethylsilyl)aryl triflate (1.50 mmol), 
CsF (1.50 mmol), Pd(dba)2 (0.015 mmol), P(o-tolyl)3 (0.015 mmol), 2 mL of toluene, 
and 2 mL of MeCN were placed in a 4 dram vial and the vial was sealed. The reaction 
mixture was stirred first at room temperature for 1 min and then heated to 110 °C for 12 
h. The mixture was allowed to cool to room temperature (CAUTION: OPENING THE 
VIAL AT HIGH TEMPERATURE CAN BE DANGEROUS!), diluted with diethyl 
ether, washed with brine, dried over anhydrous MgS04, and concentrated under reduced 
pressure. The product was isolated by flash chromatography on silica gel. Compounds 
30 31 32 33 
6, 15, 1 and 31JJ were obtained after flash chromatography, and their spectral 
properties are identical with these previously reported. In some cases, the product was 
recrystallized from hexanes/CH2Cl2 to afford a spectroscopically pure product. 
1 l//-Benzo[a]fluoren-l 1-one (21). This product was obtained as an orange solid: mp 
110-112 °C; JH NMR (CDCI3, 400 MHz) 8 7.24-7.28 (apparent triplet merged with 
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CDC13, / = 7.3 Hz, 1H), 7.41-7.48 (m, 3H), 7.56-7.63 (m, 3H), 7.76-7.78 (d, / = 8.2 Hz, 
1H), 7.96-7.98 (d, / = 8.2 Hz, 1H), 8.93-8.95 (d, / = 8.5 Hz, 1H); 13C NMR (CDC13) 8 
118 .3 , 120 .1 , 124 .0 , 124 .4 , 126 .6 , 127 .0 , 128 .7 , 129 .4 , 129 .6 , 130 .3 , 134 .4 , 134 .6 , 134 .7 , 
136 .1 , 144 .0 , 146 .3 , 195 .6 ; H R M S Calcd for C I 7 H I 0 O : 2 3 0 . 0 7 3 2 . Found: 2 3 0 . 0 7 3 4 . 
5-Methyl-l 1//-benzo[a]fluoren-11-one (23). This product was obtained as an orange 
solid: mp 141-143 °C; JH NMR (CDC13, 400 MHz) 8 2.77 (s, 3H), 7.24-7.27 (apparent 
unresolved triplet merged with CDC13, 1H), 7.40-7.48 (m, 3H), 7.50 (s, 1H), 7.57-7.60 (t, 
J =6.5 Hz, 2H), 7.92-7.95 (d, / = 8.5 Hz, 1H), 8.98-9.00 (d, / = 8.2 Hz, 1H); 13C NMR 
(CDC13) 8 21.0, 119.5, 119.9, 123.8, 124.8, 125.0, 125.5, 126.4, 129.2, 129.4, 130.5, 
133.4, 134.1, 135.0, 143.9, 144.0, 146.1, 195.4; HRMS Calcd for Ci 8 Hi 2 0: 244.0888. 
Found: 244.0893. 
5-Phenyl-ll / /-benzo[a]fluoren-l 1-one (25). This product was obtained as an orange 
solid: mp 205-207 °C; JH NMR (CDC13, 400 MHz) 8 7.24-7.28 (apparent doublet of 
triplets merged with CDC13, / = 1.1, 7.2 Hz, 1H), 7.33-7.45 (m, 3H), 7.49-7.61 (m, 8H), 
7.78-7.79 (d, J = 8.4 Hz, 1H), 9.03-9.05 (d, J = 8.2 Hz, 1H); 13C NMR (CDC13) 8 119.7, 
120.1, 124.0, 124.7, 126.2, 126.6, 127.2, 128.3, 128.7, 129.4, 129.5, 129.9, 131.0, 132.8, 
134.4, 135.0, 140.4, 143.8, 145.7, 148.6, 195.4 (one carbon missing due to overlap); 
HRMS Calcd for C 2 3 Hi 4 0: 306.1045. Found: 306.1051. 
2,6-Dimethyl-ll//-benzo[a]fluoren-l 1-one (27). This product was obtained as an 
orange solid: mp 203-205 °C; JH NMR (CDC13, 400 MHz) 8 2.51 (s, 3H), 2.69 (s, 3H), 
7.21-7.24 (m, 2H), 7.39-7.42 (t, / = 7.4 Hz, 1H), 7.55-7.57 (d, / = 8.2 Hz, 2H), 7.59-7.61 
(d, J = 1.5 Hz, 1H), 7.65 (s, 1H), 8.75 (s, 1H); 13C NMR (CDC13) 8 21.2, 22.4, 123.2, 
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123.3, 123.9, 126.8, 127.5, 128.8, 129.2, 130.5, 133.0, 134.3, 135.3, 136.7, 139.0, 144.8, 
145.5, 196.0; HRMS Calcd for C19H14O: 258.1045. Found: 258.1050. 
10//-Fluoreno[ 1,2-/;]thiophen-10-one (29). The product was obtained as an orange 
solid: mp 110-112 °C; 'HNMR (CDC13, 400 MHz) 8 7.22-7.24 (dd, / = 1.0, 7.3 Hz, 1H), 
7.28-7.30 (d, / = 5.4 Hz, 1H), 7.42-7.51 (m, 4H), 7.61-7.63 (d, / = 7.3 Hz, 1H), 7.88-7.90 
(d, J = 7.8 Hz, 1H); 13C NMR (CDC13) 8116.9, 120.5, 123.3, 124.4, 127.8, 129.1, 129.5, 
129.8, 134.4, 134.8, 136.0, 142.5, 144.9, 193.5; HRMS Calcd for CI5H8OS: 236.0296. 
Found: 236.0299. 
Procedure for the Synthesis of Fluoren-9-one 38 from 2-Bromofluoren-9-one. To a 
microwave vial was added 2-bromoflouren-9-one (0.20 mmol, 51.8 mg), Pd(PPh3)4 (10.0 
(imol, 11.6 mg), 3,4,5-trimethoxyphenylboronic acid (0.24 mmol, 50.8 mg), CS2CO3 (1M 
in H2O, 0.24 mL), and EtOH (1.5 mL). The microwave vial was capped and heated to 
110 °C for 10 min by microwave irradiation. Water (20 mL) was added and the aqueous 
layer was extracted with EtOAc. The combined organic layers were washed with brine 
and dried (MgS04). The solvent was evaporated under reduced pressure. The residue 
was purified by column chromatography on silica gel (4:1 hexanes :EtOAc) to afford 66 
mg (95%) of the product as a yellow solid: mp 137-139 °C; JH NMR (CDCI3, 400 MHz) 
8 3.91 (s, 3H), 3.95 (s, 6H), 6.80 (s, 2H), 7.28-7.32 (m, 1H), 7.48-7.56 (m, 3H), 7.67-7.69 
(m, 2H), 7.85-7.86 (d, J = 1.7 Hz, 1H); 13C NMR (CDC13) 8 56.4, 61.2, 91.2, 104.1, 
120.6, 120.8, 123.0, 124.6, 129.2, 133.2, 134.6, 135.1, 135.9, 138.2, 142.4, 143.4, 144.4, 
153.7, 194.1; HRMS Calcd for C 2 2Hi 80 4 : 346.1205. Found: 346.1210. 
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Procedure for the Synthesis of Alkyne 39 from 2-Bromofluoren-9-one. To a 
microwave vial was added 2-bromoflouren-9-one (0.20 mmol, 51.8 mg), PdCl2(PPh3)2 
(4.0 (imol, 2.8 mg), Cul (8.0 (imol, 1.5 mg), PPh3 ( 0.04 mmol, 10.5 mg), DMF (0.5 mL) 
and Et2NH (1.5 mL). The microwave vial was capped and heated to 120 °C for 15 min by 
microwave irradiation. Water (20 mL) was added and the aqueous layer was extracted 
with EtOAc. The combined organic layers were washed with brine and dried (MgS04). 
The solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (4:1 hexanes:EtOAc) to afford 60 mg (88%) of the product 
as a yellow solid: mp 145-147 °C; JH NMR (CDC13, 400 MHz) 8 3.81 (s, 3H), 6.47-6.48 
(t, J = 2.0 Hz, 1H), 6.68-6.69 (d, J = 2.4 Hz, 2H), 7.29-7.33 (dt, / = 1.8, 7.8 Hz, 1H), 
7.49-7.51 (m, 3H), 7.63-7.68 (m, 2H), 7.79 (s, 1H); 13C NMR (CDC13) 8 55.7, 88.4, 91.3, 
102.3, 109.5, 120.5, 120.8, 124.2, 124.3, 124.7 127.5, 129.6, 134.4, 134.5, 135.1, 137.8, 
143.9, 144.1, 160.7, 193.2; HRMS Calcd for C 2 3 Hi 6 0 3 : 340.1099. Found: 340.1105. 
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GENERAL CONCLUSIONS 
In this dissertation, new efficient approaches to various medicinally interesting 
heterocycles and carbocycles are described. These organic transformations occur by the 
electrophilic cyclization of functionalized acetylenes, ICl-induced dehydrations and by 
the palladium-catalyzed annulation of arynes by o-haloarencarboxaldehydes. The 
developed methodologies are quite general and can be utilized for the synthesis of 
various substituted isoxazoles, pyrazoles, oxazolium salts and fluoren-9-ones. 
Chapter 1 is a publication that describes the electrophilic cylization of 2-alkyn-l-one 
0-methyl oximes to afford oxazoles. The methodology is selective, mild and tolerant of 
many functional groups. The presence of steric bulk at the 1- or 3-position of the 2-alkyn-
1-one O-methyl oximes does not hinder the reaction. The resulting 4-iodoisoxazoles 
readily undergo palladium-catalyzed transformations to afford 3,4,5-trisubstituted 
isoxazoles in high yields. To date, this methodology has led to the most efficient 
synthesis of the potent, selective COX-II inhibitor valdecoxib from readily available 
starting materials. 
Chapter 2 describes our efforts to adapt our methodology for the iodocylization of 2-
alkyn-l-one O-methyl oximes to isoxazoles to library generation of a wide variety of 
highly substituted isoxazoles. The generation of a diverse library of isoxazoles has been 
accomplished by utilizing various palldium-catalyzed reactions to affect substitution of 
the C-I bond. These transformations allow for the construction of isoxazoles bearing 
functionally-substituted vinylic, alkynyl, amido and aryl groups. The products were 
isolated in high purity and are being evaluated for their biological potential. A 51 
member library of substituted isoxazoles has been generated. 
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Chapter 3 is focused on the synthesis of l-acyl-4-iodopyrazoles by a novel 
dehydration/iodination of 1 -acyl-5-hydroxy-4,5-dihydro-1 //-pryazolcs. Pyrazoles and 
derivatives are very important, because of their pronounced biological properties. A 
general method to construct l-acyl-3,4,5-substituted pyrazoles has been examined. Our 
dehydration/iodination methodology provides a convenient and efficient approach to 
functionalized pyrazoles. The dehydration/iodination of l-acyl-5-hydroxy-4,5-dihydro-
1//-pyrazoles occurs at room temperature to afford l-acyl-4-iodopyrazoles. 
Chapter 4 outlines an approach to oxazolium iodide salts by the electrophilic 
cyclization of alkynamides. This methodology affords the expected oxazolium salts from 
the corresponding alkynamides. However, the oxazolium salts did not undergo 
dealkylation as expected and efforts towards their dealkylation have been met with 
limited success. 
Chapter 5 illustrates arynes generated in situ from 2-(trimethylsilyl)aryl triflates and 
CsF undergo annulation by o-haloarenecarboxaldehydes in the presence of a palladium 
catalyst, providing a useful new method for the synthesis of fluoren-9-ones in good 
yields. The reaction tolerates both electron-rich and electron-deficient o-
halocarboxaldehydes. Annulation even occurs in the presence of steric congestion 
around the carbon-halogen bond. This methodology can also be used to generate larger 
benzofluoren-9-ones and heterocycles containing fluorenone derivatives. In addition to 
the various 2-(trimethylsilyl)phenyl triflate benzyne precursors examined, a naphthyne 
precursor has been employed successfully as well. 
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